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Abstract 
 
Neonatal common diseases, such as sepsis and jaundice, may damage the 
normal development of the central nervous system. Still, the cellular interactions behind 
the origin of the sequelae remain unknown. Thus, we intended to: (1) investigate the in 
vitro response of brain microvascular endothelial cells (BMEC), either alone or in the 
presence of other CNS cells, to stimuli that mimic those diseases– lipopolysaccharide 
(LPS) for sepsis and unconjugated bilirubin (UCB) for jaundice; (2) to evaluate in vivo 
the neuronal outcome and determine which cellular interactions may be involved, and 
lastly (3) to dissect if the sequelae depend on the neurodevelopmental stage in which 
neonatal inflammation occurs. 
First, we observed that both LPS and UCB induce damage of mitochondria and of 
rough endoplasmic reticulum, ultimately leading to cell death in monocultures of rat 
BMEC. In addition, these molecules cause blood-brain barrier (BBB) breakdown 
through P-glycoprotein inhibition, activation of matrix metalloproteinases (MMPs), loss 
of intercellular junctions – transient by LPS and lasting by UCB. Increased permeability 
and junctional disruption were more severe in co-cultures with astrocytes, particularly in 
LPS-treated cells. Secondly, newborn mice were treated with LPS during the first week 
of life (equivalent to human preterm birth) to examine acute-to-delayed effects in the 
developing neurovascular unit. LPS induced acute loss of body and brain weight, in 
addition to cerebellar hypoplasia. The latter was linked to neuronal loss/shrinkage, as 
well as to delayed myelination. Moreover, we observed a late pro-inflammatory 
response with acute astrogliosis in the parenchyma and microvasculature interface, 
which was lost at later days after a fast and progressive increase of activated microglia 
near the vessels. Lastly, we performed further in vivo studies to assess the acute 
effects of LPS-induced neuroinflammation during the second week of life (equivalent to 
human term birth). Alike in preterm neuroinflammation, we observed neuronal and 
white matter loss/shrinkage, with increased glial numbers. We further explored the 
existence of lasting neurodevelopment impairment in young adult age. Interestingly, 
neuroinflammation during the first week of life led to lasting neuronal loss/shrinkage, 
whereas neuroinflammation in the second week further induced lasting white matter 
injury and reduction of astrocytic population. In agreement, when dissecting the effects 
of priming during the neonatal period, animals with neuroinflammation during the first 
week had less marked effects compared to an acute young adult response whereas 
priming during the second week additionally caused neuronal loss and microgliosis. 
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In conclusion, LPS and UCB act directly on BMEC, impairing BBB integrity which 
may favor the access of blood-borne molecules into the brain. This increases the risk of 
altered neurodevelopment, as is the case of neuronal atrophy and delayed myelination 
observed in our second study. The particular susceptibility of astrocytes to LPS-
induced inflammation may not only depend on BMEC response to the stimuli but also 
on an intricate association with activated microglia. Even though young adults exposed 
to inflammation in the first week of life recover from the initial loss of astrocytes, they 
still sustain severe neuronal compromise. On the other hand, young adults subjected to 
inflammatory stimuli in the second week of life have a more marked demyelination and 
glial response. These findings contribute to a better understanding of the cellular 
interactions involved in lasting sequelae observed in sepsis survivors and how they 
depend on the window of neurodevelopmental stage after birth. 
 
Keywords: astrocytes; bilirubin; blood-brain barrier; brain microvascular endothelial 
cells; lipopolysaccharide; microglia; myelination; neonatal period; neurons; 
neurovascular unit; systemic inflammation; white matter. 
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Resumo 
 
A barreira hemato-encefálica (blood-brain barrier, BBB) é uma interface dinâmica 
entre o sangue e o parênquima encefálico, sendo as células endoteliais da 
microvasculatura encefálica (brain microvascular endothelial cells, BMEC) 
consideradas a sua base anatómica. As BMEC possuem propriedades únicas que 
regulam a passagem seletiva de compostos através do endotélio microvascular 
encefálico, tais como o transportador de efluxo da família ABC glicoproteína-P (P-
glycoprotein, P-gp) e o transporte transcelular por cavéolas. Além disso, o endotélio é 
caracterizado por elevada resistência elétrica transendotelial (transendothelial 
electrical resistance, TEER) e baixa permeabilidade paracelular devido aos seus 
coesos complexos de junções intercelulares, compostos por junções de oclusão (tight 
junctions, TJ) e de aderência (adherens junctions, AJ). As BMEC são parte da unidade 
neurovascular (neurovascular unit, NVU) que inclui adicionalmente a membrana basal 
e outras células do sistema nervoso central (central nervous system, CNS), como é o 
caso das células gliais – essenciais para a indução das propriedades da BBB, função 
neuronal e resposta imunitária. Assim, condições patológicas que afetem o 
funcionamento da NVU diminuem a função da BBB, originando ou favorecendo danos.  
Entre as condições clínicas neonatais mais comuns encontram-se a icterícia e a 
sépsis. A icterícia caracteriza-se por uma pigmentação amarela da pele devido à 
deposição nos tecidos de bilirrubina não conjugada (unconjugated bilirubin, UCB) 
formada pelo catabolismo do grupo hemo, maioritariamente da hemoglobina. A 
acumulação de UCB no encéfalo representa um risco de neurotoxicidade podendo 
levar ao aparecimento de encefalopatia bilirrubínica. Entre os diversos fatores de risco 
da icterícia neonatal encontra-se a sépsis, uma resposta sistémica inflamatória a uma 
infeção que pode causar disfunção de órgãos e eventualmente levar à morte. De facto, 
os nossos estudos anteriores mostram que tanto a resposta inflamatória como a morte 
celular desencadeadas pela UCB nos astrócitos é exacerbada na presença simultânea 
de lipopolissacárido (lipopolysaccharide, LPS). O LPS é um componente da membrana 
das bactérias Gram-negativas, frequentemente usado em estudos para mimetizar uma 
infeção e desencadear uma resposta inflamatória. A ativação do seu recetor tipo-Toll 4 
(Toll-like receptor 4, TLR4) nas BMEC origina a libertação de fatores pró-inflamatórios 
para o parênquima encefálico culminando em neuroinflamação. Os seus efeitos diretos 
sobre as BMEC podem ser exacerbados através da resposta inflamatória de outros 
tipos celulares, desencadeada quer pelo próprio LPS, quer pelas vias pró-inflamatórias 
ativadas. Este é o caso das proteínas high-mobility group box 1 (HMGB1) e autotaxina 
(ATX) que se encontram associadas a microgliose e podem levar à produção de 
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fatores neurotóxicos, e consequentemente a neurodegeneração. De realçar que as 
crianças que sobrevivem à sépsis apresentam geralmente perturbações cognitivas e 
musculares a longo termo, indicando que poderão estar envolvidos danos neuronais. 
Esta tese teve como objetivos avaliar: (i) a resposta das BMEC a estímulos que 
mimetizam a icterícia e a sépsis neonatal in vitro (LPS e UCB), em monocamada e em 
co-cultura com astrócitos (Capítulo 2); (ii) as consequências da administração de LPS 
em murganhos ao nível das interações na NVU neonatal (Capítulo 3); e (iii) se as 
sequelas duradouras dependem da fase de desenvolvimento do período neonatal em 
que a inflamação sistémica ocorre e, ainda, quais os reflexos de uma sensibilização no 
período neonatal (priming) na resposta resultante de uma nova exposição numa fase 
mais tardia (Capítulo 4). 
Iniciámos o nosso estudo in vitro determinando os efeitos diretos do LPS e da 
UCB no endotélio microvascular encefálico de rato. Tanto o LPS como a UCB 
induziram a morte celular das BMEC, assim como inibição da P-gp e ativação de 
metaloproteinases (matrix metalloproteinases, MMP). Verificou-se ainda a existência 
de danos ao nível do reticulo endoplasmático e das mitocôndrias por ambos os 
estímulos. Em células tratadas com LPS foi ainda notório o aumento de invaginações 
semelhantes a cavéolas e o enfraquecimento das junções intercelulares, ao passo que 
em células tratadas com UCB a perda das junções intercelulares foi ainda mais 
marcada. Qualquer uma das moléculas levou ao aumento da permeabilidade 
endotelial e à diminuição da TEER, tanto em monoculturas como em co-culturas com 
astrócitos. Observaram-se ainda alterações ao nível da integridade e localização das 
proteínas de TJ (zonula occludens-1 e claudina-5) e AJ (β-catenina). Em geral, os 
efeitos diretos da UCB sobre as BMEC sofreram agravamento ao longo do tempo, 
enquanto os danos causados pelo LPS foram reversíveis em monoculturas de BMEC. 
Curiosamente, em co-cultura com astrócitos os danos induzidos pelo LPS na 
monocamada continuaram a observar-se a tempos mais longos. Assim, o LPS e a 
UCB exercem efeitos tóxicos diretos sobre as BMEC, embora com mecanismos de 
ação e perfis temporais distintos. O enfraquecimento da integridade do endotélio 
encefálico após exposição a estas moléculas pode aumentar desta forma o risco de 
lesão, pelo que o tratamento clínico adequado da sépsis e da icterícia no período 
neonatal são requisitos fundamentais para diminuir ou evitar as sequelas delas 
decorrentes. 
De seguida explorámos mais aprofundadamente os efeitos resultantes de uma 
inflamação por LPS na primeira semana de vida, em ratinhos CD1 wild-type e 
transgénicos C57BL/6 CX3CR1gfp/+. Verificámos haver perda de peso corporal e 
encefálico, acompanhada de hipoplasia cerebelar. A administração sistémica de LPS 
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causou a redução da densidade neuronal e sua atrofia, juntamente com um atraso da 
mielinização. Esta alteração na formação de mielina parece não ser causada por um 
aumento da atividade fagocítica da microglia, mas sim por inibição ou atraso da 
diferenciação de células NG2. Verificou-se ainda a existência de resposta pró-
inflamatória com aumento da atividade e da expressão de biomarcadores 
inflamatórios, assim como a presença de astrogliose (células GFAP+) quer no 
parênquima encefálico quer na interface da microvasculatura. Contudo, os elevados 
níveis de células GFAP+ diminuem a tempos mais longos, ao mesmo tempo que 
ocorre um aumento rápido e progressivo de microglia ativada CX3CR1gfp/+ junto à 
microvasculatura. O nosso estudo mostrou assim que, para além do enfraquecimento 
da BBB, o LPS causa atrofia neuronal e retarda a mielinização, onde a íntima e 
complexa relação entre astrócitos e microglia se encontra envolvida. 
Para melhor avaliar os efeitos duradouros das alterações observadas no período 
neonatal, e de que modo estes dependem do dano inflamatório ser causado na 
primeira ou na segunda semana de vida, determinámos as consequências destes 
danos em animais CD1 no período correspondente a jovens adultos. Primeiramente, 
avaliámos a resposta do CNS no dia seguinte a um estímulo inflamatório induzido na 
segunda semana de vida. Verificámos a existência de perda e atrofia neuronais, além 
de uma acentuada redução de substância branca para a qual poderá contribuir a 
desmielinização. O aumento da atividade e expressão dos biomarcadores 
inflamatórios, MM-9 e HMGB1, estão associados a um aumento no número de 
astrócitos (células GFAP+) e de microglia (células Iba1+), apesar dos níveis de TLR4 
se terem mantido inalterados. De seguida avaliámos os danos duradouros em animais 
jovens adultos após indução de inflamação na primeira ou segunda semana de vida. 
Os animais com neuroinflamação na primeira semana apresentaram perda e atrofia de 
neurónios, enquanto os jovens adultos com neuroinflamação durante a segunda 
semana de vida apresentaram maioritariamente redução da substância branca e perda 
de astrócitos. Por último avaliámos a resposta a um novo estímulo de LPS em jovens 
adultos com priming durante o período neonatal, relativamente a jovens adultos que 
apenas receberam a injeção de LPS pela primeira vez enquanto adultos (resposta 
aguda adulta). Tal como verificado nos efeitos prolongados, os neurónios dos animais 
com priming na primeira semana de vida foram mais vulneráveis do que os animais 
sujeitos a priming durante a segunda semana, levando à atrofia e perda dos mesmos. 
Para além disso, o priming na primeira semana de vida levou a reduções ao nível das 
camadas neuronais do cerebelo (molecular, de Purkinje e granular), enquanto o 
priming na segunda semana induziu tanto a redução da camada granular como da 
substância branca. A expressão e atividade dos biomarcadores inflamatórios da 
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resposta com priming na primeira semana de vida mantiveram, na sua maioria, níveis 
abaixo dos observados na resposta aguda adulta, à exceção da sobreexpressão de 
ATX. Contrariamente, o priming durante a segunda semana de vida manteve níveis 
semelhantes aos da resposta aguda adulta, e com sobreexpressão tanto de ATX como 
de HMGB1. Por último avaliámos a proliferação de astrócitos e microglia. O priming na 
primeira semana induziu menor proliferação/migração de microglia relativamente à 
resposta adulta aguda, e com número de astrócitos semelhante. Curiosamente, o 
priming na segunda semana de vida resultou em números de microglia e astrócitos 
semelhantes à resposta aguda adulta, excetuando no hipocampo onde se verificou um 
decréscimo. Assim, este estudo mostra que os danos neuronais são mais marcados 
em jovens adultos com uma resposta inflamatória na primeira semana de vida (e sem 
estímulos subsequentes), enquanto as respostas da glia e da substância branca são 
mais notórias em jovens adultos com priming durante a segunda semana de vida. 
Esperamos que estudos futuros possam elucidar se a modulação dirigida à resposta 
inflamatória em ratinhos recém-nascidos, feita de modo diferente para a primeira ou 
segunda semana de vida, é capaz de prevenir as sequelas cerebrais da condição de 
sépsis neonatal no jovem adulto. 
No seu conjunto, estes resultados mostram que a sépsis e a icterícia neonatais 
comprometem a integridade endotelial levando à quebra da BBB, quer diretamente 
quer por efeitos indiretos provenientes de outras células do CNS. Nos vários estudos, 
os astrócitos revelaram ser particularmente sensíveis aos estímulos, e a microglia 
surgiu como um provável interveniente fundamental na regulação da resposta. Os 
danos a nível neuronal e da substância branca induzidos pelo LPS no período 
neonatal mantêm-se pelo menos até à idade de jovem adulto. De realçar que a 
resposta glial aquando de um segundo estímulo inflamatório na fase de jovem adulto 
difere consoante o priming tenha sido realizado durante a primeira ou a segunda 
semana de vida. Estes resultados contribuem para a clarificação dos mecanismos 
determinantes de acrescida vulnerabilidade pelo envelhecimento, dependente da fase 
de neurodesenvolvimento sujeita a sépsis, favorecendo o desenvolvimento de novas 
terapêuticas dirigidas aos alvos e determinantes envolvidos em cada uma das duas 
primeiras semanas de vida, que consigam prevenir ou diminuir as sequelas dela 
decorrentes. 
 
Palavras-chave: astrócitos; barreira hemato-encefálica; bilirrubina; células endoteliais 
da microvasculatura encefálica; inflamação sistémica neonatal; período neonatal; 
microglia; neurónios; mielinização; substância branca; unidade neurovascular. 
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1. Development of the Central Nervous System 
 
In the embryonic development, the central nervous system (CNS) derives originally 
from the neural plate. This is a thickened region of ectoderm germ cell layer, which 
later is transformed into the neural tube. In higher vertebrates such as mammalians, 
the plate is shaped and folded into neural folds that fuse in the midline, thus creating 
the neural tube. In mice, this process called primary neurulation occurs around 
embryonic day (E)8 and is completed at E9.5. The spinal neurulation ends the primary 
neurulation at E10. As for the human embryo, the folding of the neural plate begins 17–
18 days after fertilization and is completed at 26–28 days post-fertilization. In the 
second neurulation, the mesenchymal cells in the tail bud are condensed into an 
epithelial rod, creating a secondary neural tube continuous to the primary in the caudal 
sacral and coccygeal regions (Engelhardt and Liebner 2014; Greene and Copp 2009). 
During this period the primitive CNS is colonized by several progenitor cells that will 
originate the microvasculature, neurons and glia. 
 
1.1. Vessel formation, differentiation and maturation 
 
During vertebrate embryo development, the CNS vessel formation may occur by 
two different mechanisms: vasculogenesis and angiogenesis (Fig. 1.1). 
Vasculogenesis is the de novo formation of embryonic vascular network from 
angioblasts or stem cells with mesodermal/endodermal origin. On the other hand, 
angiogenesis is their subsequent expansion and remodeling via a 
mesodermal/ectodermal origin (Hellström et al. 2001). 
The ectoderm germ cell layer has no vascular progenitor cells, so the CNS 
vasculature begins via the process of vasculogenesis, around the time of the primary 
neurulation. Vascularization occurs between E9 and E10 in mouse (Bauer et al. 1993) 
and between E11 and 13 in rat (term is 19-22 days) (Stewart and Hayakawa 1994). In 
humans, this process happens between 10 and 13 gestational weeks (GW) (Virgintino 
et al. 2004). Mesenchymal cells differentiate into endothelial tubes that form a primitive 
blood vessel network, the perineural vascular plexus (PNVP), that covers the entire 
surface of the neural tube and from which new blood vessels develop (Daneman et al. 
2010; Engelhardt and Liebner 2014). These early vascular buds initially have large 
diameter, irregular shape (Bolz et al. 1996) as well as fenestrae (Stewart and 
Hayakawa 1994), though they later become smaller, thinner, regularly shaped and lose 
their fenestrae. 
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Figure 1.1 - Development of new vessels in rodent central nervous system. Around embryonic day 
(E)9/10 of murine neurodevelopment, the vascular endothelial growth factor (VEGF) induces differentiation 
and proliferation of endothelial cells from its progenitors (the angioblasts) to form a poorly differentiated 
perineural vascular plexus (vasculogenesis). Angiopoietin (Ang)-1 and -2 further induce the remodeling of 
the vascular plexus into a well-structured mature vascular system through endothelial cell sprouting and 
trimming (angiogenesis), which will later infiltrate the central nervous system. 
 
During angiogenesis, vessel growth might take place through endothelial growth, 
requiring migration of brain microvascular endothelial cells (BMEC) and tube formation 
(Ausprunk and Folkman 1977; Risau et al. 1986). Vascular sprouts invade the 
embryonic neuroectoderm towards a concentration gradient of vascular endothelial 
growth factor (VEGF)-A, which regulates vessel formation by inducing endothelial 
proliferation, migration, and tube formation (Greenberg and Jin 2005; Liebner et al. 
2011). Its receptors (VEGFR) are also involved in the directing of endothelial sprouting 
(Darland et al. 2011; Sentilhes et al. 2010). VEGFR-1 is usually associated with 
primary vascular plexus remodeling and subsequent angiogenesis, whereas VEGFR-2 
has been observed in re-inducted angiogenesis, as in pathological conditions, and its 
inhibition significantly reduces endothelial proliferation (Soares et al. 2013). 
Following formation, vessels are stabilized by angiopoietins (Ang) which are 
specific to the endothelial receptor tyrosine kinase (Tie)-2, and mediate reciprocal 
interactions between the endothelium and surrounding matrix (Fagiani and Christofori 
2013; Liebner et al. 2011). At this stage, Ang-1 and Ang-2 are the two main elements 
of this family. Ang-1 is mainly produced by mural cells, including pericytes. It mediates 
vessel maturation by mediating migration, adhesion and survival of endothelial cells 
(Hellström et al. 2001; Jain 2003; Olsen et al. 2006). It also stabilizes the vessels 
through the recruitment of mural cells, and makes vessels leak-resistant by VEGF 
induction (Jain 2003; Thurston et al. 2000). Regarding Ang-2, this molecule is 
produced by BMEC and it competitively inhibits the binding of Ang-1. Therefore, Ang-2 
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destabilizes the endothelium and is restricted to areas of vascular remodeling (Jain 
2003). Ang-2 has also been shown to antagonize angiogenesis induced by VEGF (Ley 
et al. 2004). 
During angiogenesis BMEC have high paracellular permeability (Liebner et al. 
2011), thus these cells acquire several specific properties during the differentiation 
phase that provides them barrier properties, as early as E12 in mice (Daneman et al. 
2010). This is the case of the intercellular junctions’ proteins that tightly connect 
neighboring BMEC, the tight junctions (TJ), which we will further discuss in this 
introduction. These proteins observed at E12 in mice (Bauer et al. 1993) are observed 
in humans at 10 GW (Møllgård and Saunders 1986), appearing  adult-like by 18 GW 
(Virgintino et al. 2004). As it will also be discussed later in this introduction, BMEC have 
specific transporters that endow them the ability to control the passage of molecules to 
and from the brain. Also at murine E12 it is observed the expression of the glucose 
transporter (GLUT)1 (Daneman et al. 2010). The efflux ATP-binding cassette (ABC) 
transporters are expressed at low levels during embryogenesis but increase during 
human gestational development, matching the adult brain at the time of term birth 
(Daood et al. 2008). 
In the weeks that follow, the vessels’ maturation takes place with the recruitment of 
pericytes and astrocytes for a closer contact (Liebner et al. 2011), in addition to the 
synthesis of the basement membrane. Studies have shown that pericytes contribute to 
the formation of TJ by inhibiting the expression of molecules that increase vascular 
permeability and immune cell infiltration (Daneman et al. 2010). They are recruited to 
the nascent vessels at very initial stages of development, originating from the local and 
distal mesenchyme (Sartore et al. 2001), as well as from common BMEC progenitors. 
The embryonic stem cells will differentiate into BMEC or to vascular smooth muscle 
cells depending on the stimulation by VEGF or by platelet derived growth factor 
(PDGF)-β, respectively (Yamashita et al. 2000). Pericytes proliferate and migrate 
during vascular maturation (Hellström et al. 2001), being associated with endothelial 
tubes as nascent vessels are generated (Daneman et al. 2010; Tallquist et al. 2003). 
Both BMEC and pericytes promote vessel maturation by producing extracellular 
matrix (ECM) molecules and facilitating the assembly of the matrix (Chambers et al. 
2003; Jain 2003). Indeed, as angiogenesis stops, pericytes synthesize components of 
the ECM, such as proteoglycans, collagen, and elastin. The ECM is initially formed at 
the parenchymal side of pericytes, though it progressively surrounds the pericyte 
during the development of the basement membrane (Sá-Pereira et al. 2012). The 
formation of a basement membrane around capillaries is observed as early as E14 in 
rat cortex and 8 GW in human foetuses, becoming denser and wider in the postnatal 
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brain (Roediger et al. 2010). The intact basement membrane stabilizes the newly 
formed vessels and affects the vascular branching pattern (Jain 2003; Sá-Pereira et al. 
2012). It will not be before 2–3 weeks of age (in rodents) that this process is halted and 
the cortex becomes well vascularized and mature (Saunders et al. 2012). 
 
1.2. From precursor cells to neurons and glia 
 
Soon after the beginning of vasculogenesis, the neural precursor cells (NPC) begin 
to differentiate into neurons and glia (Fig. 1.2). It is their “neuron-to-glia switch” that 
determines how many neurons or glial cells are formed per brain region (Daneman et 
al. 2010; Freeman 2010). This process is regulated by transcription factors that 
determine cell fates and specify subtype identities. Neuronal differentiation of cortical 
NPC takes place following the activation of the pro-neural genes neurogenins (Yuan 
and Hassan 2014). Murine neurogenesis is initially promoted, starting at E11, being 
followed by the proliferation of astrocytes and oligodendrocyte precursor cells (OPC) 
around E17 (Hirabayashi et al. 2009; Namihira et al. 2009). 
 
 
 
Figure 1.2 - Timeline of rodent neural precursor cell differentiation. Following neurulation, neural 
precursor cells (NPC) go through the process of neurogenesis in order to originate neurons. Later, due to 
the expression of different factors, NPC undergo astrogenesis forming immature astrocytes that will only 
fully mature and ensheath the microvessels after birth. Simultaneous to the developing of astrocytes, there 
is proliferation of oligodendrocyte precursor cells (OPC) that will mature into myelinating oligodendrocytes. 
Myelination occurs from the postnatal and throughout adulthood. 
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In the human CNS, there is evidence of contacts between the developing 
astrocytes and blood vessels as early as 15 GW (Marin-Padilla 1995). However, CNS 
astrogenesis in rodent occurs directly after birth being induced by cytokines secreted 
from newborn neurons that promote the expression of glial fibrillary acidic protein 
(GFAP) in glial precursors (Molofsky et al. 2012). The association of astrocytes with 
blood vessels is most significant during the first postnatal week, around postnatal day 
(PND)5 (Daneman et al. 2010; Molofsky et al. 2012; Ullian et al. 2001). Around PND7, 
their cellular processes are mostly filopodial (i.e., actively growing) and overlap, being 
trimmed only at the end of the second week of life. By the end of the third week, 
astrocytic processes ramify while the distal ones become thinner and densely infiltrate 
the brain tissue, thus turning these cells into a mature appearance (Bushong et al. 
2003; Bushong et al. 2004; Freeman 2010). 
As for OPC, these are generated during embryogenesis and even in early 
postnatal life (Miron et al. 2011). They migrate from their sites of origins to colonize the 
grey matter and the future white matter tracts as early as at murine E19 (Daneman et 
al. 2010; Miyamoto et al. 2014). OPC that are NG2+ cells differentiate into mature 
myelin-forming oligodendrocytes (Wigley et al. 2007). Initial events in myelination are 
stimulated by electrical activity in axons, suggesting that electrically active axons will be 
preferentially myelinated (Wake et al. 2011). Release of glutamate from synaptic 
vesicles stimulates the development of cholesterol-rich signaling domains between 
oligodendrocytes and axons, locally increasing the synthesis of myelin basic protein 
(MBP), the major protein in the myelin sheath. Astoundingly, a single multipolar 
oligodendrocyte can interact with up to 40 segments on multiple axons (Simons and 
Trotter 2007; Wake et al. 2011), thus deviations from their normal development may 
induce lasting neuronal damages.   
 
1.3. The “unclosed” origin of microglia 
 
The true origin of microglia has long been discussed, with derivative hypothesis 
ranging from (1) the outermost connective tissue of the vessels (the vascular 
adventitia), (2) to the neuroectoderm as oligodendrocytes and astrocytes, (3) to an 
intrinsic population of hematopoietic stem cells in the CNS, (4) to deriving from 
circulating monocytes, or even (5) from the peripheral mesodermal/mesenchymal 
tissues (Chan et al. 2007). 
The origin of microglia from monocytes was for years the most accepted 
hypothesis given that these cells can cross the blood-brain barrier (BBB) into the 
parenchyma and differentiate into macrophages that are microglia-like. In fact, 
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macrophages and microglia are quite similar in terms of shared surface markers, 
receptors, activated phenotypes, turning their molecular distinction into a difficult task 
(Perego et al. 2013; Vainchtein et al. 2014; Varnum and Ikezu 2012). Nonetheless, 
microglia exist in normal brain as a stable population which can renew itself 
(Kettenmann et al. 2011). In addition, a recent study proposes that resident microglia 
are positive for both the ionized calcium-binding adapter molecule (Iba)1 and the 
fractalkine (CX3CL1) receptor (CX3CR1), whereas Iba1+CX3CR1- myeloid cells are 
most likely of peripheral monocyte/macrophage origin (Le Blon et al. 2014). 
Furthermore, adult microglia express the markers cluster or differentiation (CD)68 and 
CD204 associated with monocytes and macrophages, but developing microglia do not 
(Rezaie et al. 2002).  
The migration of microglial progenitor cells from the mesodermal/mesenchymal 
tissues into the CNS is unanimously accepted nowadays (Kettenmann et al. 2011; 
Nayak et al. 2014) (Fig. 1.3). Most experiments point to the origin of these primitive 
precursors in the yolk sac, and that their proliferation and differentiation is dependent 
on several transcription factors and growth factor receptors (Saijo and Glass 2011). In 
mouse development microglia progenitors migrate from the embryonic yolk sac prior to 
E8.5, surrounding the neuroepithelium around E9.5. One day later they enter the 
developing brain via the circulatory system (Nayak et al. 2014). In the human brain, 
microglia colonization coincides not only with vascularization but also with radial glia 
formation, neuronal migration, and myelination. When colonizing the brain, microglia 
have an amoeboid morphology rather than the ramified seen in the adult resting cells. 
In fact, they only become completely ramified in rodents by PND28. In humans, 
however, ramified microglia are observed in the cortex up to 35 GW (Harry and Kraft 
2012; Nayak et al. 2014). 
Interestingly, recent studies might resurface the hypothesis of a neuroectoderm 
origin like oligodendrocytes and astrocytes. It has been shown that after depletion of 
microglia, the CNS completely repopulates with new microglia through the proliferation 
of NPC cells that differentiate into microglia (Elmore et al. 2014b). Thus, the true origin 
of microglia continues to be an open chapter in the development of the CNS. 
 
2. Blood-Brain Barrier and the Neurovascular Unit 
 
In 1885, Paul Ehrlich experimentally demonstrated that vital dyes injected into the 
circulatory system stain all organs of the mammalian body except the brain and spinal 
cord and attributed this observation to a low affinity of nervous tissue to the dye 
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(Ehrlich 1885; Ehrlich 1906). About 30 years later, an Ehrlich's student, Edwin 
Goldmann, noticed the opposite phenomenon by injecting trypan blue directly into the 
cerebro-spinal fluid (CSF), which stained all CNS and none of the peripheral organs 
(Goldmann 1913), suggesting the presence of a barrier between the CNS and the 
circulation. The term bluthirnschranke (german for blood–brain barrier), was first used 
by Lewandowsky (Lewandowsky 1900) while studying the limited permeation of 
potassium ferrocyanate into the brain. Further studies showed that endothelial tight 
junctional complexes physically limit solute exchanges between the blood and the 
brain. This was achieved by injecting horseradish peroxidase intravascularly, showing 
diffusion between endothelial cells lining skeletal and cardiac vessels, though it did not 
pass between BMEC in cerebral microvasculature (Reese and Karnovsky 1967). 
 
 
Figure 1.3 - Timeline of microglia development in rodents. Microglia precursors migrate from the 
embryonic yolk sac to colonize the central nervous system (CNS) early in development. These cells will 
proliferate throughout the CNS during the remaining embryonic development. Their maturation will only 
occur in the postnatal period, acquiring a fully ramified phenotype by postnatal day 28. 
 
 
Major BBB functions include: (1) maintenance of CNS homeostasis, (2) protection 
of brain from extracellular environment, (3) constant supply of nutrients by specific 
transport systems and (4) direct inflammatory cells to act in response to changes in 
local environment (Lee et al. 2006; Persidsky et al. 2006; Petty and Lo 2002). 
Maintenance of homeostasis is achieved through the regulation of ion balance 
(Hawkins and Davis 2005; Persidsky et al. 2006; Wolburg and Lippoldt 2002)  and of 
compounds influx/efflux (Chaudhuri 2000; Khan 2005). This is essential in protection 
against harmful substances, variations in blood composition and breakdown of 
concentration gradients (Kniesel and Wolburg 2000; Petty and Lo 2002; Wolburg and 
Lippoldt 2002). The BBB is present in all brain regions, except in those regulating 
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autonomic nervous system and endocrine glands of the body, where blood vessels 
permit diffusion of molecules across the vessel wall (Ballabh et al. 2004).  
 
2.1. Components of the neurovascular unit 
 
In the developing brain, capillaries are differentiated and matured into the BBB 
(Lee et al. 2006). Only capillary vessels have complete BBB properties, since leakiness 
increases as the vessel diameter increases (Hawkins and Davis 2005; Marchi et al. 
2004). Although BBB permeability itself is controlled by the biochemical properties of 
BMEC (Pardridge 1999), brain microvascular biology results overall from interactions of 
these cells with the basement membrane and neighboring glial cells (Kaur and Ling 
2008), such as microglia and astrocytes, as well as neurons and perivascular pericytes 
(Wolburg and Lippoldt 2002; Zlokovic 2008; Zozulya et al. 2008). Altogether these 
constitute the neurovascular unit (NVU) (Fig. 1.4) (Choi and Kim 2008; Persidsky et al. 
2006), essential for both health and function of the CNS (Hawkins and Davis 2005). 
 
 
Figure 1.4 - Schematic overview of the neurovascular unit (NVU). NVU is composed of endothelial 
cells, basement membrane, astrocytes and microglia, neurons and pericytes. From (Cardoso et al. 2010). 
 
 
2.1.1. Basement membrane: wrapping the vessels 
The basement membrane is an essential part of the BBB. It surrounds BMEC and 
engulfs pericytes, anchoring the cells in place and establishing the connection with the 
surrounding brain resident cells (Carvey et al. 2009). BMEC, pericytes and astrocytes 
all cooperate to generate and maintain the basement membrane that is constituted by 
3 apposed laminas, composed of different ECM classes of molecules (Persidsky et al. 
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2006; Weiss et al. 2009). These are structural proteins (collagen and elastin), 
specialized proteins (fibronectin and laminin) and proteoglycans (Adibhatla and 
Hatcher 2008; Wolburg et al. 2009). The basement membrane also includes matrix 
adhesion receptors, known as cell adhesion molecules (CAM), as well as signaling 
proteins, which form an extensive and complex matrix (Carvey et al. 2009). These 
molecules are expressed in the vascular cells, neurons and supporting glial cells and 
are essential for maintenance of the BBB. Disruption of the basement membrane can 
lead to alterations in the cytoskeleton of BMEC, which in turn affects TJ proteins and 
barrier integrity. Matrix metalloproteinases (MMP) are known to digest the basement 
membrane, which leads to reduced anchoring of BMEC and matrix–BMEC signaling 
(Carvey et al. 2009). Accordingly, disruption of ECM has been strongly associated with 
increased BBB permeability in several pathological conditions (Carvey et al. 2009; 
Hawkins and Davis 2005; Zlokovic 2008). 
 
2.1.2. Neurons in the neurovascular unit 
Little is known about the developmental role that neurons have on the BBB 
phenotype. However, there is some evidence that neurons can regulate the function of 
blood vessels in response to metabolic requirements by inducing expression of 
enzymes unique for BMEC (Persidsky et al. 2006). Also, BMEC and astrocytic 
processes are directly innervated by noradrenergic, serotonergic, cholinergic, and 
GABA-ergic neurons, among others (Hawkins and Davis 2005). Moreover, mature 
endothelium has a reciprocal function in inducing a stable brain microenvironment that 
enables proper neuronal activity (Choi and Kim 2008). 
 
2.1.3. Microglia, patrollers of the central nervous system 
Microglia play a very important role in immune responses of the CNS, surveying 
local microenvironment and changing the phenotype in response to homeostatic 
disturbance of the CNS. In fact, these cells present themselves in two forms: resting 
and activated microglia. When resting, cells have small bodies and long, thin 
processes; in contrast, activated microglia assume a phagocytic morphology by shifting 
from long to short processes (Zlokovic 2008). In accordance with the macrophage 
population in other organs, these cells have diverse effector functions (Ransohoff and 
Perry 2009). As microglia are found in perivascular space, it is thought that their 
interactions with BMEC may contribute to the BBB properties (Choi and Kim 2008). 
Still, the exact mechanisms on how this occurs remain unknown. 
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2.1.4. Pericytes in barrier integrity  
Pericytes (also known as vascular smooth muscle cells, mural cells, or 
myofibroblasts) are important cellular constituents of the capillaries and post-capillary 
venules (Dore-Duffy 2008), having a close physical association with the endothelium. 
They share the same basement membrane with BMEC (Bagley et al. 2005) and cover 
22 to 32% of the capillaries (Kim et al. 2006). The location of pericytes on the 
microvessel and the degree of coverage varies considerably between different 
microvessel types (Allt and Lawrenson 2001), seeming to correlate with the degree of 
tightness of the interendothelial junctions (Lai and Kuo 2005). The vascular pericyte 
synthesizes most elements of the basement membrane including a number of 
proteoglycans. In addition, pericyte synthesis and release of laminal proteins is thought 
to be a critical step in the differentiation of the BBB (Dore-Duffy et al. 2006). 
Proper association of pericytes with microvascular endothelia is essential to 
maintain structural support and junctional integrity (Braun et al. 2007; Lai and Kuo 
2005). Pericytes and BMEC communicate with each other through several apparatuses 
such as gap junctions, TJ, adhesion plaques (Allt and Lawrenson 2001) and soluble 
factors (Bagley et al. 2005). 
The association of pericytes to blood vessels has been suggested to regulate 
BMEC proliferation, migration and differentiation (Persidsky et al. 2006). There is also 
evidence that pericytes can induce and up-regulate P-glycoprotein (P-gp) functional 
activity in these cells (Dohgu et al. 2005). Furthermore, interactions between pericytes 
and BMEC are important for the remodeling and maintenance of the vascular system 
via the secretion of growth factors or modulation of the extracellular matrix. There is 
evidence that pericytes are involved in the transport across the BBB as well (Allt and 
Lawrenson 2001). Pericytes make regulatory adjustments in response to stress stimuli, 
as during severe and prolonged O2 deprivation (Al Ahmad et al. 2009). 
Pericytes show rich contents of α-smooth muscle actin, which is a characteristic of 
the vascular smooth muscle cell, suggesting a contractile ability of pericytes both in 
vitro (Kelley et al. 1987; Shepro and Morel 1993) and in vivo (Peppiatt et al. 2006). The 
physical contacts of pericytes' cellular processes over interendothelial junctions, 
coupled with the α-smooth muscle actin contents, point to a functional role of pericytes 
in controlling blood flow (Peppiatt et al. 2006), as well as in regulating junctional 
permeability (Edelman et al. 2006). Pericytes have been shown to migrate away from 
brain microvessels in rapid response to hypoxia and traumatic brain injury. Therefore, 
both of these conditions are associated with increased BBB permeability (Hawkins and 
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Davis 2005). The disruption of BBB caused by the detachment of pericytes reinforces 
the idea of pericytes' role in junctional permeability (Nishioku et al. 2009). 
 
2.1.5. Astrocytes as inductors of barrier properties 
Astrocytes are glial cells whose endfeet form a lacework of fine lamellae closely 
apposed to the outer surface of the BBB endothelium and respective basement 
membrane (Abbott 2002). They play a major role in promoting proteoglycan synthesis 
with a resultant increase in BMEC charge selectivity and playing an important role in 
the induction of BBB functions (Bernoud et al. 1998; Yamagata et al. 1997). Astrocytes 
are also important for proper neuronal function, and the close proximity of neuronal cell 
bodies to brain capillaries suggests that interactions between all these elements are 
essential for a functional NVU (Persidsky et al. 2006). 
In some areas of the CNS the microvessels lack astrocytic ensheathment but still 
exhibit some BBB features, which are likely due to soluble factors acting from the glia 
limitans or the subarachnoid CSF (Abbott 2002). Subsequent studies also showed loss 
and restoration of barrier integrity in vivo following a temporary focal loss of astrocytes 
(Persidsky et al. 2006; Willis et al. 2004). Attempts to recover BBB properties in BMEC 
cultures have included co-culturing BMEC with astrocytes and/or astrocyte-conditioned 
medium (Colgan et al. 2008). Astrocytes may therefore modulate the BBB phenotype 
without being directly involved in the physical BBB properties. Studies using non-
contact co-cultivation with astrocytes revealed that the secretion of factors into the 
medium contribute to the barrier properties of human BMEC (HBMEC) by up-regulating 
the tight junctional proteins zonula occludens (ZO)-1 and occludin, and reducing the 
transendothelial permeability across the HBMEC (Colgan et al. 2008; Siddharthan et al. 
2007). Interestingly, astrocytes are also able to endow non-neural endothelial cells with 
BBB properties (Hayashi et al. 1997), whereas enteric glia, which share morphological, 
biochemical, and functional properties with astrocytes, accelerates the formation of the 
characteristics of the BBB in spinal cord capillaries (Jiang et al. 2005). 
 
2.1.6. Endothelial cells 
BMEC were demonstrated to play a key role in BBB properties as it was observed 
that horseradish peroxidase could not pass the endothelial layer from either direction, 
and that brain capillaries from amphibians have high electric impedance, indicative of 
restriction to the movement of ions, despite the absence of surrounding astrocytes 
(Hawkins et al. 2006). It is now accepted that the cerebral endothelium forms the 
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anatomic basis of the BBB in higher animals (Hawkins et al. 2006) and that the 
capillaries make up the primary part of the BBB (Khan 2005).  
BMEC interact intimately with other brain cells of the NVU, and hence can act as 
mediators between blood and brain (Calabria and Shusta 2008). They regulate the 
selective transport and metabolism of substances from blood to brain as well as in the 
opposite direction from the parenchyma back to the systemic circulation (Zheng et al. 
2003). The BMEC barrier line is the most critical for preventing toxic substances from 
entering the brain (Ueno 2007). Communication between BMEC and other surrounding 
cells enhances the barrier functions consequently resulting in maintenance and 
elaboration of proper brain homeostasis (Choi and Kim 2008). 
The BMEC lining the cerebral capillaries differs fundamentally from other vascular 
endothelia in their capacity to regulate the passage of molecules and cells to and from 
the neural parenchyma (Ge et al. 2005; Weksler et al. 2005). The capillary endothelium 
in the brain is 50-100 times tighter than peripheral microvessels as a result of special 
properties that cause severe restriction of the paracellular pathway for diffusion of 
hydrophilic solutes (Abbott 2002). BMEC cytoplasm has uniform thickness with no 
fenestrae, low pinocytotic activity and a continuous basement membrane (Chaudhuri 
2000; de Boer and Gaillard 2006). In addition, BMEC have a negative surface charge 
that repulses negatively charged compounds (de Boer and Gaillard 2006). They have a 
greater number and volume of mitochondria compared with endothelium in other 
organs. These characteristics enhance the energy potential (Persidsky et al. 2006), 
providing energy for enzymes to break down compounds and allowing various selective 
transport systems to actively transport nutrients and other compounds into and out of 
the brain (de Boer and Gaillard 2006). 
BMEC are tethered to the basement membrane through focal adhesions, which 
consist mainly of transmembrane proteins (Kumar et al. 2009) that also participate in 
intercellular adhesion (Wolburg et al. 2009). The transmembrane proteins have been 
classified into three families of CAM according to their structure: selectins, 
immunoglobulin superfamily, and integrins (Lee and Benveniste 1999). In BMEC, 
integrins play an important role during angiogenesis and in the maintenance of 
vascular integrity (Wolburg et al. 2009). They function as adhesion receptors, in 
addition to transmitting chemical signals and mechanical forces between the ECM and 
the cytoskeleton (Yuan 2002). As in other cell types, the three primary elements of the 
cytoskeleton are actin filaments, intermediate filaments and microtubules. Actin 
filaments are composed of globular monomers of G-actin, which polymerize to form 
helical and asymmetrical filaments of F-actin that form contractile bundles and 
filamentous networks, essential for the maintenance of cell shape and integrity 
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(Kierszenbaum 2007). At the BMEC, bands of F-actin are anchored to proteins 
involved in the adhesion to ECM (Kierszenbaum 2007) and linked to membrane and 
cytosolic proteins involved in intercellular junctions to form a structure denoted as the 
actin-rich adhesion belt (Stamatovic et al. 2008), sometimes also referred to as 
perijunctional actin (Terry et al. 2010). 
 
Intercellular junctions 
BMEC lining the vascular wall have narrow junctional complexes that eliminate 
gaps or spaces between cells and prevent any free diffusion of blood-borne substances 
into the brain parenchymal space (Weiss et al. 2009; Zlokovic 2008). In fact, the 
cerebral microvasculature lining is characterized by the presence of an elaborated 
junctional complex that includes mainly TJ and adherens junction (AJ) proteins 
(Hawkins and Davis 2005) (Fig. 1.5). 
 
Tight Junctions 
TJ are the main structures responsible for the barrier properties. These are 
elaborate structures located on the apical region of BMEC. They function both as a 
seal that regulates lateral diffusion between the apical and basolateral plasma 
membrane domains, which enables asymmetric distribution of membrane constituents, 
and as a limit to paracellular permeability (Ge et al. 2005; Hawkins et al. 2005; Hawkins 
et al. 2006; Persidsky et al. 2006). Studies using TJ from different tissues with varying 
transendothelial and transepithelial electrical resistances (TEER) figured out a 
correlation between increased organization of cytoplasmic fibrils and decreased 
membrane permeability (Huber et al. 2001). The BBB TJ should not be regarded as 
isolated barrier molecules, but as highly dynamic structures that are under the close 
regulation of the brain microenvironment (Wolburg et al. 2009). 
Another role for TJ as dynamic heteromeric signaling complexes has been 
unraveled, involving the control of gene expression, cell proliferation and differentiation 
(Gonzalez-Mariscal et al. 2009). The signaling at TJ is bi-directional, so that signals are 
transmitted from the cell interior to forming or existing TJ to regulate its assembly and 
function, whereas TJ coordinately receive and transmit information back to the cell 
interior to regulate gene expression and subsequent cellular responses (Terry et al. 
2010). 
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Figure 1.5 - Endothelial cells at the blood–brain barrier present an elaborated junctional complex 
formed by tight junctions and adherens junctions. A, Tight junctions are located on the apical region of 
endothelial cells and form an intricate complex of parallel, interconnected, transmembrane and 
cytoplasmatic strands of proteins arranged as a series of multiple barriers. B, Adherens junctions are 
located below the tight junctions and are composed of transmembrane glycoproteins linked to the 
cytoskeleton by cytoplasmatic proteins, giving place to the adhesion belt. From (Cardoso et al. 2010). 
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The BBB TJ of mammalian species is characterized first of all by the highest 
complexity in the vasculature of the body (Kniesel and Wolburg 2000). Structurally, TJ 
form an intricate complex of parallel, interconnected, transmembrane and 
cytoplasmatic strands of proteins arranged as a series of multiple barriers (Wolburg 
and Lippoldt 2002). The transmembrane proteins are integral membrane proteins that 
interact with those of neighboring plasma membrane and form the TJ barrier (Petty and 
Lo 2002). The cytoplasmic TJ accessory proteins are involved in the connection of 
integral TJ to the actin cytoskeleton (Lee et al. 2004; Persidsky et al. 2006; Petty and 
Lo 2002; Weiss et al. 2009). 
 
Claudins 
The claudins are a family of transmembrane TJ proteins that seem to fulfill the task 
of establishing barrier properties (Ueno 2007; Zlokovic 2008). These proteins are 
integral membrane proteins that form dimers and bind homotypically to other claudin 
molecules in adjacent BMEC (Huber et al. 2001; Petty and Lo 2002) and are believed 
to be responsible for permeability restriction (Tsukita et al. 2001). Although 
overexpression of claudins can induce cell aggregation and formation of TJ-like 
structures (Yamamoto et al. 2008), occludin expression does not result in the TJ 
formation. Thus, it appears that claudins form the primary seal of the TJ, and occludin 
acts as an additional support structure (Persidsky et al. 2006).  
The claudins are not randomly distributed throughout the organs, appearing to be 
expressed in a tissue-specific manner. Claudin-1 and claudin-5 are associated with 
maintenance of normal BBB function (Vorbrodt and Dobrogowska 2003) and are 
important in angiogenesis and in disease processes with increased vessel permeability 
(Wolburg and Lippoldt 2002). In line with the role of claudin-5 in permeability, claudin-5 
knockout mice are characterized by a size-selective BBB defect (Nitta et al. 2003), 
whereas down-regulation of claudin-5 expression correlates with breakdown of the 
BBB (Argaw et al. 2009). Lately, new functions of claudin family proteins in response to 
cellular stress (Romanitan et al. 2010), as well as in the regulation of embryonic 
morphogenesis (Gupta and Ryan 2010) were suggested. 
 
Occludin 
The transmembrane occludin is highly expressed and consistently stains in a 
continuous pattern along the cell margins in the cerebral endothelium, whereas it is 
much more sparsely distributed in non-neural endothelium (Hawkins and Davis 2005). 
It has been shown that high levels of occludin ensure decreased paracellular 
permeability (Huber et al. 2001) and high TEER of the BMEC monolayers (Persidsky et 
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al. 2006), having therefore an active role in BBB function (Yamamoto et al. 2008). 
However, it must be seen more in a regulatory context than as a major structural 
protein in the establishment of the barrier properties (Wolburg and Lippoldt 2002). 
Results of several knockout and knockdown experiments indicate that occludin is not 
essential for the formation of TJ (Hawkins and Davis 2005) and that normal expression 
and localization of other junctional proteins compensate for occludin loss (Zlokovic 
2008). The cytoplasmic C-terminal domain provides the connection of occludin with the 
cytoskeleton via accessory proteins (Shimizu et al., 2008). 
 
Junctional adhesion molecules 
The JAM family consists of JAM-1, JAM-2, and JAM-3. These transmembrane 
proteins mediates homophilic and probably also heterophilic interactions in the TJ 
(Stamatovic et al. 2008; Vorbrodt and Dobrogowska 2003; Wolburg and Lippoldt 2002). 
A tissue-specific distribution of JAM was observed, reflecting the involvement of these 
proteins in different interendothelial junctions. In fact, JAM-1 is predominantly 
expressed in brain (Aurrand-Lions et al. 2001; Bernacki et al. 2008), accounting for the 
network of TJ strands unique to the brain vascular system, whereas JAM-2 is highly 
expressed in lymphatic endothelial cells, and JAM-3 is found in most endothelial 
contacts ranging from brain vasculature to high endothelium venules (Aurrand-Lions et 
al. 2001). Interestingly, JAM are also expressed in circulating monocytes, neutrophils, 
lymphocyte subsets, and platelets, as well as in dendritic cells (Ogasawara et al. 2009; 
Ueno 2007). JAM-1 is involved in cell-to-cell adhesion, organizing the tight junctional 
structure, and taking part in the formation of TJ together with occludin and claudins 
(Vorbrodt and Dobrogowska 2003). JAM also play a role in developmental processes 
and regulate the transendothelial migration of leukocytes (Persidsky et al. 2006; 
Stamatovic et al. 2008). Although the functions of JAM are still largely unknown in 
mature BBB, it has been suggested that altered expression of JAM-1, in addition to 
affecting the junctional tightness, may also disturb leukocyte trafficking, with 
implications for immune status within the diseased CNS (Zlokovic 2008). 
 
Cytoplasmatic proteins 
Submembrane TJ-associated proteins such as ZO proteins (ZO-1, ZO-2 and ZO-3) 
serve as recognition proteins for TJ placement and as a support structure for signal 
transduction proteins (Huber et al. 2001). ZO-1 is mostly expressed in endothelial and 
epithelial cells that normally form the TJ assembly (Kniesel and Wolburg 2000; 
Persidsky et al. 2006). Though it is also expressed in other cell types that do not form 
TJ, there is no TJ without ZO-1. ZO-1 molecules are located in the cytoplasmic side of 
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the BMEC plasma membranes delimiting the interendothelial cleft (Vorbrodt and 
Dobrogowska 2003) and connecting transmembranous TJ proteins with the actin 
cytoskeleton. Loss or dissociation of ZO-1 from the junctional complexes is associated 
with increased barrier permeability (Choi and Kim 2008). ZO-2 has significant 
homology to ZO-1 and it was thought to be restricted exclusively to the TJ region 
(Kniesel and Wolburg 2000), however, it has also been found in non-TJ containing 
tissues. ZO-2 is not only an extremely important structural protein, but also a nuclear 
factor influencing gene expression (Wolburg et al. 2009) and blocking cell cycle 
progression (Gonzalez-Mariscal et al. 2009). ZO-3 binds occludin and ZO-1 directly, 
but not ZO-2 (Kniesel and Wolburg 2000). The complex formed by ZO proteins is 
considered to be involved in cadherin-based cell adhesion through their binding to α-
catenin and to actin filaments. In adverse conditions, as chemical stress or mechanical 
injury, ZO-1 and ZO-2 concentrate at the nucleus and associate with proteins involved 
in the regulation of gene transcription and cell proliferation (Gonzalez-Mariscal et al. 
2009). 
Other cytoplasmic proteins are cingulin, AF-6 and 7H6. Phosphoprotein cingulin is 
located at the cytoplasmatic side of TJ as well. It connects to ZO and JAM proteins, 
AF-6 and myosin, implying a role as a scaffold between transmembrane proteins and 
the cytoskeleton (Cordenonsi et al. 1999; Sandoval and Witt 2008). There are studies 
that also imply a role of cingulin in regulation of TJ permeability (Cordenonsi et al. 
1999). 7H6 phosphoprotein seems to be correlated with TJ impermeability to ions and 
large molecules. There is evidence that this protein may detach from TJ when ATP 
levels decrease, resulting in increased paracellular permeability (Bernacki et al. 2008; 
Mitic and Anderson 1998). 
 
Adherens Junctions 
Below the TJ, in the basal region of lateral plasma membrane there are AJ that 
give place to a continuous belt – the adhesion belt (Petty and Lo 2002). AJ mediate the 
adhesion of BMEC to each other, the contact inhibition during vascular growth and 
remodeling, the initiation of cell polarity, and the regulation of paracellular permeability 
(Hawkins and Davis 2005), in addition to contributing to the barrier function (Carvey et 
al. 2009). Cell–cell adhesion through actin filaments linking (Cook et al. 2008) involves 
VE-cadherin and catenins, constituents of AJ (Perrière et al. 2007). The cadherin family 
and their intracellularly associated catenin proteins form complexes of central 
importance to the sorting and morphogenic processes of developing animal tissues and 
in maintaining the integrity and identity of adult tissues (Tao et al. 1996). 
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Cadherins 
Ca2+-dependent cell–cell adhesion is dependent on a family of transmembrane 
glycoproteins named cadherins (Navarro et al. 1998), which present a certain degree of 
cell type specificity. VE-cadherin, also known as cadherin-5, is an integral membrane 
glycoprotein expressed exclusively in cells of vascular epithelial origin, whereas neural 
(N)-cadherin is expressed in cells of the nervous tissue, vascular smooth muscle cells, 
and myocytes (Navarro et al. 1998). VE-cadherin is an important determinant of 
microvascular integrity both in vitro and in vivo (Vorbrodt and Dobrogowska 2003). It 
clusters at cell junctions and mediates cell adhesion, inhibits cell proliferation, and 
decreases cell permeability and migration when overexpressed in various cell types 
(Cook et al. 2008). All cadherins contain a plasma membrane-spanning domain and a 
cytoplasmic domain associated with catenins, other molecular components of the 
junctional complex (Vorbrodt and Dobrogowska 2003). VE-cadherin's expression at cell 
junctions, however, is independent of β-catenin binding, which appears to be required 
only for junction stabilization (Cook et al. 2008). 
 
Catenins 
Catenins were first characterized as linking the cytoplasmic domains of cadherin 
cell–cell adhesion molecules to the cortical actin cytoskeleton. Catenins' major role is to 
anchor the cadherin complex to the actin cytoskeleton but they also participate in cell 
and developmental signaling pathways (Stamatovic et al. 2008). There are four types 
of catenin proteins: α-, β-, δ- and γ-catenin. α- and β-catenin are located in 
interendothelial junctions of BBB-type brain capillaries and their expression is required 
for cadherins to work as adhesion molecules (Vorbrodt et al. 2008). β-catenin is 
essential in BMEC for normal vascular patterning. It is a structural protein that 
participates in cell–cell adhesion and is also involved in the Wingless signaling pathway 
and in gene expression (Cook et al. 2008; Vorbrodt et al. 2008), serving as a mediator 
in regulation of P-gp and other multidrug efflux transporters in brain vasculature (Lim et 
al. 2008). In addition, β-catenin is linked to the cell membrane in a complex with VE-
cadherin and platelet–endothelial cell adhesion molecule (PECAM-1 or CD31). This 
adhesion molecule mediates homophilic adhesion (Wolburg et al. 2009). Upon 
stimulation with growth factors this membrane associated complex is dissociated, 
releasing another source of β-catenin for movement to the nucleus and transcription 
(Petty and Lo 2002). It is possible that the up-regulation of β-catenin accounts for the 
maintenance of TJ protein assembly and barrier function (Vorbrodt et al. 2008). δ-
catenin has been implicated as a regulator of the NF-κB transcription factor (Perez-
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Moreno et al. 2006), while γ-catenin is closely related to β-catenin and can substitute it 
in the cadherin–catenin complex (Vorbrodt and Dobrogowska 2003). 
 
Main pathways across the Blood-Brain Barrier 
The BBB is more than an impermeable wall. BMEC have a unique pattern of 
receptors and specific transport systems that facilitate the uptake of important nutrients 
and hormones, in addition to active pumps that help to regulate the concentrations of 
ions, metabolites and xenobiotics in the brain (Weksler et al. 2005; Zheng et al. 2003; 
Zlokovic 2008). The BMEC are able to efficiently supply the brain with the metabolites 
required while contributing to the maintenance of the brain's ionic homeostasis and 
protecting the CNS from a large variety of potentially harmful hydrophobic compounds 
(Betz 1992; Choi and Kim 2008). Passage of molecules across BMEC can occur 
between adjacent cells (the paracellular pathway) or through the cells (the transcellular 
pathway) (Pardridge 1999). In the endothelium, the relationship of paracellular and 
transcellular permeability is of crucial importance for the regulation of overall 
transendothelial permeability (Wolburg et al. 2009). When it comes to the paracellular 
passage, ions and solutes diffuse between adjacent cells according to their 
concentration gradient (Petty and Lo 2002). As for the transcellular pathway, it involves 
different mechanisms including passive diffusion of lipophilic compounds, receptor-
mediated shuttling and transcytosis. Small lipophilic molecules, such as oxygen, CO2 
and ethanol (Abbott 2002), can pass the BBB freely by diffusion (Zheng et al. 2003), 
whereas hydrophilic molecules, such as peptides and proteins, may enter the brain 
through specific transport mechanisms (Norsted et al. 2008). For that, an elaborate 
system of transport proteins such as GLUT1 and ABC transporters, among others, is 
expressed on the luminal and abluminal BMEC membranes (Hawkins et al. 2002). 
Polar and lipid-insoluble molecules do not cross the BBB (Scherrmann 2002).  
 
Caveolae 
Caveolae are sites of endothelial transcytosis, endocytosis, signal transduction, 
and act as docking sites (Simionescu et al. 2002; Wolburg et al. 2009). Caveolae are 
dynamic pieces of membrane that are either opened for receiving and releasing 
material or closed for processing, storage, and delivery to the cell (Anderson 1993). 
These invaginations of the plasma membrane are rich in the structural and functional 
coat protein caveolin (Fig. 1.6). Caveolin-1 is the major structural protein of caveolae 
and is involved in various aspects of vesicular trafficking and signal transduction 
pathways (Huber et al. 2001). In the BBB, the presence of both caveolin-1 and -2 in 
microvessels was demonstrated for BMEC of rats, rhesus monkeys, porcine and of 
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normal human brain samples (Virgintino et al. 2002). Caveolin-1 appears to act not as 
a determinant of caveolae invagination and internalization but rather as a regulator that 
stabilizes caveolae at the plasma membrane and reduces the endocytic potential of 
caveolae domains (Nabi and Le 2003). Caveolin-1 also appears to constitute an early 
and critical modulator that controls signaling pathways leading to the disruption of TJ 
proteins (Zhong et al. 2008) as indicated by the localization of caveolae close to 
junctional cell contacts and the fact that both occludin and ZO-1 are organized within 
TJ by association with caveolin-1 (Smith and Gumbleton 2006).  
 
 
 
Figure 1.6 - Caveolin-1 is the major structural protein of caveolae. Caveolae are involved in various 
aspects of vesicular trafficking and signal transduction pathways. From (Cardoso et al. 2010). 
 
 
Glucose transporter-1 
GLUT1 ensures nutrient delivery, supplying glucose for the brain (Fig. 1.7) 
(Persidsky et al. 2006), which is its main energy source. GLUT1 is highly restricted to 
BMEC (Wolburg et al. 2009) with higher density at the abluminal membrane than at the 
luminal. The asymmetrical distribution provides homeostatic control for glucose influx 
into the brain by preventing accumulation at levels higher than in the blood (Zlokovic 
2008). Interestingly, GLUT1 may also be present at peripheral nerve pericytes 
transporting D-glucose from the circulating blood into the brain and peripheral nervous 
parenchyma in cooperation with that on the BMEC (Shimizu et al. 2008).  
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ATP-binding cassette transporters 
ABC transporters, as P-gp and the multidrug resistance associated proteins, have 
the potential to reduce the penetration of many drugs into the brain and increase their 
efflux from the brain (Fig. 1.7). P-gp is a transporter for the acquisition of the multidrug 
resistance phenotype, as it prevents the entry of blood-borne substances into the brain 
and facilitates their transport out of brain parenchyma (Choi and Kim 2008). The 
expression of this efflux transporter among blood–brain interface is still under 
investigation. In fact, although P-gp in the brain has been thought to be primarily 
located in the apical or luminal membranes of BMEC (Gazzin et al. 2008; Virgintino et 
al. 2002), it was also reported that such protein localizes to both the luminal and the 
abluminal membranes of the BMEC (Bendayan et al. 2006). These apparently 
contradictory findings can be reconciled by the recent studies of Tai et al. (2009), which 
showed that the transporter is present in both membranes but P-gp molecules 
associated with the apical membrane are nearly 3 times greater than that on the 
basolateral membrane. The localization of the transporter in both poles would permit 
that the efflux of molecules from the brain endothelium can be initiated at the luminal 
membrane, whereas the elimination of drugs from the brain occurs due to the 
abluminal membrane P-gp that acts in concert with the luminal transporter. It appears 
to exist an association between P-gp and caveolin-1, as the down-regulation of 
caveolin-1 enhances the transport activity of P-gp (Barakat et al. 2007; Demeule et al. 
2000). P-gp is also expressed at the endothelial subcellular level along the nuclear 
envelope and in caveolae, cytoplasmic vesicles, Golgi complex, and rough 
endoplasmic reticulum (Bendayan et al. 2006; Tai et al. 2009). In addition to EC, P-gp 
is also expressed at the plasma membrane of both pericytes and astrocytes, 
suggesting that this glycoprotein may regulate drug transport processes in the entire 
BBB (Bendayan et al. 2006).  
 
2.2. Crucial interactions within the developing neurovascular unit 
 
During embryonic and fetal development there are fundamental crosstalks and 
interdependence between the vascular and the neuronal systems. Integrated 
responses in neurons, glia, brain blood vessels, and circulating peripheral cells all 
contribute to the pathogenesis of injury and mechanisms of repair after stroke and 
trauma (Hayakawa et al. 2014). 
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Figure 1.7 - Endothelial cells comprise a large variety of specific transporters and receptors, which 
regulate brain concentrations of nutrients, hormones, metabolites, and xenobiotics. For simplicity, 
only the glucose transporter-1, the insulin receptor and the ABC transporters, as the multidrug resistance-
associated protein and the P-glycoprotein, and respective substrates, are represented. From (Cardoso et 
al. 2010). 
 
 
2.2.1. The neurovascular coupling 
The neurovascular coupling describes increased regional cerebral blood flow in 
response to physiological neuronal activation and decreased regional cerebral blood 
flow in response to neuronal deactivation (Fig. 1.8) (Yao and Tsirka 2014). This is due 
to the fact that neuronal activation causes glutamate-induced Ca2+ influx in 
postsynaptic neurons and astrocytes that in turn activate the production of vasodilators, 
like nitric oxide (NO) (Dreier 2011). Neurovascular coupling can be mediated by 
neuronal signaling mechanisms via glial pathways, or by diffusion of products of 
neuronal activity without the involvement of glial cells (Attwell and Iadecola 2002). 
Specific receptors for the vasoactive mediators released by neurons exist on BMEC, 
smooth muscle cells and on astrocytes. Therefore, the pericytes in the capillaries effect 
contraction or dilation in response to the stimuli released in their vicinity as well as 
through direct neuronal innervation (Hamel 2004; Iadecola 2004; Stanimirovic and 
Friedman 2012). In addition, after brain injury, neural growth factor (NGF) upregulates 
VEGF production and induces reparative neoangiogenesis and wound-healing 
(Lazarovici et al. 2006). In turn, BMEC nourish neighboring neurons, release trophic 
factors, guide developing axons, protect neurons against stress and provide a niche for 
supporting NPC (Guo et al. 2008; Makita et al. 2008; Ohab et al. 2006). It has also 
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been described that BMEC modulates the self-renewal and neurogenesis of neural 
stem cells (Li et al. 2006). Therefore, the mutual modulation of NPC and BMEC 
promotes the proliferation/migration of these cells, ultimately controlling their fate 
(Vissapragada et al. 2014). 
 
 
Figure 1.8 - Schematic model of neurovascular coupling. The release of glutamate by neurons causes 
elevated cytoplasmic Ca
2+
 in astrocytes leading to the production of vasodilator nitric oxide (NO). NO leads 
the endothelium to signal the surrounding smooth muscle cells to relax, resulting in vasodilation and 
increasing blood flow. On the other hand, low levels of glutamate lead to vasoconstriction. 
 
 
2.2.2. Vascular niches 
The neurovascular coupling may also be associated with neurogenesis and 
oligodendrogenesis. Neurogenic niches are the micro-anatomical units where 
neurogenesis occurs in the adult mammalian brain. In rodents, these niches are mainly 
located in the subventricular zone of the lateral ventricles and in the subgranular zone 
of the dentate gyrus in the hippocampus (Butti et al. 2014). There the progenitor cells 
are in close proximity to the capillaries (Goldenberg et al. 2008; Tavazoie et al. 2008) 
that lack astrocyte endfeet and pericyte coverage (Fig. 1.9), giving them direct access 
to vascular and blood-derived signals. Within this vascular niche, BMEC secret a 
number of diffusible signals such as VEGF, brain-derived neurotrophic factor (BDNF), 
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and the pigment epithelium-derived factor, as well as unidentified factors that affect 
neural precursors, promoting stem-cell renewal and subverting stem-cell fate decisions 
(Ramirez-Castillejo et al. 2006; Shen et al. 2004; Tavazoie et al. 2008). Therefore, the 
vascular compartment within the niche has the unique opportunity to regulate neural 
stem-cell behavior, which is further influenced by ependymal cells and the CSF 
(Tavazoie et al. 2008). 
 
Figure 1.9 - Stem cell niches are micro-anatomical units where neural stem cells interact intimately 
with ependymal cells and with capillaries, mainly within the subventricular zone. Neural stem cells 
receive signals from ependymal cells and the cerebro-spinal fluid, as well as from capillaries, which lack 
astrocyte endfeet and pericyte coverage and therefore give them direct access to vascular and blood-
derived signals. From (Cardoso et al. 2010). 
 
BMEC also have a fundamental role in oligodendrocyte differentiation. In adverse 
conditions, the mature oligodendrocytes secrete high levels of MMP-9 to promote 
vascular remodeling (Seo et al. 2013), which as abovementioned degrades the 
basement membrane and may induce BBB breakdown if exacerbated (Miyamoto et al. 
2014). However, the close proximity of OPC with BMEC may help the mutual 
remodeling and repair of these cells (Pham et al. 2012). In this oligovascular niche, 
BMEC may promote the switch of NPC into oligodendrocyte linage cells and stimulate 
the proliferation of OPCs through the release of trophic factors, such as the BDNF and 
the basic fibroblast growth factor (bFGF) (Arai and Lo 2009; Xing et al. 2012), as well 
as increase their mobility through VEGF (Hayakawa et al. 2011; Hayakawa et al. 
2012b). As the neurovascular niche, the oligovascular niche may therefore provide an 
important mechanism for both angiogenesis and oligodendrogenesis in the adult white 
matter. 
 General Introduction 
 
27 
Lastly, pro-inflammatory and other immunological mediators can also regulate 
these niches by controlling several processes in neural precursors such as migration, 
proliferation, quiescence, cell-fate choices and survival of neural stem cells (Gonzalez-
Perez et al. 2012). 
 
2.2.3. Axon-myelination 
OPCs receive direct synaptic input from neurons giving rise to an axon-OPC 
synaptic communication. In this manner, neuron activation increases OPC proliferation, 
differentiation and myelination (Barateiro and Fernandes 2014; O'Rourke et al. 2014). 
Myelin forms a complex and dynamic process of cell-cell interaction that supports 
axonal integrity and survival, and can be modified by functional experience (Nualart-
Marti et al. 2013). Myelination initiates in response to axon-glia recognition mediated by 
membrane CAMs triggering reorganization of the glial cytoskeleton and cell polarization 
(White and Krämer-Albers 2014). When mature, oligodendrocytes form multilayered 
stack of membranes tightly attached at their cytosolic and external surfaces – the 
myelin sheets – that wrap neuronal axons (Fig. 1.10) and speed the conduction of 
action potentials to provide efficient impulse propagation in large size animals 
(Barateiro and Fernandes 2014). Each oligodendrocyte as the capacity to myelinate 
oligodendrocytes myelinate up to 50 axonal segments simultaneously (White and 
Krämer-Albers 2014). These myelinated axon segments of nerve fibers are known as 
internodes and are delimited by the areas of naked axons where action potentials are 
generated, the nodes of Ranvier (Nualart-Marti et al. 2013). Myelin internodes have a 
high electrical resistance, and promote rapid conduction of the action potential from 
one node of Ranvier to the next. Thus, myelin enhances the integration of information 
across spatially distributed neural networks supporting cognitive and motor functions 
(O'Rourke et al. 2014). In addition, as axons are not only electrically but also 
metabolically isolated, oligodendrocytes provide trophic support to axons and promote 
their viability (Blank and Prinz 2014; Simons et al. 2014). 
 
2.2.4. Astroglia-neuron crosstalk 
Astrocytes are also important for proper neuronal function and, as indicated by the 
enervation of brain capillaries by neurons, the interactions between these elements are 
essential for an efficient NVU. Below we discuss some of the main interactions 
between these cells. 
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Figure 1.10 - Development of oligodendrocytes and myelination. Immature oligodendrocyte precursor 
cells that are positive for NG2 differentiate into myelinating mature oligodendrocytes. Myelin sheets 
connect with axons via cell adhesion molecules (CAMs). Adapted from (Lee and Fields 2009). 
 
Axonal ensheathment by astrocytes 
Astrocytes are involved in axonal guidance during CNS development (Marchetti 
1997). When in close contact with both axons and oligodendrocytes, astrocytes form 
membranous blebs (Ioannidou et al. 2014) that ensheath axons and synapses by 
extending thousands of thin processes, with typically only one or two in contact with 
blood vessels or CNS boundaries (Freeman 2010; Molofsky et al. 2012). The 
percentage of synapses ensheathed by astrocytic processes as well as the absolute 
number of synapses ensheathed by one astrocyte varies greatly with synapse type and 
brain region. In the cortex, astrocytic processes ensheath a substantial amount of 
neuronal synapses, of nearly ∼90% (Magistretti and Chatton 2005). In the 
hippocampus ∼60% of synapses are ensheathed by astrocyte processes (Ventura and 
Harris 1999) while in the cerebellum 67% of parallel fibers and 94% of climbing fiber 
synapses are connected to astrocytic extensions (Xu-Friedman et al. 2001). In addition, 
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there are differences between species. In rodents, one astrocyte ensheathes 
thousands of synapses (Bushong et al. 2002) while in the human cortex it might be 
more than one million (Oberheim et al. 2006). Astrocyte ensheathment is subject to 
dynamic modulation (Hatton 1997). Structural assembly of excitatory synapses can be 
mediated by physical contact with astrocytes as well as by different astrocyte-secreted 
proteins (Elmariah et al. 2005). When cultured in the presence of astrocytes or of 
astrocyte-conditioned medium, neurons can form 10 times more excitatory synapses 
and significantly increase synaptic functionality compared to monocultures (Ullian et al. 
2001). Aside from promoting excitatory synapse formation, astrocytes can also 
stimulate the formation of inhibitory synapses by secreting molecules that regulate 
presynaptic and postsynaptic differentiation (Elmariah et al. 2005; Hughes et al. 2010). 
 
Regulation of neuronal activity-dependent blood-flow 
As aforementioned, astrocytes can recognize vasodilator mediators secreted by 
neurons, and thus play a key role in the regulation of blood flow. During neuronal 
activity, glutamate is released and acts via neuronal N-methyl-ᴅ-aspartate (NMDA) 
receptors to activate neuronal NO synthase (nNOS), resulting in the release of NO. 
This molecule acts on smooth muscle cells, increasing blood flow (Fergus and Lee 
1997). In addition, glutamate released by neurons can act on astrocyte metabotropic 
glutamate receptors, leading to the release of vasoactive messengers from astrocytic 
endfeet and to simultaneous changes in vessel diameter (Takano et al. 2006; Zonta et 
al. 2003). This suggests that astrocytes may contribute to the neurovascular coupling, 
regulating cerebral blood flow by triggering either vasodilation or vasoconstriction 
(Howarth 2014), depending on which signaling pathway dominates.  
 
2.2.5. Microglia-neuron crosstalk 
Alike the remaining glial cells, microglia are also in close communication with 
neurons. These brain-resident immune cells account for 10–20 % of glial cells, with 
similar numbers to neurons (Yao and Tsirka 2014), and showing from brain region to 
brain region different densities, molecular characteristics, morphologies and even 
responsiveness (Neiva et al. 2014). The microglia-neuron interaction is a complex 
process that modulates healthy neuronal functions by several processes such as 
glutamate uptake, removal of cell debris, production of neurotrophic factors (Fig. 1.11), 
as well as physical association with endangered neurons in the case of detrimental 
conditions  (Kettenmann et al. 2011; Perego et al. 2011). Hence, healthy CNS ensures 
that microglial cells exert a protective role and do not develop unwanted patterns of 
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activation with damaging consequences for the neighboring cells (Figueiredo et al. 
2008). Neurons maintain microglial resting state through physical contact or release of 
neurotransmitters, peptides and/or growth factors which bind to receptors on the 
microglial membrane (Bessis et al. 2007; Kraft and Harry 2011). In example, the 
physical connection of CX3CL1 (expressed by neurons) and CX3CR1 (expressed by 
microglia), not only keeps microglia in a resting surveillance state but it is also involved 
in synaptic pruning (Neiva et al. 2014), as discussed further ahead. The neuronal 
release of neurotrophins, such as NGF for example, controls the expression of MHC-
class II in microglia (Neumann et al. 1998), whereas the neuronal secretion of CD22 
inhibits microglial release of pro-inflammatory cytokines by acting on CD45 receptor 
(Mott et al. 2004). The physical interaction between neuronal CD200 and its receptor 
CD200R present on cells of myeloid origin, including macrophages and microglia, may 
be important for controlling tumor necrosis factor (TNF)-α released by microglia. Loss 
of CD200 implicates a more activated morphology along with increased expression of 
CD11b, CD45 and of inflammatory mediators (Broderick et al. 2002; Lyons et al. 2007). 
These interactions demonstrate the need of a mutual control between neuronal and 
microglial functions in order to maintain the integrity of CNS circuits. 
 
 
Figure 1.11 - Microglia-neuron crosstalk in central nervous system (CNS) in health and inflammatory 
conditions. In healthy CNS, fractalkine (CX3CL1) released by neurons connects with its receptors on 
microglial cells (CX3CR1) keeping them on a resting state. In addition, binding of the neuronal CD200 to 
its microglial receptor (CD200R) inhibit the production of pro-inflammatory cytokines. Also, microglia clear 
the debris and damaged cells, as well as excessive glutamate. However, under inflammatory conditions 
the bonds CX3CL1/CX3CR1 and CD200/CD200R are disturbed, leading to the activation of microglia with 
associated production of pro-inflammatory cytokines and accumulation of debris and glutamate in the 
extracellular medium. 
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2.2.6. Synaptic pruning by glia 
For normal neuronal synaptic activity, the removal of excess excitatory synapses is 
fundamental during embryogenesis and in the postnatal brain (Ponomarev et al. 2012; 
Tremblay and Majewska 2011). In the same manner, synapse pruning is equally 
important in the mature CNS in order to prevent epileptic activity and in the adaptive 
remodeling of neural circuits. Microglia are able to monitor synaptic activity and 
remodel specific regions of neuronal dendrites by synaptic stripping and thus limiting 
secondary neurodegeneration after brain injury (Kettenmann et al. 2011; Kraft and 
Harry 2011). Still, these cells are not alone in synaptic pruning. Recent studies have 
reported that astrocytes can control synapse elimination by releasing signals that 
activate the complement cascade (reviewed in Clarke and Barres 2013). Still, 
astrocytes may have a more direct role in neuronal debris and synapse elimination. 
Astrocytes not only express phagocytic proteins (Lööv et al. 2012; Sokolowski et al. 
2011; Yu et al. 2008), but they are also able to phagocyte in response to 
developmental axon death (al-Ali and al-Hussain 1996), to brain injury engulfing whole 
dead cells and peptides (Jones et al. 2013; Lööv et al. 2012), to lipopolysaccharide 
(LPS) (Kalmár et al. 2001), and even in healthy CNS conditions (Nguyen et al. 2011). 
This shows the significance of microglial and astrocytic phagocytic activities in synapse 
elimination to sculpt neural circuits, regulating neuronal function from development to 
degeneration. 
 
 
3. Main mechanisms of the inflammatory responses in the developing 
brain 
 
The inflammatory reactions in the CNS to protect neurons from more serious 
damage are known as ‘neuroinflammation’. The effects of neuroinflammation on the 
developing brain are still a growing area in research. In the healthy developing brain 
inflammatory mediators play an important role in neurogenesis, apoptosis and pruning 
of neuronal processes. However, during pro-inflammatory conditions the developing 
neural circuits may be negatively affected.  
 
3.1. From the periphery to the parenchyma 
 
The first line of defense against pathogens is the local innate immune system that 
begins the process of tissue repair and restoration of homeostasis. Peripheral innate 
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immune cells include natural killer cells, natural killer T cells, mast cells, granulocytes 
and T cells (Amor et al. 2014). CNS-specific T cells residing at the limitants of the brain 
coordinate the CNS communication with the periphery while mediating their local 
functions. These cells are not only involved in the immune response in inflammatory 
scenarios but also in the maintenance of the functional plasticity of the healthy brain 
(Schwartz et al. 2013). In addition, the complement system of the innate immune 
response helps antibodies and phagocytic cells to clear pathogens. Given that it can be 
“recruited” by the adaptive immune response, it is considered a link between the two 
types of immune response. The adaptive system is directed to the infectious agent and 
as so, if the source is a neuron, it can contribute to neuronal damage. Overall, the 
extent and type of adaptive T-cell-mediated immune response is determined by the 
local innate response (Amor et al. 2014). 
 
3.1.1. Antigen Presentation  
In the peripheral immune system, the main antigen presenting cells (APC) are the 
dendritic cells (DC). These are essential for antigen processing, transport to lymphoid 
organs, and subsequent antigen-specific activation of naïve T cells, linking innate and 
adaptive immunity. Differentiated DC express both CD11c and MHC-class II, which can 
be further induced upon activation and subsequent maturation of the cells (Olah et al. 
2011). In the brain, activated microglia can express markers of APC, including MHC-
class II and CD86 (David and Kroner 2011), which allow them to interact with T 
lymphocytes and to recognize and respond to an antigenic peptide (Bomstein et al. 
2003; Butovsky et al. 2001; Schwartz et al. 2006). In addition, during inflammation 
BMEC are capable of presenting antigens to T cells and their expression of MHC-
classes I/II and co-stimulatory molecules are upregulated by microglia-derived TNF-α 
(Turesson 2004; Yang et al. 2013). The release of chemoattractive factors therefore 
recruits and guides immune cell populations to the CNS, with presentation of antigens 
to T cells subsequently helping the adaptive immunity in resolving the potential source 
of injury (Kettenmann et al. 2011).  
 
3.1.2. The blood-brain barrier as a signaling interface 
BMEC are the first cells of the CNS to contact with toxic molecules in the systemic 
circulation, as so they might be the first players in the signaling mechanisms that 
trigger neuropathology. During injury BMEC produce mediators like cytokines and NO 
(Brix et al. 2012; Jayakumar et al. 2012), which are secreted into either the CNS 
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compartment or the blood. In fact, vascular signals cause the release of cytokines by 
BMEC into the brain parenchyma determining the subsequent action of other brain 
cells, and in the same manner there are signals released from the brain parenchyma 
into the periphery via BMEC (Carvey et al. 2009; Lee and Slutsky 2010; Paolinelli et al. 
2011). 
During systemic inflammation, blood-borne cytokines might affect the function of 
the CNS by crossing the BBB for direct interaction with brain tissue. The number of 
cytokines that do so is considerably large, ranging from interleukin (IL)-1β, to IL-6, and 
to TNF-α (Quan 2008). In addition, BMEC are able to recognize and respond to 
microbial infection, being directly activated through the recognition of pathogen-
associated molecular patterns (PAMP), like LPS, by Toll-like receptors (TLR) (Mallard 
et al. 2009). Hence, BMEC have cytokine binding sites, which alter intracellular function 
(receptors) or convey these molecules across the BBB (transporter). Given that BMEC 
transfer information from the blood to the CNS, the vascular system plays a key role in 
immune-CNS communication, responsible for activation of brain circuits and 
consequent CNS-mediated effects. 
 
3.1.3. Recruitment and extravasation of leukocytes  
The response of BMEC to the inflammatory stimuli can induces the activation of 
microglia and astrocytes by itself, However, recent studies suggest that there may be a 
maximum number of microglia allowed to proliferate in the brain and that the 
proliferation of microglia depends on its local cell expansion and self-renewal (Smith et 
al. 2014). Therefore, there might urge in different disease processes to recruit to the 
CNS additional immune cells from the blood-circulation to help resolve the 
inflammatory response and restore homeostasis. Leukocyte recruitment occurs only 
under certain defined host conditions and is tightly controlled by the highly specialized 
BBB. Therefore, monocyte-derived macrophages are usually excluded from the healthy 
host brain and are recruited only to resolve an acute CNS injury (Schwartz et al. 2013). 
Interestingly, resting T cells are unable to cross the healthy BBB given that the 
endothelium limits their passage to newly activated lymphocytes (Engelhardt 2006). 
The paracellular transport of myeloid cells requires chemokine receptors and other 
adhesion molecules. In this process there is also expression of novel surface antigens 
and production of mediators that build up and maintain the inflammatory response of 
the brain tissue (Kraft and Harry 2011).  Pro-inflammatory mediators may activate 
BMEC leading them to increase the expression of CAM of the E-selectin subfamily 
(Engelhardt 2009). The chemokine CCL-2 (or monocyte chemoattractant protein-1) and 
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the monocytes expressing its receptor (CCR-2) are increased during inflammation, in 
what appears to be a direct link to the recruitment of monocytes (D'Mello et al. 2009). 
The binding of the BMEC selectins to the integrins on monocytes causes them to slow 
and roll along the luminal surface of the vessel, in a process called tethering. When 
reaching the paracellular junctions they transmigrate into the brain (Carvey et al. 2009) 
in a well-regulated process with rapid junction restoration (Wallez and Huber 2008). 
In addition to paracellular migration, leukocytes may also enter the brain by 
transcellular migration (Carman and Springer 2004) in a process that requires the 
involvement of MMP to digest the basement membrane (Man et al. 2007). 
Mononuclear cells are able to penetrate directly through the cytoplasm of BMEC by 
diapedesis, which does not disrupt TJ (Engelhardt and Wolburg 2004). Even though 
JAM-1 is located at TJ, this protein can redistribute to the apical surface of the 
endothelium during inflammation or monocyte transmigration to bind to the monocytes’ 
integrins (Ivey et al. 2009; Nourshargh et al. 2006). After the leukocytes enter the 
BMEC, the luminal membrane closes before the opening of the abluminal membrane in 
order not to create a fluid-filled channel through the cell (Carman and Springer 2008; 
Wallez and Huber 2008). 
The majority of these recruited monocyte-derived macrophages arrive with a delay 
relative to the initial injury-associated breach of the BBB to facilitate the resolution of 
the local immune response. They do so by displaying an anti-inflammatory activity 
required for the regulation of the activated microglia (Schwartz et al. 2013). Still, it is 
important to notice that in areas of BBB disruption this process may enhance the 
infiltration of circulating lymphocytes and monocytes/macrophages, or even 
components of plasma, such as fibrinogen, that trigger microglial response (Kraft and 
Harry 2011). 
 
3.2. Glia’s response to inflammation 
 
Microglia and astrocytes are essential for proper neuronal functioning. They 
quickly intercede when neurons become injured or stressed, and their pathological 
impairment could have disturbing consequences on brain function (Streit 2002). 
 
3.2.1. Astrocytes’ activation 
During inflammation, astrocytes may be targeted by pro-inflammatory cytokines or 
be directly infected by several pathogens, given that they express receptors that allows 
them to recognize various types of pathogens, like TLR2 (Combes et al. 2012). Their 
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activation is morphologically identified by the hypertrophy of their cellular processes, in 
addition to proliferation (also known as astrogliosis) and redistribution around 
inflammatory cells. At a molecular level there is upregulation of intermediate filament 
proteins, mainly of GFAP, and of neural stem cell markers vimentin and nestin 
(Hernandez et al. 2002; Pekny et al. 2007). These GFAP+ cells control the adult 
neurogenesis, and may even be precursors to neurons that are added in the adult life 
(Pekny et al. 2007). Depleting GFAP would alter astrocytes’ differentiation state into 
more immature cells (Emsley et al. 2004). In addition, reactive astrocytes also 
synthesize intercellular mediators that mediate tissue repair (Akrout et al. 2009; Pekny 
et al. 2014). This is the case of CX3CL1 and of high-mobility group-box-1 (HMGB1). 
The latter is a damage-associated molecular-pattern molecule that promotes 
neurovascular remodeling through endothelial progenitor cells (Hayakawa et al. 
2012a). In addition, astrocytes may decrease brain inflammation by inhibiting microglia 
from producing IL-12, and thus blocking these cells from presenting antigens (Dietrich 
2002; Dietrich et al. 2003). Reactive gliosis ranges in a scale from mild to very 
prominent (Fig. 1.12). The latter is connected to the formation of a glial scar, where 
reactive astrocytes form a physical barrier around a lesion separating it from the 
surrounding tissue [for further reading, (Raposo and Schwartz 2014)], and that has 
been reported in several models for degenerative and inflammatory disorders (Bao et 
al. 2012; Grigorian et al. 2011; Wu et al. 2012). However, astrocytes might also 
produce several pro-inflammatory molecules which ultimately increase permeability, 
promote lymphocyte trafficking and could further damage the CNS (Hansson and 
Rönnbäck 2003; Langford and Masliah 2001). Nonetheless, astrocytic activation is in 
its majority a neuroprotective attempt to supports CNS regeneration. 
 
3.2.2. Microglia’s response to inflammation 
As abovementioned, microglia are the principal immune cells of the CNS, 
surveying local microenvironment and changing the phenotype in response to 
homeostatic disturbances (Ransohoff and Perry 2009). These disturbances may be 
due to release of “danger factors” such as HMGB1, chemokines CCL2 and CCL21, 
among others (Kraft and Harry 2011), or due to the loss of stimulation of microglial 
membrane by ligands such as CD200, CX3CL1, neurotransmitters and neurotrophins 
(Biber et al. 2007; Pocock and Kettenmann 2007). As abovementioned, CX3CL1 
induces a resting state on CX3CR1+ microglia. The interruption of this complex allows 
microglial activation and enhanced response to activating signals. Once activated, 
microglia perform several macrophage-like functions including phagocytosis, remove 
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cellular debris, inflammatory and anti-inflammatory cytokine production, antigen 
presentation and even promote remyelination (Garden and Möller 2006). Though their 
activation may trigger neurotoxic pathways, as being part of the innate immune system, 
they are interference is indeed crucial in controlling inflammation and in the mediation 
of neuroprotection and repair (Amor et al. 2014; Olah et al. 2012). 
 
Figure 1.12 - Schematic representation of the different stages of reactive astrogliosis. In the healthy 
central nervous system (CNS) astrocytes have no-overlapping domains. The individual domains are 
preserved in mild to moderate reactive astrogliosis, though most cells display hypertrophy and express 
high levels of GFAP. The proliferation of GFAP
+
 astrocytes is further promoted in severe reactive 
astrogliosis, with additional overlap of astrocytic domains. Finally, there may be glial scaring with 
astrocytes bordering the damaged regions with recruitment of several immune cells. Adapted from 
(Sofroniew and Vinters 2010). 
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Types of microglia 
Microglia can shift activity states depending on surrounding conditions. Under 
normal conditions they are characterized by a small cell body with fine, ramified 
processes and low expression of surface antigens. In this “resting” state, microglial 
cellular processes are in surveillance mode, being constantly in motion to monitor their 
environment for signals from the surrounding cells. Upon brain injury, microglia rapidly 
proliferate and transform their morphology from long to short processes, the “active” 
state, also releasing proinflammatory molecules and increasing the expression of 
immunomodulatory surface antigens (Kettenmann et al. 2011; Weinstein et al. 2010). 
Microglia’s “resting” is not a non-active state. As upcited, these cells are constantly 
monitoring the normal CNS. Not only neurons but also astrocytes appear to take part in 
the maintenance of this state given that they too express CX3CL1, and their 
conditioned medium is capable of increasing ramification of blood monocytes in culture 
(Wollmer et al. 2001). Other molecules secreted by astrocytes can induce this state, as 
is the case of TGF-β, macrophage-colony stimulating factor (M-CSF), and 
granulocyte/macrophage-colony stimulating factor (GM-CSF) (Schilling et al. 2001).  
Microglial activation is increasingly recognised as an early sign of CNS 
inflammation. As part of the innate immunologic system, microglia recognize the injury 
or pathogen and quickly initiates production of pro-inflammatory molecules (Abbott et 
al. 2010). Circulating pro-inflammatory cytokines like IL-1, IL-6 and TNF-α are major 
activators of microglial cells, via a cyclooxygenase (COX)2-dependent mechanism that 
subsequently produces prostaglandin E2 and may induce fever. Blood-borne proteins 
such as thrombin, plasminogen activator, and the complement system have also been 
shown to activate microglia (Ryu et al. 2000; Siao and Tsirka 2002; Webster et al. 
2000). Activated microglia are able to recruit the appropriate cells to clear debris, and 
minimize primary neuronal damage and the secondary wave of neuronal death (Turrin 
and Rivest 2006).  
Microglia’s morphological responses differ depending on the type of insult. Soluble 
signals from endangered neurons and astrocytes, as well as plasma-derived factors, 
induce microglia’s proliferation and transform their morphology to bushy, to 
hypertrophic or to rod shapes with reduced cellular processes. These morphological 
forms in microglial activation may interchange during the progression from the ramified 
to the amoeboid macrophage-like appearance (Karperien et al. 2013; Kettenmann et 
al. 2011; Perego et al. 2011; Weinstein et al. 2010). Local densities of microglia can 
also increase by proliferation, to provide more cells for both defense against the stimuli 
and for protection and restoration of tissue homeostasis. When not at rest, microglia 
display altered expressions of inflammatory cytokines, induction of surface molecules 
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for cell-cell and cell-matrix interactions. All of these aim to recognize possible 
complement proteins deposited on the aberrant synapses or neuritis that need to be 
removed (Rezaie et al. 2002; Stence et al. 2001). 
Microglial activation does not imply that all cells are activated, and in fact more 
than one functional state can coexist. As upcited, there is regional heterogeneity in the 
microglia population. A reason to such heterogeneity may be due to differences in the 
expression of multiple proteins by microglia of different CNS regions, and from white to 
gray matter. Neurotrophins, for example, were seen in microglia that not only showed a 
region-specific pattern but also differed within the regions themselves, being produced 
by certain subpopulations (Schmid et al. 2009). Interestingly, this profile is paralleled by 
heterogeneity of oligodendroglial subpopulations in subregions of gray and white 
matter (de Haas et al. 2008; Kitada and Rowitch 2006). 
Following defense activation, microglia may assume reparation functions and 
eventually reverse to a resting state or remain primed. Post-activated microglia may 
remain morphologically undistinguishable from the unactivated cells, though having 
long-lasting functional adjustments Studies on microglial activation after stroke indicate 
that long-term activation of microglia in the subventricular zone is important for 
regulating long-lasting neurogenesis in this area (Kettenmann et al. 2011; Thored et al. 
2006). 
 
Microglial phenotypes 
Several reports have discussed the existence of two distinct sub-populations of 
activated microglia in the normal mouse brain: type M1 and type M2 (Fig. 1.13). Both 
types have similar phagocytic activity, but they show distinct phenotypes such as cell-
surface markers, mRNA expression, and growth factor dependency. In fact, one has a 
pro-inflammatory phenotype (classical activation) associated with demyelination, while 
the other displays an anti-inflammatory and reparative phenotype (alternative 
activation) responsible for remyelination (Durafourt et al. 2012; Lacy-Hulbert and Moore 
2006; Olah et al. 2012). 
M1 microglia can be triggered in response to GM-CSF, LPS, as well as pro-
inflammatory cytokines interferon (IFN)-γ and TNF-α (Durafourt et al. 2012). This type 
is characterized by increased chemotaxis, production of inflammation mediators and 
cytokines, and they have high capacity to present antigen mediating both innate and 
adaptive responses (Gabrusiewicz et al. 2011). They upregulate the expression of 
several receptors such as TLR2/4 (for pathogen recognition), Fc (to bind antibodies), 
CCR7 (of which the ligand is CCL21) and of CD80 (for T cells activation) (Durafourt et 
al. 2012). M1 also has high superoxide production with consequent toxic effects and 
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cell death of cholinergic and dopaminergic neurons (Sawada 2009). In addition, the 
classical activation phenotype includes production of NO, reactive oxygen species 
(ROS), TNF-α and IL-1β, IL-6 and IL-12 (Butovsky et al. 2005; Perego et al. 2011; 
Voisin et al. 2010). Still, a report by Sawada and collaborators demonstrate that even 
though microglia activated by LPS and IFN-γ may be neurotoxic in aged mice, in the 
neonatal brain it can actually be neuroprotective (Sawada 2009). 
 
 
 
Figure 1.13 - Induction of microglia phenotypes. A pro-inflammatory immune cell M1 phenotype is 
acquired upon the classical activation of resting microglia (M0) by interferon (IFN)-γ, tumor necrosis factor 
(TNF)-α, granulocyte macrophage colony-stimulating factor (GM-CSF) or lipopolysaccharide (LPS). The 
binding LPS to Toll-like receptors triggers the release of pro-inflammatory cytokines and free radicals, thus 
amplifying the neuroinflammatory response. On the other hand, interleukin (IL)-4, IL-10, IL-13 or 
macrophage colony-stimulating factor (M-CSF) induce an anti-inflammatory M2 phenotype representing a 
beneficial activation state promoting repair that scavenges debris and releases anti-inflammatory 
mediators. According to the stimuli, there may be an alternative classic activation (M2a), a lower activation 
sate (M2b) or a classical deactivation (M2c).The activation of IL-4 receptor promotes the activation of 
phenotypes M2a and M2c, whereas the activation of M-CSF receptor favors the activation of M2c. 
 
 
The “alternative” M2 phenotype is an apparently beneficial activation state, more 
related to a fine tuning of inflammation, scavaging of debris and promotion of 
angiogenesis (Perego et al. 2011). Is has been proposed that microglia in the normal 
CNS exhibit a phenotype of M2-like cells (Ponomarev et al. 2012). This phenotype can 
be triggered by M-CSF, IL-4, IL-10 and IL-13 (Durafourt et al. 2012). According with the 
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type of polarization distinct M2 populations can be differentiated, called M2a, M2b, and 
M2c, which differ in some cell surface properties and capacity to secrete immune 
mediators (Leidi et al. 2009). IL-4 promotes an alternative activation state or M2a, 
whereas IL-10 promotes a classical deactivation profile or M2c. Both M2a and M2c 
phenotypes reduce pro-inflammatory mediators. As for M2b activation profile, it shows 
expression of both M1 and M2c markers (Fenn et al. 2012; Mantovani et al. 2004; 
Mosser and Edwards 2008). Interestingly, experiments demonstrated that LPS can 
induce a M2b phenotype, with significantly upregulated expression of IL-4 receptor, 
which is re-directed towards a less inflammatory M2a profile following IL-4 addition 
(Fenn et al. 2012). In general, M2 phenotype is characterized by the expression of the 
scavengers receptors CD163 and CD204, the mannose receptors CD206 and CD209, 
as wells as the secretion of collagen (Durafourt et al. 2012; Gabrusiewicz et al. 2011; 
Voisin et al. 2010). The overexpression of M-CSF receptor (M-CSFR) expressed in 
activated microglial cells stimulates a 2- to 3-fold greater phagocytic capacity compared 
with GM-CSF-induced cells (Leidi et al. 2009). Unlike M1, the M2 type has low 
superoxide production with a protective effect on cholinergic neurons (Sawada 2009). It 
can also promote remodeling and tissue repair by releasing growth factors and 
modulating the immune response (Schwartz 2010). Activated microglia alter gene 
expression patterns towards protective and anti-inflammatory mediators such as IL-10, 
insulin-like growth factor (IGF)-1, TGF-β, BDNF and glial cell line-derived neurotrophic 
factor (GDNF), inducing neurotrophin-dependent protective activity in damaged 
neurons (Butovsky et al. 2005; Sawada 2009; Weinstein et al. 2010). 
The M1 profile is transient with microglia returning to a surveying state. Recent 
studies demonstrate that IFN-γ and LPS stimulation promotes the M1 phenotype by 
targeting M2-associated genes, downregulating the IL-1  receptor (IL1 Rα1) (Louafi et 
al. 2010; Martinez-Nunez et al. 2011). Its regulation by several anti-inflammatory 
mediators is fundamental to attenuate microglial activation and promote the anti-
inflammatory M2 profile (Fenn et al. 2012). There are studies advocating that two-
phenotypes is a simplification and at least one additional activation state exists, as it is 
for T cells (Olah et al. 2012). 
 
Motility and migration 
Several steps and intermediate stages can be identified in microglia, including 
characteristics of process withdrawal, transition or hyper-ramification, and subsequent 
formation of new protrusions along with motility and migration (Kettenmann et al. 
2011). In the motility movement, resting microglial cells actively scan their environment 
with motile processes in highly random directions. By moving the fine processes 
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scanning can occur without cellular migration and therefore maintaining the proper 
functioning of the neuronal system (Davalos et al. 2005; Nimmerjahn et al. 2005). Still, 
the entire cell can migrate within brain tissue including translocation of their soma.  
The motility of microglia is controlled by autotaxin (ATX), a phospholipase D, 
expressed during the CNS development and in the normal adult brain. It converts 
lysophosphatidylcholine into lysophosphatidic acid (LPA), which is the true molecule 
that cells need to migrate (Liu et al. 2009). During normal neurodevelopment, ATX and 
LPA are involved in the differentiation of oligodendrocyte precursor cells (Yuelling and 
Fuss 2008). However, under pathological conditions like LPS administration, ATX is 
upregulated not only in microglia (Awada et al. 2014) but also in reactive astrocytes 
(Savaskan et al. 2007), allowing microglia to actively move to a lesion or site of 
infection following chemotactic gradients. There are a number of receptor systems that 
control the migration of microglial cells. Filopodia protrusion and dynamic rebuilding are 
needed for motility and directed migration (Kettenmann et al. 2011). However, rapid 
morphologic responses are diminished in neurodegenerative disorders and in the aged 
brain, where these cells show less motility and fewer processes, supporting the 
hypothesis of an impaired microglial functionality (Damani et al. 2011; Meyer-
Luehmann et al. 2008). Interestingly, ATX has the ability to minimize microglia cell 
death induced by oxidative stress suggesting a potential beneficial role for ATX (Awada 
et al. 2012; Awada et al. 2014). 
 
Phagocytosis by microglia 
Appearance of microglial cells with lipid- or myelin-loaded organelles in brain tissue 
sections points to phagocytic activity. The accumulation of cellular debris due to 
inadequate removal of dead and damaged cells may be detrimental to neighboring 
cells, and eventually lead to early onset of degenerative disorders and premature cell 
aging. Hence, the mechanism of clearance by phagocytosis is crucial in normal brain 
development and function, as well as in pathology and following regeneration 
(Schwartz et al. 2013). Microglia play a fundamental role by phagocyting apoptotic cells 
during development, and by pruning synapses in the postnatal brain (Kettenmann et al. 
2011). In addition, they may also phagocyte molecules and debris such as amyloid-β 
deposits. The activation of the receptor for advanced glycation end-products (RAGE), a 
cell surface receptor present in microglia and other CNS cells, that also recognizes 
HMGB1 for example, contributes to the clearance of this exceeding molecule that could 
ultimately lead to Alzheirmeir’s disease (Kraft and Harry 2011). Other studies also 
suggest that phagocytosis of injured tissue is important for remodeling and may limit 
secondary damage after brain injury (Zhao et al. 2007). During primary demyelination, 
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for example, microglial capacity to present antigen or to activate T cells are 
considerably low. However, during the following remyelination the accumulation and 
phagocytic activity of microglia is markedly downregulated. Clearance of debris by 
microglia may thus create an environment that is beneficial for regeneration (Voß et al. 
2012). 
Microglia and astrocytes express “scavenger receptors” that regulate the uptake of 
several substrates (Husemann et al. 2002). Their expression allows microglia to 
interact with astrocytes and neurons, and properly respond to their sent signals (Färber 
et al. 2005). GDNF and M-CSF are known to increase the phagocytic capability of the 
microglia (Chang et al. 2006; Mitrasinovic and Murphy 2003), whereas the prostanoid 
receptor subtype 2 (EP2) downregulates phagocytosis (Liang et al. 2005; Shie et al. 
2005). The expression of purinergic receptors may control microglial phagocytosis, 
given that the activation of P2Y6 receptors are associated with the induction of 
activated microglia and the triggering of phagocytosis, whereas activation of P2X7 
receptors suppresses phagocytosis (Fang et al. 2009; Inoue et al. 2009; Koizumi et al. 
2007). The differential expression of these receptors in response to the intensity of 
tissue injury, the type of injurious stimuli, or the presence of other soluble signals may 
control the degree of microglial response (Kraft and Harry 2011). 
 
 
4. Common neonatal clinical conditions 
 
Human newborns, especially preterm, are at high risk of brain damage (Brochu et 
al. 2011). In postnatal rats, a stage of brain development equivalent to 22-28 weeks 
gestation in humans, the BBB is still not fully mature and the blood vessels present 
leakage of plasma proteins (Saunders et al. 2012). Thus, neuroinflammation during 
brain development may alter brain functions profoundly, contributing to lasting cognitive 
deficits, changes in neurogenesis and to different behavioral phenotypes and 
psychiatric disorders in adulthood (Conrad et al. 2014; Drouin-Ouellet et al. 2011; 
Elmore et al. 2014a; Green and Nolan 2014; Malaeb et al. 2014). Among the most 
common neonatal clinical conditions are unconjugated hyperbilirubinemia and sepsis, 
which have been shown to deteriorate cognitive ability as well as to increase the risk of 
developing dementia, cerebral palsy, among others (Przekop and Sanger 2011; 
Widmann and Heneka 2014). The dose and timing of neonatal insult and offspring age 
now emerge as important factors for evaluating neuropsychiatric disorders in adults 
who experienced early life infection (Majidi Zolbanin et al. 2014).   
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4.1. Neonatal jaundice 
 
Physiological jaundice of the neonate is characterized by a preferential deposition 
of unconjugated bilirubin (UCB) in brain regions such as the basal ganglia, the 
hippocampus and the cerebellum, giving a yellowish color to the tissue (Brites 2012; 
Watchko 2006). Even though this condition is usually benign and UCB levels return to 
normal at the end of the first week of life, still there may be bilirubin-induced neurologic 
dysfunction with consequent minor brain deficits or with more severe encephalopathy 
as is the case of kernicterus that might even cause death (Shapiro 2010). UCB 
encephalopathy affects 0.5-2.4 children per 100,000 live births in North America and 
Europe (Burgos et al. 2012) and therefore it is important to understand the “how” 
behind such brain dysfunctions. 
 
4.1.1. Bilirubin metabolism in newborns 
UCB is a tetrapyrrolic molecule and the main product of the catabolism of heme, 
which is mostly present in erythrocyte hemoglobin. UCB has low aqueous solubility due 
to its structure, requiring albumin as a carrier protein to transport it in the blood. After 
birth there is a massive destruction of erythrocytes, due to their shorter lifespan, 
favoring the accumulation of UCB in the serum (Stevenson et al. 2011). In addition, 
UCB clearance in the newborn no longer occurs by the maternal machinery and has 
therefore to be done by its own less effective UDP-glucuronosyl transferase. This 
enzyme is responsible for converting molecules into more soluble forms to be 
eliminated from the body by the kidneys. Therefore, the immaturity of this enzyme 
further favors UCB accumulation (Dennery et al. 2001; Gourley 1997; Kawade and 
Onishi 1981). In the same manner, there is increased intestinal absorption of UCB due 
to the presence of intestinal β-glucuronidase (an enzyme that deconjugates the 
conjugated bilirubin species) combined with poor intestinal flora that usually 
metabolizes UCB into excretable products (Takimoto and Matsuda 1971; Vitek et al. 
2000). Breast-feeding is believed to increase the concentration of β-glucuronidase, 
promoting the reabsorption of UCB and consequent enterohepatic circulation (Gourley 
1997). A small percentage of UCB also circulates in the blood unbound to albumin, 
named free bilirubin (Bf). This form can easily bind to phospholipid membranes or even 
diffuse through them (Brito et al. 2006; Stevenson et al. 2011). The low serum levels of 
UCB in normal infants may have a protective effect against oxidative stress injury. 
However, these same levels are considered to be high and possibly hazardous in 
preterm infants and even in normal adults (Gkoltsiou et al. 2008; Stevenson et al. 2001; 
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Watchko and Maisels 2003). Therefore, and given its high incidence, it is extremely 
important to understand the impact of hyperbilirubinemia on brain development. 
 
4.1.2. Bilirubin’s neurotoxicity 
During neonatal hyperbilirubinemia, BBB disturbances may facilitate the entrance 
of Bf into the brain parenchyma (Palmela et al. 2012), which would consequently 
damage the remaining cells of the CNS (Fig. 1.14). BMEC are the first brain cells to 
have direct contact with circulating UCB, either in its free form or bound to albumin. It 
has been shown that UCB impairs the cellular membrane structure, properties and 
function (Brito et al. 2004; Brito et al. 2001). Thus, even though the brain endothelium 
was long viewed as a site for UCB crossing (Katoh-Semba and Kashiwamata 1980), it 
is now known that this process is at the expense of compromising the endothelial 
barrier (Palmela et al. 2012). 
BMEC and neurons are particularly sensitive to this molecule, and their contact 
can ultimately lead to cell death by both apoptosis and necrosis (Akin et al. 2002; 
Falcão et al. 2005; Falcão et al. 2007; Palmela et al. 2011). In addition, UCB triggers 
the release of pro-inflammatory cytokines by BMEC (Palmela et al. 2011) and glia 
(Fernandes et al. 2006; Fernandes et al. 2004; Silva et al. 2010), as well as to oxidative 
stress in both vascular and nerve cells (Brito et al. 2008a; Brito et al. 2008b; Palmela et 
al. 2011). 
Transporters are also affected by UCB, especially in BMEC. An increased 
expression and plasma membrane localization of GLUT1 (Cohen et al. 2006) translates 
into high glucose levels inside these cells. This process is then deeply connected with 
UCB toxicity by further producing the upcited oxidative stress (Kapitulnik et al. 2012). In 
addition, efflux transporters are also altered with an in vivo significant basolateral to 
apical active efflux of this molecule (Sequeira et al. 2007) that is in agreement with the 
increased expression of P-gp in brain samples from a kernicterus case (Brito et al. 
2013). Interestingly, P-gp expression in the rat vasculature increases with animal age, 
reaching its maximum level in adulthood. Hence the results in the kernicterus case may 
be a protective mechanism to overcome the possible immaturity of neonatal blood 
vessels to efflux UCB from the brain parenchyma, compared to the adult animals 
(Gazzin et al. 2011; Gazzin et al. 2008). 
The interaction of UCB with brain cells has been shown to disassemble the 
cytoskeleton of neurons (Silva et al. 2002), which may also be involved in the 
impairment of the TJ and AJ seen in BMEC (Palmela et al. 2012). In the particular case 
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of BMEC, the disruption of the endothelial monolayer leads to increased permeability 
that has been shown to be connected with angiogenesis (Pipili-Synetos et al. 1993; 
Rigau et al. 2007; Wei et al. 2003). Indeed, brain samples from an autopsy material of 
a kernicterus case showed more vessels, though with a poorly defined lumen (Brito et 
al. 2012), which is associated with immature vessels alike for P-gp. 
At last, UCB toxicity is accompanied by neuronal dysfunction, along with 
impairment of oligodendrogenesis, of myelination, and of the dendritic arborization in 
the cerebellum (Barateiro et al. 2013; Barateiro et al. 2012; Bortolussi et al. 2012). 
Moreover, other studies with kernicterus samples have shown neuronal dysfunction in 
different brain areas, particularly in the basal ganglia (Hachiya and Hayashi 2008). 
Altogether, UCB is able to trigger an injurious response in the neonatal BBB and 
neighboring cells. 
 
 
Figure 1.14 - Main alterations occurring at the neurovascular unit during hyperbilirubinemia. 
Unconjugated bilirubin (UCB) circulates in the blood bound to albumin, however when in high levels the 
interaction of free UCB (Bf) with the endothelium is enhanced leading to a greater passage across it into 
the parenchyma. Entrance is facilitated by increased numbers of caveolae and disruption of the 
intercellular junctions. The production of pro-inflammatory mediators and free radicals further induce 
damaging effects in pericytes, as well as astrocytes’ and microglia reactivity, neurodegeneration and 
decreased number of mature myelinating oligodendrocytes. 
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4.2. Neonatal sepsis 
 
Sepsis is a whole-body inflammatory response to a severe bloodstream infection. 
In past years its incidence has increased by 70% up to 37.7 hospitalization cases per 
10,000 population, of which 17% ended in death (Hall et al. 2011). In the children 
younger than 5 years that percentage increases to 68%. Human newborns, especially 
preterm, are at high risk (Brochu et al. 2011) and, indeed, the neonatal period (0-27 
days) accounts for 41% of deaths, particularly due to preterm births by sepsis (Black et 
al. 2010; Kissoon et al. 2011). The system’s attempt to eliminate the pathogens may 
increase by itself the permeability of the BBB, induce severe brain damage and 
ultimately lead to sepsis-associated encephalopathy (SAE). SAE is characterized by 
acute to lasting deficits in cognitive functions that may become permanent even after 
the patient’s recovery (Widmann and Heneka 2014), mostly associated with neuronal 
and astroglial dysfunction (Semmler et al. 2008; Stocchetti 2005). 
 
4.2.1. Endotoxin recognition 
LPS is an endotoxin from the wall of gram negative bacteria that is recognized by 
the innate immune system, hence being widely used in both in vitro and in vivo models 
to mimic sepsis. Interestingly, LPS appears not to cross the BBB given that its 
concentration does not increase in the brain parenchyma after administration (Banks 
and Erickson 2010). So, its neurologic effects appear to result from a direct contact 
with BMEC and consequent activation of a number of signaling pathways that lead to 
the release of inflammatory mediators (Berg et al. 2011; Grab et al. 2011; Tripathi et al. 
2009). As upcited, microglia and BMEC express TLRs that interact and respond to 
various PAMPs. In the case of LPS, its interaction with BMEC is through TLR4 in a 
process that requires the accessory proteins CD14 and myeloid differentiation 2 (MD2) 
(Shimazu et al. 1999; Ulevitch and Tobias 1995). The cytoplasmic protein regions of 
TLR4 interacts with the signaling adaptor myeloid differentiation factor 88 (MyD88) that 
transduces the signal to IL-1 receptor-associated kinase (IRAK)-1 and IRAK-2, 
resulting in transcriptional responses mediated primarily by the protein complex that 
controls the transcription of DNA, NF-κB, the extracellular-signal-regulated kinase 
(ERK), stress-activated protein kinases such as c-Jun N-terminal kinases (JNK) and 
p38. At last, it leads to the synthesis and release of pro-inflammatory mediators 
including cytokines, chemokines and IFN, as well as the upregulation of CAM (Armant 
and Fenton 2002; Karikó et al. 2004; Mallard et al. 2009; Spencer et al. 2011). In 
addition, there can be activation of COX-2 in BMEC that, as upcited, can culminate in a 
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fever response (Karikó et al. 2004; Kis et al. 2006; Spencer et al. 2011). In fact, 
administration of LPS is known to induce sickness behavior in mice, including weight 
loss (Lawson et al. 2013; Walker et al. 2013). COX-2 is also expressed by neurons, 
however, they do not influence the inflammatory response (Aid et al. 2010). All these 
mediators help in the clearance of bacteria, but at the same time also impair CNS 
functions that may induce brain damage (Nayak et al. 2014). 
 
4.2.2. Sepsis neurotoxicity 
The recognition of circulation leads to a cascade of events that ultimately alter the 
normal functioning of the CNS (Fig.1.15). One of the first events triggered by LPS on 
BMEC is the upregulation of the vascular CAM (VCAM-1), a protein that mediates the 
adhesion of immune cells to the vascular endothelium, and it also plays a part in 
leukocyte-endothelial cell signal transduction (Norman et al. 2008; Ramirez et al. 2012; 
Ruiz-Valdepeñas et al. 2011; Steiner et al. 2010). This is simultaneous with the 
increase in chemokines CCL2 and CCL3, where CCL2 establishes a chemotactic 
gradient for the directional cell migration into the brain parenchyma, and CCL3 is 
responsible for the initial recruitment and activation of immune cells (Chui and Dorovini-
Zis 2010). Also involved in the macrophage recruitment induced by LPS is the release 
of GM-CSF from BMEC (Dohgu et al. 2011), which in turn stimulates the production of 
granulocytes and monocytes (Erickson and Banks 2011). Surprisingly, a recent study 
affirms that acute neonatal LPS administration does not trigger peripheral monocyte 
recruitment (Yao et al. 2013). The compromise of integrity of the barrier properties by 
LPS stimulation, on the other hand, has a general consensus. Indeed endocytosis is 
augmented, with a significant increase in the area and number of endocytic vesicles 
(Defazio et al. 1997) (Banks and Erickson 2010; Banks et al. 1999; Defazio et al. 1997) 
and an impaired P-gp efflux transporter function (Salkeni et al. 2009). Moreover, TEER 
decreases following LPS treatment with a simultaneous increase in transendothelial 
permeability to the well-established tracers Evan’s Blue-bound to albumin (EBA) and 
sodium fluorescein (NaF) (Nishioku et al. 2009; Ramirez et al. 2012; Ruiz-Valdepeñas 
et al. 2011). The reason behind this could be directly related to the fragmentation and 
low expression of TJ and AJ proteins in BMEC (Li et al. 2012; Stolp et al. 2011; 
Veszelka et al. 2007). 
Direct effects on BMEC can also be exacerbated via the response of other cell 
types. Even though LPS does not cross a normal functioning BBB, not all brain 
microvessels sustain barrier properties. In fact, neurons and glial cells may respond 
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directly to LPS in circumventricular organs (Ott et al. 2010). As previously mentioned, 
astrocytes play an important role in the induction of BBB functions and in the 
modulation of the BBB phenotype without needing to be directly involved in the 
physical BBB properties (Colgan et al. 2008; Hayashi et al. 1997; Siddharthan et al. 
2007). Nonetheless, exposure of BMEC to conditioned medium from LPS-treated 
astrocytes has been reported to aggravate BBB disruption (Landoni et al. 2012). In 
fact, astrocytes exposed to LPS release high levels of pro-inflammatory cytokines, 
particularly by immature cells (Falcão et al. 2005), directly influencing 
neurodegeneration (Falcão et al. 2014). In addition, in vivo prenatal exposure to LPS 
triggers extensive astrogliosis in the white matter with consequent inhibition of 
oligodendrocyte maturation (van den Heuij et al. 2014). Interestingly, BBB disruption 
under inflammatory conditions has also been verified in co-cultures of BMEC with other 
CNS cells, as is the case of pericytes (Veszelka et al. 2007) and of microglia (Kacimi et 
al. 2011; Sumi et al. 2010). This phenomenon could be associated with augmented 
production of vasodilator NO by microglia, pericytes and BMEC (Kacimi et al. 2011; 
Kovac et al. 2011), showing the susceptibility of these cells to LPS. The in vivo 
administration of LPS is during the postnatal period also activates microglia in the white 
matter (Pang et al. 2010), with potential long-lasting defects in oligodendroglial 
maturation and myelination (Favrais et al. 2011; Volpe 2011). Moreover, in vivo 
administration of LPS also has a long-term impact in the production of hippocampal 
neurons, displaying less synaptic contacts as well as decreased dendritic volume and 
complexity (Valero et al. 2014). Equally to other inflammatory conditions, LPS also 
induces microglia to release pro-inflammatory cytokines that mediate alterations in 
neuronal network activity and apoptosis (Nimmervoll et al. 2013), as well as other 
inflammatory mediators like HMGB1 (Lamar et al. 2011), MMP-9 and -2 (Konnecke and 
Bechmann 2013) and ATX (Awada et al. 2012). 
Even though in the particular case of sepsis gender appears not to influence LPS-
response (Pang et al. 2010), still there are some discrepancies in the inflammatory 
response depending on the age, concentration, single or multiple injections, time of 
exposure, for what we believe it is important to understand the immune reasons behind 
such differences. 
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Figure 1.15 - Main alterations occurring at the neurovascular unit during neuroninflammation 
associated to sepsis. The activation of Toll-like receptors in endothelial cells and in circulating immune 
cells increases the production of cyclooxygenase (COX)-2, vasodilator nitric oxide (NO), and 
proinflammatory mediators, affecting the blood-brain barrier permeability and promoting the expression of 
cellular adhesion molecules (CAM). This would lead to the subsequent activation of other central nervous 
system resident cells, including microglia and astrocytes, which will further promote the production of pro-
inflammatory mediators and contribute to neurodegeneration and demyelination. Adapted from (Drouin-
Ouellet and Cicchetti 2012). 
 
Chapter 1 
 
50 
4.2.3. Sepsis as an aggravating factor of jaundice 
Sepsis is an important risk factor for neonatal hyperbilirubinemia or neonatal 
neurotoxicity (Gamaleldin et al. 2011; van Imhoff et al. 2011). Though clinical evidence 
is limited, it has been demonstrated that the neurotoxicity of UCB is amplified by the 
simultaneous exposure to LPS. In astrocytes simultaneously exposed to UCB and LPS, 
there is an over secretion of pro-inflammatory cytokines as well as an aggravation of 
necrosis-like and apoptotic cell death versus exposure to UCB alone, an effect that is 
sustained in more immature cells (Falcão et al. 2005; Fernandes et al. 2004). Neurons 
are also particularly susceptible to UCB and LPS damage. Pre-exposure to UCB 
followed by an inflammatory stimulus leads to an exacerbated apoptosis and to a 
greater neuritic breakdown (Falcão et al. 2007). Hence, LPS potentiates the 
immunostimulatory properties of UCB which, alongside with the exacerbation in glial 
immature cells, might thus point to the increased susceptibility of premature newborns 
to hyperbilirubinemia effects when associated with sepsis. Up to date, little is known 
about the effects induced on BMEC by joint exposure to these two neurotoxins.  
 
 
 
Altogether, developing prenatal/neonate inflammatory response can subsequently 
influence brain development. Nonetheless, few studies focus on the acute and lasting 
behavioral and cognitive consequences of an inflammatory insult during the embryonic 
or perinatal period.  
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5. Global aims of the thesis 
 
The main goal of the present work was to explore the effects of two frequent 
neonatal conditions, hyperbilirubinemia and systemic inflammation, on the developing 
neurovascular unit through the administration of UCB and/or LPS. 
As a first step we aimed to investigate the acute and delayed cellular effects of 
UCB and LPS, alone or in combination, on the brain microvascular endothelium. 
Therefore we intended to evaluate the functioning of the endothelium by assessing cell 
viability as well as transport and efflux pathways in BMEC. We additionally sought to 
explore the effects on the integrity of BMEC by evaluating the structure of organelles 
and intercellular junctions, the latter also in co-cultures with astrocytes.  
Given that astrocytes worsened the integrity of BMEC in co-cultures exposed to 
LPS, we further aimed to explore the acute effects of this endotoxin in the premature 
neurovascular unit. Thus we intended to evaluate cerebellar morphology, possible 
neuronal and white matter defects, as well as the response of inflammatory 
biomarkers. For deeper understanding of this neonatal condition we planned to study 
the processes of myelination, reactivity of glial cells and their interaction with the 
endothelium in CX3CR1gfp/+ transgenic mice. 
Lastly, the presence of acute-to-delayed damaging effects induced by LPS on the 
premature neurovascular unit, led us to further dissect the acute impact of 
neuroinflammation in the term brain. In addition, we intended to determine in young 
adult mice if the consequences were lasting and whether they were dependent of the 
neonatal age of LPS-treatment. We also aimed to determine the results of neonatal 
priming in the response to a second inflammatory stimulus. 
All together, we expect that the present study will contribute to elucidate the 
causes behind the sequelae observed in sepsis survivors, in order to define possible 
targets and timing of novel therapeutic strategies. Indeed, we believe that 
neuroprotective therapies will only be fully successful by understanding the different 
mechanisms involved in early and late neonatal inflammatory responses. 
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Abstract 
 
Sepsis and jaundice are common conditions in newborns that can lead to brain 
damage. Though lipopolysaccharide (LPS) is known to alter the integrity of the blood-
brain barrier (BBB), little is known on the effects of unconjugated bilirubin (UCB) and 
even less on the joint effects of UCB and LPS on brain microvascular endothelial cells 
(BMEC). Monolayers of primary rat BMEC were treated with 1 mg/ml LPS and/or 50 
μM UCB, in the presence of 100 μM human serum albumin, for 4 or 24 h. Co-cultures 
of BMEC with astroglial cells, a more complex BBB model, were used in selected 
experiments. LPS led to apoptosis and UCB induced both apoptotic and necrotic-like 
cell death. LPS and UCB led to inhibition of P-glycoprotein and activation of matrix 
metalloproteinases-2 and -9 in monocultures. Transmission electron microscopy 
evidenced apoptotic bodies, as well as damaged mitochondria and rough endoplasmic 
reticulum in BMEC by either insult. Shorter cell contacts and increased caveolae-like 
invaginations were noticeable in LPS-treated cells and loss of intercellular junctions 
was observed upon treatment with UCB. Both compounds triggered impairment of 
endothelial permeability and transendothelial electrical resistance both in mono- and 
co-cultures. The functional changes were confirmed by alterations in immunostaining 
for junctional proteins b-catenin, ZO-1 and claudin-5. Enlargement of intercellular 
spaces, and redistribution of junctional proteins were found in BMEC after exposure to 
LPS and UCB. LPS and/or UCB exert direct toxic effects on BMEC, with distinct 
temporal profiles and mechanisms of action. Therefore, the impairment of brain 
endothelial integrity upon exposure to these neurotoxins may favor their access to the 
brain, thus increasing the risk of injury and requiring adequate clinical management of 
sepsis and jaundice in the neonatal period. 
 
 
 
 
 
Keywords: blood-brain barrier; endothelial cells; lipopolysaccharide; unconjugated 
bilirubin; astrocytes; P-glycoprotein; metalloproteinases; tight junctions; adherens 
junctions; transmission electron microscopy. 
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1. Introduction 
 
The blood-brain barrier (BBB) is a dynamic interface between blood and brain 
compartments that protects nerve tissue from insults. Brain microvascular endothelial 
cells (BMEC), possessing unique properties, are considered the main constituents of 
the barrier. They regulate the selective passage of substances through the expression 
of specific influx and efflux transport systems (Cardoso et al. 2010). ATP-binding 
cassette (ABC) transporters, such as the efflux transporter P-glycoprotein (P-gp), 
export potentially toxic compounds. A relevant transcellular vesicular transport 
mechanism at the BBB occurs through caveolae, which are dynamic pieces of 
membrane enriched in cholesterol and sphingolipids, as well as in the structural protein 
caveolin-1 (Cardoso et al. 2010). Additionally, BMEC display cohesive intercellular 
junctional complexes, composed of tight junctions (TJs) and adherens junctions (AJs). 
TJs are formed by transmembrane proteins like claudins, occludin, tricellulin, junctional 
adhesion molecules, and cytoplasmic proteins, like the zonula occludens (ZO) family 
(Mariano et al. 2011). TJs are responsible for high transendothelial electrical resistance 
(TEER) and low paracellular permeability at the BBB (Deli 2009, Wolburg and Lippoldt 
2009). AJs are constituted by the transmembrane proteins vascular endothelial 
cadherins, nectins, platelet-endothelial cell adhesion molecule, and by the cytoplasmic 
catenins, comprising β-catenin (Niessen 2007). BMEC, pericytes and astrocytes share 
a thick basement membrane that is composed of various extracellular matrix (ECM) 
classes of molecules (Cardoso et al. 2010). Matrix metalloproteinases (MMPs) are 
known to digest basement membrane proteins and impair TJs integrity (Cardoso et al. 
2010). Pathological conditions affecting the integrity of intercellular junctions, BBB 
transporters or the basement membrane impair the barrier function of the BBB, which 
can lead to or further increase brain damage.  
Sepsis reflects an uncontrolled systemic inflammatory response to an infection that 
can cause organ dysfunction, eventually leading to shock or even death (Akrout et al. 
2009). Lipopolysaccharide (LPS) is the major component of the outer membrane of 
Gram-negative bacteria. It may circulate in low levels in the blood in certain diseases 
(Dohgu and Banks 2008), but high levels suggest infection or sepsis. Rat BMEC have 
been shown to express the Toll-like receptors (TLR) 2, 3, 4, 6 and the membrane 
cluster of differentiation 14 (CD14), which binds LPS (Nagyõszi et al. 2010, Singh and 
Jiang 2004). When activated, these receptors trigger the release of pro-inflammatory 
cytokines into the brain parenchyma and induce neuroinflammation. Our previous 
studies have shown that binding of LPS to rat primary BMEC co-cultured with 
astrocytes leads to increased permeability, reduced TEER, alterations in intercellular 
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junctions assembly, as well as to inhibition of P-gp activity (Veszelka et al. 2007). 
These changes in BBB integrity may favor the access of neurotoxins as well as of 
microbial pathogens to the brain (Dohgu and Banks 2008). 
Unconjugated bilirubin (UCB), the principal end product of heme catabolism, 
circulates in the plasma almost entirely bound to albumin due to its low solubility in 
aqueous medium, and the concentrations of unbound (free) bilirubin are in the nM 
range (Brites and Brito 2012). At low or slightly elevated concentrations as those 
reported for Gilbert patients, who present up to 100 μM total serum bilirubin and a UCB 
to albumin molar ratio of 0.2, UCB is a powerful antioxidant, able to provide protection 
against cardiovascular diseases and cancer (Brito et al. 2006, Vítek et al. 2002, 
Yesilova et al. 2008). It was also shown that UCB formed by upregulation of heme 
oxygenase-2, which is constitutive and highly concentrated in neurons, protects these 
nerve cells from H2O2-induced loss of cell viability. However, at higher concentrations, 
UCB is no longer beneficial but instead induces neuronal death (Doré et al. 1999). This 
dual behavior was observed in our own laboratory, where 10 nM free UCB were shown 
to protect neurons from H2O2-induced neuronal death, nuclear factor (NF)-κB activation 
and tumor necrosis factor (TNF)-α secretion, whereas 100 nM was neurotoxic 
(Gualazzi et al. 2007). These observations support the notion that UCB acts as a 
double-edged sword, either beneficial at low concentrations, or detrimental at elevated 
levels. Accordingly, in the experimental conditions that we have been consistently 
using with different cell types (Falcão et al. 2005, Fernandes et al. 2009, Gordo et al. 
2006), which reproduce a moderate or severe hyperbilirubinemia [UCB to human 
serum albumin (HSA) molar ratios of 0.5 and 1.0, respectively], toxicity is observed and 
oxidative stress appears as a relevant event (Brito et al. 2004, Brito et al. 2008a, Vaz et 
al. 2010). Hyperbilirubinemia is particularly common in the neonatal period due to the 
shorter life span of fetal erythrocytes, together with the immaturity of the hepatic 
clearance system (Brito et al. 2006). These high levels of UCB become neurotoxic by 
inducing oxidative and nitrosative stress, mainly in neurons (Brito et al. 2008b, Brito et 
al. 2010), and the release of pro-inflammatory cytokines by astrocytes (Fernandes et 
al. 2007) and microglia (Silva et al. 2010). Our most recent studies revealed that 
human BMEC exposed to UCB are also under nitrosative stress, as indicated by the 
upregulation of endothelial nitric oxide synthase and production of nitrites, the end-
product of nitric oxide, and release cytokines, such as the vascular endothelial growth 
factor and interleukin (IL)-6 (Palmela et al 2011). Interestingly, both nitric oxide and 
these cytokines are known to increase BBB permeability (de Vries et al. 1996, Deli et 
al. 2005). Despite such indication of a hyperpermeability of the BBB upon exposure to 
UCB, direct evidence of the disruption of the barrier properties by UCB exposure has 
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never been provided. Hyperbilirubinemia and sepsis frequently occur as associated 
pathological conditions in newborn infants. Sepsis is considered as a neurotoxicity risk 
factor during neonatal hyperbilirubinemia (Maisels et al. 2009) and a recent prospective 
study indicated that jaundiced infants with encephalopathy were more likely to have a 
coexistent infection than hyperbilirubinemic infants without brain damage (Manning et 
al. 2007). Our previous studies showed that the inflammatory response and cell death 
in astrocytes are exacerbated by LPS (Falcão et al. 2005, Fernandes et al. 2004). 
However, the effects produced by the combination of these compounds have never 
been studied in BMEC. The aim of this study was to reveal the effects of LPS and 
UCB, alone or in combination, on the morphological and functional characteristics of rat 
BMEC in conditions mimicking sepsis and moderate to severe hyperbilirubinemia. 
 
2. Materials and Methods 
2.1. Cell Cultures 
Animal care followed the recommendations of European Convention for the 
Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes 
(Council Directive 86/ 609/EEC) and National Law 1005/92 (rules for protection of 
experimental animals). Formal approvals to conduct all animal procedures in the 
experiments have been obtained from the Animal Experimentation Committee of the 
Biological Research Centre, Hungarian Academy of Sciences (Hungary), and from the 
local authorities (Permit number: XVI./03835/001/2006). 
Primary cultures of rat BMEC were prepared from 2-week-old Wistar rats, as 
previously described (Kis et al. 2001, Perrière et al. 2005, Veszelka et al. 2007). Briefly, 
meninges were removed from forebrains and gray matter was minced into small pieces 
in Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F12 (DMEM/F12, Biochrom 
AG, Germany), and digested in DMEM/F12 containing 1 mg/ml collagenase CLS2 
(Worthington, USA) for 1.5 h at 37ºC. Cell pellet was separated by centrifugation in 
20% bovine serum albumin-DMEM/F12 (1000xg, 20 min). Microvessels were further 
digested with 1 mg/ml collagenase-dispase (Roche Applied Sciences, Switzerland) in 
DMEM/F12 for 1 h at 37ºC. Microvessel endothelial cell clusters were separated on a 
33% continuous Percoll (Pharmacia, Sweden) gradient, collected and washed in 
DMEM/F12 before plating (1.5x105 cells/cm2) onto collagen type IV and fibronectin 
coated cell culture inserts or multiwell plates. Cultures were maintained in DMEM/F12 
supplemented with 15% fetal bovine serum (FBS) (Biochrom AG), 1 ng/ml basic 
fibroblast growth factor (Roche Applied Sciences), 100 μg/ml heparin (Biochrom AG),  
5 μg/ml gentamycin and 4 μg/ml puromycin (Perrière et al. 2005) (medium I) at 37ºC 
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with a humidified atmosphere of 5% CO2, for 2 days. On day 3, cells received new 
medium, which contained all components of medium I except puromycin (medium II). 
Primary cultures of glial cells were prepared from newborn Wistar rats (Kis et al. 
2001, Perrière et al. 2005, Veszelka et al. 2007). Meninges were removed, and cortical 
pieces were mechanically dissociated in DMEM containing 5 mg/ml gentamicin and 
10% fetal bovine serum and plated in poly-L-lysin coated 12-well dishes and kept for 
minimum 3 weeks before use. In confluent astroglia cultures 90% of cells were 
immunopositive for the astroglia cell marker glial fibrillary acidic protein, while the 
remaining 10% was immunopositive for CD11b, a marker of microglia. 
For co-culture, BMEC in cell culture inserts were placed into multiwells containing 
glia at the bottom of the wells with endothelial culture medium in both compartments. 
When BMEC became almost confluent 550 nM hydrocortisone was added to the 
culture medium (Hoheisel et al. 1998), for 1 day. 
 
2.2. Treatment of Endothelial Cells 
UCB (Sigma-Aldrich, USA), was purified according to the method of McDonagh 
and Assisi (1972) and stock solutions were extemporarily prepared in 0.1 M NaOH, 
under light protection, and the pH adjusted to 7.4 by addition of equal amounts of 0.1 M 
HCl. A stock solution of LPS (Escherichia coli O111:B4; Calbiochem, Germany) was 
prepared in PBS. Confluent monolayers of rat BMEC received medium II with 2% FBS, 
and were divided into four groups: untreated cells (control), 1 μg/ml LPS, 50 μM UCB, 
in the presence of 100 μM human serum albumin (fraction V, fatty acid free, Sigma-
Aldrich), or a combination of both, for 4 h and 24 h at 37ºC. The concentration of LPS 
was selected to mimic sepsis (Cepsinskas et al. 2008, Tien et al. 2010, Wang et al. 
2004) and was shown to induce damage to rat BMEC in our previous study (Veszelka 
et al. 2007). The use of albumin mimics the in vivo condition, where there is equilibrium 
between the bilirubin fraction that is bound to albumin, the one that is free in circulation 
and the one that binds to cells. Therefore, albumin functions as a sink for bilirubin, so 
that bilirubin may be continuously released from albumin as it binds to cells, therefore 
perpetuating the fraction that is available for interaction with cells and thus enhancing 
the effects. The UCB condition mimics moderate to severe hyperbilirubinemia in a term 
or a preterm infant, respectively (Ahlfors et al. 2003). In fact, studies performed in our 
lab showed that a group of full term neonates with moderate jaundice present a molar 
ratio of 0.42 (~195 μM bilirubin and ~445 μM serum albumin) (Brito, 2001), and that a 
preterm infant with a bilirubin to albumin molar ratio of 1.0 (~493 μM bilirubin and ~498 
μM serum albumin) at the second day of life dyed on the fourth with the diagnosis of 
kernicterus (Brito et al. 2012). In the present experimental conditions, the concentration 
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of unbound UCB (free UCB), determined by the peroxidase method (Roca et al. 2006), 
was 12 nM, which is close to the 19 nM value found in the moderate jaundiced infants 
studied (Brito 2001). The absence of biliverdin in the UCB-treated samples was 
assured by continuous absorbance spectra from 300 to 800 nm (Maghzal et al. 2009), 
which revealed no peaks at 380 and 665 nm.  
 
2.3. Cell Death Evaluation 
Standard evaluation of rat BMEC cytotoxicity was performed by measuring the 
release of LDH from cells with damaged plasma membrane into the incubation medium 
using a cytotoxicity detection kit (Roche Molecular Biochemicals, Germany), as 
previously described (Cepsinskas et al. 2008). The reaction was performed in a 96-well 
microplate and the absorbance measured at 490 nm, using a PR 2100 microplate 
reader from Bio-Rad (USA). All readings were corrected for possible interference of 
UCB absorption and the results expressed as percent of LDH release. Cytotoxicity was 
calculated as percentage of the total LDH release from untreated cells lysed with 2% 
Triton X-100 for 30 min. To evaluate apoptosis, cells fixed in freshly prepared 4% 
paraformaldehyde solution in phosphate buffer saline (PBS) were immunostained with 
Hoechst 33258 dye for 2 min at room temperature, and mounted in Glycerol Mount. 
Apoptotic nuclei were identified by condensed chromatin or nuclear fragmentation, and 
counted for each independent experiment in at least five random microscopic fields 
(400x) per sample, as described previously (Fernandes et al. 2004), using a Leica DFC 
490 camera (Leica, Germany) adapted to an AxioScope.A1 microscope (Zeiss, 
Germany). Although the fluorescence emission 
of Hoescht 33258 dye at 461 nm overlaps with the absorption of UCB at 460 nm, the 
possible quenching by UCB absorption does not interfere with the obtained results 
since apoptosis was evaluated based on morphology and not on fluorescence intensity. 
Activity of caspase-3 was measured by a colorimetric method (Calbiochem, Darmstadt, 
Germany), as usual in our lab (Palmela et al. 2011). Briefly, cells were harvested, 
washed with ice-cold PBS, and lysed for 30 min, on ice, in the lysis buffer [50 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4); 100 mMNaCl; 0.1% (w/v) 
cholamidopropyldimethylammonio-1-propanesulfonate; 1 mM dithiothreitol; 0.1 mM 
ethylenediaminetetraacetic acid]. The lysate was centrifuged at 10 000xg for 10 min at 
4ºC and the supernatants were collected and stored at -80ºC. The activity of caspase-3 
was determined by enzymatic cleavage of chromophore pNA from the substrate, 
according to manufacturer’s instructions. The proteolytic reaction was carried out in 
protease assay buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 
7.4); 100 mM NaCl; 0.1% (w/v) cholamidopropyldimethylammonio-1-propanesulfonate; 
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10 mM dithiothreitol; 0.1 mM ethylenediaminetetraacetic acid; 10% (v/v) glycerol], 
containing 2 mM substrate Ac-DEVD-pNA. Following incubation of the reaction 
mixtures for 2 h at 37ºC, the formation of pNA was measured at 405 nm with a 
reference filter of 620 nm. The results were expressed as relative activity vs. control 
samples. 
 
2.4. Functional Assay for P-gp 
Activity of P-gp was determined by measuring cellular accumulation of the P-gp 
substrate R123 per mg of protein content (Veszelka et al., 2007), and results were 
expressed as fold-change as compared to the respective control. In brief, treated rat 
BMEC were washed, and incubated for 1 h at 37ºC with Ringer–Hepes solution (118 
mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 5.5 mM D-glucose, 20 mM 
Hepes, pH 7.4) containing 10 μM R123. The solution was quickly removed, rat BMEC 
were washed three times with PBS and solubilized in 0.1 M NaOH. R123 content was 
determined using a Polarstar Galaxy fluorescent plate reader (BMG Labtechnologies; 
excitation at 505 nm, emission at 538 nm). The fluorescence emission of R123 is not 
quenched by bilirubin’s absorption, as the absorption of UCB is at 460 nm. Verapamil 
(100 μM, 30 min pre-incubation) was used as a reference P-gp inhibitor for the positive 
control (1.9-fold at 4 h and 2.8-fold at 24 h). Protein content was evaluated by the 
Bradford method (Bradford 1976) using Bio-Rad’s Protein Assay reagent (Bio-Rad). 
 
2.5. Gelatin Zymography 
Determination of MMP-2 and MMP-9 was evaluated as previously described (Silva 
et al. 2010). In short, aliquots of culture supernatants were analyzed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) zymography in 0.1% gelatine–
10% acrylamide gels under non-reducing conditions. After electrophoresis, gels were 
washed for 1 h with 2.5% Triton X-100 (in 50 mMTris pH 7.4, 5 mM CaCl2, 1 μM ZnCl2) 
to remove SDS and renature the MMPs species in the gel. Then the gels were 
incubated in the developing buffer (50 mM Tris pH 7.4, 5 mM CaCl2, 1 μM ZnCl2) 
overnight to induce gelatin lysis. For enzyme activity analysis, the gels were stained 
with 0.5% Coomassie Brilliant Blue R-250 (Bio-Rad) and destained in 30% 
ethanol/10% acetic acid/H2O. Gelatinase activity, detected as a white band on a blue 
background, was quantified by computerized image analysis and normalized with total 
cellular protein using Quantity One 1-D Analysis Software (Bio-Rad). 
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2.6. TEM Analysis 
Rat BMEC mono-cultures grown on inserts were fixed with freshly prepared 4% 
paraformaldehyde in 0.05 M cacodylate buffer (pH 7.5) for 30 min at 4ºC. After washing 
with cacodylate buffer several times, the membranes of the cell culture inserts with the 
cells were removed from their support and placed into 24-well chamber slide and were 
post-fixed in 1% OsO4 for 30 min. Following washing with distilled water, the cells on 
the membrane were dehydrated in graded ethanol, block-stained with 1% uranyl 
acetate in 50% ethanol for 30 min and embedded in Taab 812 (Taab; Aldermaston, 
UK). Following polymerization at 60ºC for 12 h, 50–60 nm ultrathin sections were cut 
perpendicularly for the membrane using a Leica UCT ultramicrotome (Leica 
Microsystems, UK) and examined using a Hitachi 7100 transmission electron 
microscope (Hitachi Ltd., Japan). Electron micrographs were made by Veleta, a 2κ x 2κ 
MegaPixel side-mounted TEM CCD camera (Olympus). Electron micrographs were 
edited by Adobe Photoshop CS3 (Adobe Photoshop Incorporation, CA, USA). 
 
2.7. Evaluation of the Monolayer Integrity 
The flux of Na-F (MW: 376 Da) across endothelial monolayers and co-cultures was 
determined as previously described (Kis et al. 2001, Veszelka et al. 2007). Briefly, cell 
culture inserts were transferred to 12-well plates containing 1.5 ml Ringer–Hepes 
solution in the abluminal compartments. Culture medium from luminal compartments 
was replaced by 0.5 ml Ringer–Hepes solution containing 10 μg/ml Na-F. Inserts were 
transferred at 20, 40 and 60 min to new wells containing Ringer–Hepes solution. Na-F 
levels were measured using a Hitachi F-2000 fluorescence spectrophotometer 
(excitation: 440 nm, emission: 525 nm). Flux across cell-free inserts was also 
measured. Endothelial permeability coefficient was calculated as previously described 
(Deli et al. 2005, Veszelka et al. 2007) and results were expressed in cm/s or as fold-
change compared to the respective control. TEER of mono-cultures and co-cultures, 
reflecting the paracellular permeability for mainly sodium ions in the present culture 
conditions, was measured using a STX-2 electrode coupled to an EVOM resistance 
meter (World Precision Instruments, USA). TEER readings of cell-free inserts (~100 Ω 
cm2) were subtracted from the values obtained with cells. For comparison of the data 
between mono-cultures and co-cultures TEER of cells treated with no addition (control) 
was considered 100%. 
 
2.8. Immunostaining for Intercellular Junctions 
BMEC in mono-culture or co-cultured with astrocytes were stained for junctional 
proteins ZO-1, claudin-5 and β-catenin. Cultures were washed in PBS and fixed with 
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ethanol (95%)–acetic acid (5%) (v/v) for 10 min at -20ºC (Veszelka et al. 2007). Cells 
were blocked with 3% BSA and incubated with primary antibodies anti-ZO-1 (1:200), 
anti-claudin-5 (1:200), and anti-β-catenin (1:200) (Invitrogen, USA) overnight at 4ºC. 
Incubation with secondary antibody Cy3-labelled anti-rabbit IgG (1:200) (GE 
Healthcare, UK) and Alexa 488 anti-mouse IgG (1:500) (Invitrogen) lasted for 1 h at 
room temperature. Nuclei were counterstained with Hoechst 33258 dye. Between 
incubations cells were washed three times with PBS. Coverslips were mounted in Gel 
Mount (Biomeda, USA) and staining was examined by a Nikon Eclipse TE2000 
fluorescent microscope (Nikon, Japan) and photographed using a Spot RT digital 
camera (Diagnostic Instruments, USA) or using a Leica DFC 490 camera (Leica, 
Germany) adapted to an AxioScope.A1 microscope (Zeiss, Germany).  
 
2.9. Statistical Analysis 
Results of at least three different experiments were expressed as mean ± S.E.M. 
Differences between groups were determined by one-way ANOVA using Prism 5.0 
(GraphPad Software, San Diego, CA) followed by multiple comparisons 
Bonferronipost-hoc correction. Statistical significance was considered when P values 
were lower than 0.05. 
 
3. Results 
3.1. LPS, UCB and their Combination Induce Cell Death in Rat BMEC 
 
Primary cultures of rat BMEC are commonly used as simplified in vitro models of 
the BBB (for review see Deli et al. 2006 and Tóth et al. 2011). In order to evaluate the 
impairment of rat BMEC viability by exposure to LPS and UCB, we assessed necrosis-
like cell death by determining the release of intracellular lactate dehydrogenase (LDH) 
into the incubation medium. As seen in Fig. 2.1A, LPS triggered a mild, though not 
statistically significant, elevation of LDH release, which attained maximum levels of 
9.4% and 16.2% at 4 and 24 h, respectively, corresponding to an overall time-
dependent elevation (P<0.01) in the extent of cell death. With UCB, higher values were 
achieved (16.9% at 4 h and 21.4% at 24 h, P<0.01 and P<0.05, respectively, as 
compared to the respective control), reflecting a time-dependent loss of cell viability 
(P<0.05). There was no aggravation in necrosis-like cell death when cells were 
exposed to both LPS and UCB (LDH release at 24 h: 20.3%, P<0.05 as compared to 
the respective control), even though it similarly increased with the time of exposure 
(P<0.01). 
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Either UCB or LPS induced apoptosis in BMEC, as observed by staining 
endothelial nuclei with Hoechst 33258 dye followed by analysis of nuclear 
morphological features (Figs. 2.1B,C), in accordance with previous demonstrations 
(Palmela et al. 2011, Shiori et al. 2009). LPS induced apoptotic cell death in a time-
dependent manner (P<0.01), reaching 18.0% (P<0.05) after 24 h treatment. When 
exposed to UCB, the percentage of cells with apoptotic morphology was already 
significantly increased at 4 h (19.6%, P<0.001) and sustained at 24 h (20.7%, 
P<0.001). As for LDH, there was no increment in UCB-induced apoptotic cell death by 
co-incubation with LPS. In contrast, apoptosis raised from 13.1% in LPS-treated cells 
to 18.7% in cells treated with both LPS and UCB for 4 h (P<0.01 as compared to LPS 
alone). To note that this difference disappeared as the incubation was extended to 24 h 
and death continued to increase in cells treated with LPS alone. 
We also studied the activity of caspase-3 (Fig. 2.1D). LPS induced no significant 
alterations in caspase-3 activity at the time-points studied, reaching a maximum 
elevation of 1.2-fold at 4 h. On the other hand, cells exposed to UCB had a significant 
increase in caspase-3 activity at the earliest time-point, attaining 1.9- and 2.0- folds for 
UCB and UCB with LPS, respectively (P<0.05). At 24 h cells treated with UCB alone 
revealed a sustained caspase-3 activity (1.7-fold, P<0.05). 
 
3.2. Activity of ABC Transporter P-gp is Impaired by LPS and UCB 
We studied the effects of LPS and UCB on the efflux transporter P-gp activity  
(Fig. 2.2), based on the measurement of cellular accumulation of rhodamine 123 
(R123), the main substrate dye used to assess P-gp function. Accumulation of the 
substrate reflects a decreased activity of the efflux transporter, as have been 
recognized and used, particularly in primary cultures of BMEC (Fontaine et al. 1996, 
Veszelka et al. 2007). Results were expressed as fold-change from control, which 
presented ~114 ng R123/mg protein. P-gp activity was already diminished following 4 h 
exposure to LPS or UCB, as indicated by the 1.2-fold elevation in intracellular levels of 
R123 (P<0.05). Exposure to both LPS and UCB increased P-gp inhibition with time 
(P<0.05) and aggravated the inhibition induced by LPS alone at 24 h (1.2-fold for LPS 
vs. 1.4-fold for LPS plus UCB, P<0.05). 
 
3.3. Activities of MMP-2 and MMP-9 are Increased by LPS and UCB 
It has been known that the release of active MMPs is related to the opening of the 
BBB in LPS-injured brain tissue (Lee et al. 2011). The activities of MMP-2 and MMP-9 
released by rat BMEC after exposure to the insults were similar (Fig. 2.3). Significant 
increases in the activity of secreted MMPs were already observed at 4 h for both LPS 
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(1.7-fold for MMP-9 and 1.8-fold for MMP-2, P<0.05) and UCB (1.9-fold for MMP-9 and 
MMP-2, P<0.05), which were less marked at 24 h treatment though still statistically 
significant. No significant aggravation of the effect was observed by simultaneous 
exposure to both neurotoxins, either at 4 or at 24 h. 
 
 
Figure 2.1 – Lipopolysaccharide (LPS) and unconjugated bilirubin (UCB) induce cell death in brain 
microvascular endothelial cells. Culture medium was collected for determination of lactate 
dehydrogenase (LDH) activity (A). Nuclei were stained with Hoechst 33258 dye and morphological 
features of apoptosis are pointed (arrows) (B). The number of apoptotic nuclei was counted and results 
were expressed as percentage of the total number of nuclei (C). Cell lysates were obtained for caspase-3 
activity determination (D). Results are mean ± S.E.M. from at least five independent experiments 
performed in duplicate. Scale bar, 20 μm. *P<0.05, **P<0.01 and ***P<0.001 vs respective control; 
§
P<0.05, 
§§
P<0.01 vs LPS at the same time-point; 
#
P<0.05 and 
##
P<0.01 from 4 h. 
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Figure 2.2 – Lipopolysacharide (LPS) and unconjugated bilirubin (UCB) inhibit P-glycoprotein (P-
gp) activity in brain microvascular endothelial cells. To evaluate if P-gp is functioning properly, it was 
measured the protein’s ability to remove the substrate rhodamine 123 (R123). After treatment, cells were 
incubated for  0 min with 10 μM R12 . Total protein extracts were collected, R12  accumulation 
fluorescent emission was determined and results were expressed per mg of protein. Values presented are 
means ± S.E.M., from at least four independent experiments performed in duplicate. *P<0.05, **P<0.01 
and ***P<0.001 vs respective control; 
§
P<0.05 vs LPS at the same time-point; 
#
P<0.05 from 4 h.  
 
 
Figure 2.3 – Lipopolysaccharide (LPS) and unconjugated bilirubin (UCB) activate metallopro-
teinase-9 (MMP-9) and metalloproteinase-2 (MMP-2) released by brain microvascular endothelial 
cells. A representative gel from one experiment is shown, where MMP-2 and MMP-9 were identified by 
their apparent molecular mass of 67 and 92 kDa, respectively (A). The intensity of the bands was 
quantified by scanning densitometry and results for MMP-9 (B) and MMP-2 (C) were standardized with 
respect to total protein content. Results are mean ± S.E.M. from at least four independent experiments 
performed in duplicate. *P<0.05 and **P<0.01 vs respective control; 
##
P<0.01 from 4 h. 
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3.4. LPS and UCB Alter Unique Ultrastructure of Rat BMEC 
Transmission electron microscopy (TEM) investigated in detail the impairment of 
rat BMEC monolayers exposed to the neurotoxins (Fig. 2.4). In cell cultures treated 
with LPS or UCB, several signs of cell damage and the presence of apoptotic bodies 
released by rat BMEC were detected, confirming the occurrence of apoptotic 
processes. Our observations include heavily damaged mitochondria that were swollen 
and more electron dense than in control cells, indicating an impairment in mitochondrial 
function in both conditions. In addition, the rough endoplasmic reticulum was typically 
swollen in the treated cells. This alteration may indicate a lesion of the synthesis of 
lipids or metabolism of sugars, and also impairment in their detoxification function. 
Moreover, it was observed irregularly shaped vacuoles and holes in the cytoplasm, 
together with unevenness and little projections instead of a rather smooth, elongated 
shape of the rat capillary endothelial cell. Appearance and abundance of caveolae-like 
invaginations in the plasma membrane was frequently found in LPS-treated cells, an 
effect that was not so evident in cells incubated with UCB. TEM analysis revealed 
shortened extension of intercellular contacts in LPS-treated cells and no intact cell-cell 
junctions could be detected in UCB-treated cells. 
 
3.5. Exposure to LPS and UCB Impair the Barrier Function of Rat BMEC 
TEER and paracellular permeability to small molecule tracers provide information 
on barrier integrity in various in vitro BBB models (Deli et al. 2005, Tóth et al. 2011, 
Calabria and Shusta 2008). We have demonstrated that LPS treatment caused a 
concentration- and time-dependent decrease in TEER and increased permeability to 
tracers in rat BMEC co-cultured with astrocytes (Veszelka et al. 2007), but, so far, such 
features have not been explored in cells exposed to UCB or to both neurotoxins, either 
in co-cultures or in BMEC mono-cultures. 
Permeability to sodium fluorescein (Na-F) was of ~1.9x10-5 cm/s in control BMEC 
monolayers. LPS exposure induced an elevation of permeability to 3.4x10-5 cm/s at 4 h 
(P<0.01), and only a moderate increase after 24 h exposure (2.1x10-5 cm/s, P<0.05 vs. 
4 h) (Fig. 2.5A). Similarly, cells treated with UCB showed an increased permeability at 
4 h treatment (4.0x10-5 cm/s, P<0.01), with a sustained effect at 24 h. Alterations in 
permeability were significantly higher after simultaneous exposure to both insults at  
24 h compared to those treated with LPS alone (P<0.05). 
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Figure 2.4 – Lipopolysaccharide (LPS) and unconjugated bilirubin (UCB) disrupt ultrastructure of 
brain endothelial cells. Cells were treated with no addition (control) (A,D,E), LPS (B,F,G) or UCB (C,H,I) 
and were analyzed by transmission electron microscopy. Black arrows, tight intercellular junctions; grey 
arrows, disruption of the plasma membrane; arrowheads, invaginations of the plasma membrane; a, 
apoptotic cells bodies; m, mitochondria; N, cell nuclei; RER, rough endoplasmic reticulum; v, vacuole. 
Representative results from one of four independent experiments are shown. 
 
TEER was assessed after exposure to LPS and/or UCB for 4 h and 24 h  
(Fig. 2.5B), and results were compared with those obtained in controls (~42 Ω.cm2 after 
subtracting the values of cell free inserts). LPS treatment led to a significant decrease 
in TEER after 4 h exposure (20 Ω.cm2, P<0.01) and monolayers partially recovered 
from the early onset damage at 24 h, as indicated by higher resistance levels (36 
Ω.cm2, P<0.05 vs. 4 h). On the other hand, UCB caused lower values through longer 
periods of exposure, as indicated by the TEER decrease at 4 h  
(24 Ω.cm2, P<0.05) and at 24 h (21 Ω.cm2, P<0.001). Incubation with both LPS and 
UCB for 24 h did not aggravate UCB-induced effect, but TEER values were 
significantly lower than for 24 h treatment with LPS alone (P<0.01 as compared to the 
respective control, and P<0.05 from LPS alone). 
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Figure 2.5 – Lipopolysaccharide (LPS) and unconjugated bilirubin (UCB) disrupt the endothelial 
monolayer. Permeability to sodium fluorescein (Na-F_Pe) (A) and transendothelial electrical resistance 
(TEER) (B) were determined after exposure. All values presented are means ± S.E.M. from at least four 
independent experiments performed in duplicate. *P<0.05, **P<0.01 and ***P<0.001 vs respective control; 
§
P<0.05 vs LPS at the same time-point; 
#
P<0.05 from 4 h. 
 
 
Co-cultures of BMEC with astrocytes are accepted as more complex and tighter in 
vitro models of the BBB since astrocytes induce the barrier properties of BMEC 
(Cardoso et al. 2010, Deli et al. 2005, Tóth et al. 2011). To reinforce our observations, 
a set of experiments was performed in rat BMEC co-cultured with glial cells where the 
paracellular permeability to Na-F and the TEER were assessed 24 h after treatment 
(Fig. 2.6). In co-cultures, untreated BMEC had higher TEER (2   Ω.cm2) and lower 
permeability (2.1x10-6 cm/s) values than mono-cultures. The permeability pattern was 
similar to that of mono-cultures, though in general 2-fold greater and there was a 
significant increase induced by LPS. Regarding TEER, the response to the neurotoxins 
was also similar in both models, but the alterations resulting from the presence of 
astrocytes were more modest as compared with mono-cultures, as well as in 
comparison with those observed for permeability, particularly in UCB-treated cells. 
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Figure 2.6 – Effects of lipopolysaccharide (LPS) and unconjugated bilirubin (UCB) on endothelial 
integrity in mono-cultures and cocultures. Permeability to sodium fluorescein (Na-F_Pe) (A, B) and 
transendothelial electrical resistance (TEER) (C, D) were determined in monocultures (A,C) and  
co-cultures (B,D) after 24 h exposure. All values presented are means ± S.E.M. from at least two 
independent experiments performed in triplicate. **P<0.01 and ***P<0.001 vs respective control; 
§§
P<0.01 
and 
§§§
P<0.001 vs LPS at the same time-point. 
 
3.6. Junctional Proteins in Rat BMEC are Altered by LPS and UCB 
Cellular expression and localization of the AJ protein β-catenin was also assessed 
in mono-cultures both at 4 h and at 24 h (Fig. 2.7). After LPS treatment cell contours 
were hardly visible at 4 h, whilst β-catenin was relocated at the membrane at 24 h.  
β-catenin appeared as small dots in LPS-treated cells, which were particularly evident 
at 4 h incubation, contrasting with the normal staining observed in control cells. 
Treatment with UCB also revealed alterations in the distribution of β-catenin, which 
varied with the time of exposure. In fact, a short incubation led to a transient 
translocation of the protein from the membrane to the cytosol; this effect appears to be 
transient as at 24 h the presence of the protein was clearly noticed at intercellular 
contacts. Interestingly, an overall increase in fluorescence intensity of β-catenin was 
detected in cells treated for 24 h with UCB (1.3-fold from control, P<0.01), whereas a 
decrease was observed for LPS (0.7-fold, P<0.01). As a result of these opposite 
variations, no significant change in the fluorescence intensity was observed in cells 
simultaneously treated with LPS and UCB. 
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Figure 2.7 – Lipopolysaccharide (LPS) and unconjugated bilirubin (UCB) modify the distribution of 
β-catenin in brain endothelial cells. Cells in mono-culture or co-cultured with astrocytes were fixed and 
immunostained with an antibody against β-catenin to evaluate its cellular localization (scale bars, 40 and 
20 μm, respectively). Disruption of the monolayer with gaps between endothelial cells (*), alterations in 
protein patterns (arrowheads) with the presence of dot-like staining (yellow arrow), and perinuclear 
distribution (arrows) are indicated. Representative results from one of two independent experiments are 
shown. 
 
Disorganization of the monolayer together with gaps between endothelial cells was 
also detected in cells exposed to the neurotoxins. In rat BMEC co-cultured with 
astrocytes not treated with LPS or UCB (control) for 24 h, β-catenin was mainly located 
at the plasma membrane. Compared to mono-cultures, LPS-treated cells also showed 
greater expression of β-catenin but with visible large intercellular spaces. In UCB-
treated cells, on the other hand, the intensity of β-catenin immunostaining in the 
cytoplasm was weaker and that at the cell contours was greater than in monocultured 
cells at the same period. In BMEC treated with LPS and UCB, β-catenin was noticeable 
not only at the plasma membrane but also in the cytosol including the perinuclear 
region. Moreover, the staining revealed intercellular gaps. 
Immunostaining for TJ proteins ZO-1 and claudin-5 was performed in mono-
cultures and co-cultures after 24 h of treatment with the neurotoxins (Figs. 2.8  
and 2.9). In control cells, the contour line observed for ZO-1 appeared thicker in co-
cultures than in mono-cultures, similarly to that observed for β-catenin. Despite the 
beautiful labelling obtained for claudin-5 in mono-culture control cells, the contours 
appeared lighter than in co-cultures. Moreover, the staining observed in the cytosol 
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nearly disappeared in co-cultures and, therefore, the main immunostaining was at the 
plasma membrane when endothelial cells were co-cultured with astrocytes, for both 
ZO-1 and claudin-5. In mono-cultures, cells exposed to LPS or UCB alone, or to their 
combination, showed altered morphology and staining patterns for ZO-1 and claudin-5, 
as compared with untreated cells that showed elongated shape and well delineated 
contours. Cells treated with UCB, or its combination with LPS, showed fragmented 
staining for claudin-5, suggesting an impairment of the intercellular junctions. 
Moreover, spaces were visible between adjacent cells, further confirming the damaged 
connection between cells following treatment with the insults. Unlike the simplified 
model, co-cultured cells treated with LPS looked more altered at this time-point. They 
showed large spaces between cells and less staining for ZO-1 at the membrane, with 
more cytoplasmic and perinuclear immunoreactivity. On the other hand, UCB seemed 
to have a greater effect on claudin-5 with a decrease in plasma membrane 
immunoreactivity. 
 
 
 
 
 
Figure 2.8 – Lipopolysaccharide (LPS) and unconjugated bilirubin (UCB) alter zonula occludens-1  
(ZO-1) expression in brain endothelial cells. Cells, either in mono-culture or co-cultured with astrocytes, 
were fixed and immunostained with an antibody against ZO-1 to evaluate its cellular localization and 
pattern of expression, as well as integrity of the monolayer. Disruption of the monolayer with gaps between 
endothelial cells (*), alterations in protein patterns (arrowheads) and perinuclear distribution (arrows) are 
indicated. Representative results from one of two independent experiments are shown. Scale bar, 20 μm. 
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Figure 2.9 – Lipopolysaccharide (LPS) and unconjugated bilirubin (UCB) alter expression of 
claudin-5 in brain endothelial cells. Cells, either in mono-culture or co-cultured with astrocytes, were 
fixed and immunostained with an antibody against claudin-5 to evaluate its cellular localization, pattern of 
expression and integrity of the monolayer. Disruption of the monolayer with gaps between endothelial cells 
(*) and alterations in protein patterns (arrowheads) are indicated. Representative results from one of two 
independent experiments are shown. Scale bar, 20 μm. 
 
4. Discussion 
In the present study, confluent monolayers of primary rat BMEC were used alone 
or in co-culture as in vitro models of the BBB. The integrity of the endothelial barrier 
and its functional and morphological characteristics were evaluated after treatment with 
LPS and/or UCB. Our study shows that LDH release in primary rat BMEC is 
significantly modified by UCB and by both insults combined, but that at least 77% of  
cells are viable, which is a desirable experimental condition to perform functional 
studies such as the assessment of P-gp and MMPs activities. Necrotic-like cell death 
induced by the same concentration of LPS was reported in transformed bovine BMEC 
by Karahashi et al. (2009), though the extent was over 40% at 24 h and no significant 
damage was seen at 4 h. Such divergent viability data may not only reflect different 
reactions to neurotoxins between species and between cell lines and primary cultures 
(Silva et al. 2006), but can mostly be due to the fact that this study was performed with 
medium supplemented with 10% FBS, unlike our own models. In studies performed in 
similar conditions to ours, namely with no addition of soluble CD14, there is also little 
LPS-induced LDH release for up to 16 h, being this the maximum time studied (Shiori 
et al. 2009). Still, our conditions are suitable for LPS interaction with BMEC given that 
our medium contains 2% FBS, which has soluble CD14, and that EC also express 
membrane CD14 in the presence of LPS (Singh and Jiang 2004). LDH release induced 
by UCB is in agreement with our previous observations in a cell line of human BMEC 
(Palmela et al. 2011), although in a slightly different range. Apoptotic cell death 
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resulting from exposure to LPS is observed in rat primary BMEC, and the present data 
are in agreement with that obtained in cell lines of rat, bovine and human BMEC 
(Karahashi et al. 2009, Liu et al. 2004). UCB-induced apoptosis, based on analysis of 
nuclear morphology with Hoechst staining and confirmed by caspase-3 activity, is in 
line with our previous observations in a human BMEC line treated with UCB (Palmela 
et al. 2011), as well as with those of Akin et al. (2002) in bovine BMEC. An interesting 
observation from this study is that the cell damage shown by LDH release, apoptotic 
cell death and caspase-3 activation tend to be higher and occur earlier in UCB-treated 
cells than in LPS-exposed ones. Accordingly, LPS did not further enhance UCB-
induced cell demise. On the other hand, while no significant apoptosis or caspase-3 
activation were detected by LPS alone at 4 h, cells co-exposed to both insults at this 
time-point exhibited a similar profile to that of UCB.  
P-gp is an important efflux transporter at the BBB, which protects the nervous 
system from toxic compounds. Therefore, its inhibition compromises brain protection 
and promotes toxicity. The retention of R123 by LPS in our experiments reflects an 
impairment of the transporter activity and confirms previous reports obtained both in 
vitro (Harz et al. 2006, Veszelka et al. 2007) and in vivo (Salkeni et al. 2009, Sequeira 
et al. 2007). The data collected also revealed an inhibition of P-gp activity by UCB, 
which is a substrate of P-gp in bovine BMEC (Sequeira et al. 2007). Brain UCB levels 
were increased in P-gp deficient mice (Watchko et al. 1998) and in rats treated by P-gp 
inhibitors (Hankø et al. 2003, Watchko et al. 1998). It is interesting to point out that 
ongoing studies in our laboratory revealed higher expression of P-gp in the brain 
parenchyma (endothelial cells, astrocytes and neurons) of a human newborn infant 
who died from kernicterus, the most severe pathologic outcome of hyperbilirubinemia 
(Brito et al. 2013). These results suggest that the increase in P-gp expression may be a 
compensatory mechanism to overcome the lack of efficiency in its activity at the BBB. 
On the other hand, if UCB levels inside endothelial cells are extremely elevated, the 
transporter might not have the capacity to export both UCB and R123 simultaneously, 
resulting in higher R123 contents. 
MMPs are a family of proteases, important in normal development and in 
endothelial cell migration given their ability to degrade the ECM surrounding BBB 
capillaries (Galvéz et al. 2001). As ECM plays an important role in the induction of BBB 
properties (Cardoso et al. 2010), the activity pattern of secreted MMPs after exposure 
to LPS and/or UCB was investigated in the present study. Both MMP-2 and MMP-9 
have similar activity patterns, which may be due to a homologous function. Our data 
are in agreement with previous studies where it has been proven that exposure to LPS 
results in enhanced secretion of active MMP-2 in human umbilical vascular endothelial 
 LPS and/or UCB impair the integrity and function of BMEC 
 
101 
cells (Kim et al. 2000), and that microglial cells treated by UCB secrete active MMP-2 
and MMP-9 (Silva et al. 2010). Released MMPs may lead to degradation of the ECM 
and weaken the barrier properties of the BBB by impairing the integrity of the basement 
membrane (Tilling et al. 1998), which might then favour the access of neurotoxins to 
the brain. Interestingly, activation of MMPs is more marked at 4 h than at 24 h, 
consistent with the striking alterations observed at earlier time for permeability and 
TEER. 
Ultrastructural analysis has indicated that apoptotic cell bodies are visible following 
both LPS and UCB treatments, supporting our apoptosis data obtained by fluorescence 
microscopy. All treated cells presented disruption of the organelles, but it was 
interesting to notice that the impairment of ultrastructure was more marked for UCB 
than for LPS. This observation is consistent with the greater extent of apoptotic and 
necrotic-like cell death by UCB and might be related to UCB interaction with cell 
membranes and perturbation of their dynamic properties that we have previously 
demonstrated (Brito et al. 2001, Rodrigues et al. 2002). Another important observation 
is the enhanced formation of caveolae-like structures after LPS exposure, in line with 
previous observations in rats (Kittel 1999, Kittel et al. 2007). Caveolin-1 plays an 
important role in capillary formation and, when up-regulated, it activates MMP-2 and 
MMP-9 (Kim et al. 2000, Phillips and Birnby 2004) [63,69]. These MMPs were 
particularly amplified after exposure to LPS for 4 h, thus pointing to a possible relation 
between these partners. 
Rat BMEC exposed to LPS still present TJs, though the TJ-stiched membrane 
length appeared shorter compared to untreated samples, whereas TJs are hardly 
visible in UCB-treated cells. This observation may suggest that paracellular passage of 
UCB across the endothelial monolayer may be facilitated. Although a TEM study by 
Böhm et al. [1995] reported UCB-induced damage of both cell and nuclear membranes 
in human basal skin cells, as far as we know, this is the first report describing UCB-
induced ultrastructural alterations in endothelial cells forming the BBB. 
Our permeability results on brain endothelial mono-cultures are in line with those 
recently obtained by He and collaborators (2011), where a short exposure to LPS 
induced hyperpermeability and TEER decrease in a BMEC line. Moreover, a study 
reports that TLR4 and CD14 mRNA levels increase up to 3 h after LPS exposure and 
then gradually decrease, though remaining detectable for up to 9 h (Singh and Jiang 
2004). This observation might explain why LPS effects in mono-cultures become less 
marked as the incubation is prolonged. This fact, together with the higher activity of 
MMPs by a short exposure, shall then contribute to the greatest impairment of barrier 
indicators observed at 4 h. In co-cultures, the present results are supported by our 
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previous reports that LPS elevates permeability and decreases TEER (Veszelka et al. 
2007). It has been long stated that astroglial cells strengthen BMEC barrier properties 
(Cardoso et al. 2010, Deli et al. 2005, Tóth et al. 2011) and prevent the increase of 
endothelial permeability after several stimuli, such as hypoxia or ischemia (Gesuete et 
al. 2011, Kondo et al. 1996). The protective effect of glial cells against LPS-mediated 
injury was also demonstrated in bovine brain endothelial cells (Descamps et al. 2003). 
Nonetheless, it has been proven that, in inflammatory conditions, astrocytes increase 
human BMEC permeability via IL-1β secreted to the cell culture supernatant and this 
could be reversed through a monoclonal antibody against IL-1β (Didier et al. 2003). 
Regarding UCB, no former studies have been performed on its effects on brain 
endothelial barrier properties. Raimondi et al. (2006) demonstrated that exposure of 
human intestinal cell line Caco-2 to UCB decreases transepithelial electrical resistance 
and increases the paracellular flux of 10 kDa dextran. Our present findings obtained in 
rat BMEC regarding UCB-induced decrease in TEER and increase in permeability are 
consistent with the data found in Caco-2 epithelial cells (Raimondi et al. 2006). Unlike 
the intestinal cells, rat BMEC monolayers do not recover at later time-points, indicating 
high endothelial sensitivity to UCB toxicity and a greater potential of UCB for 
neurotoxicity. Endothelial cells treated with both compounds for 24 h displayed more 
serious barrier dysfunction as compared with LPS alone, pointing to a failure of the 
recovery process that might happen when sepsis occurs simultaneously with 
hyperbilirubinemia. IL-6 is released by human BMEC, which additionally produce nitric 
oxide (Palmela et al. 2011), a molecule that contributes to enhance the permeability of 
the barrier (Cardoso et al. 2010). Rat BMEC produce prostacyclin, as we have 
previously demonstrated (Kis et al. 1999). Thus, changes in prostanoid, especially 
prostacyclin synthesis (Bachschmid et al. 2003) may also contribute to the observed 
endothelial permeability alterations. Interestingly, an increased permeability and a 
decreased TEER were also observed when each of the neurotoxins, or their 
combination, were added to BMEC in co-culture with astrocytes. This observation, 
relying in an in vitro model that more closely resembles the in vivo condition, reinforces 
the data obtained in the simpler model of the BBB composed of BMEC alone. 
Analysis of the AJ protein distribution pattern revealed a decreased localization at 
intercellular junctions at 4 h exposure to LPS, UCB or their combination, which is 
partially reversed at 24 h, as well as a disorganization of the endothelial sheet, 
particularly evident in co-cultured cells. Also interesting was the perinuclear 
accumulation of β-catenin, which was associated with a disruption of the  
VE-cadherin/β-catenin complexes during inflammation (Barbieri and Weksler 2007, 
Ding and Yuan 2007). Therefore, the production of cytokines by astrocytes and BMEC 
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exposed to LPS or UCB (Fernandes et al. 2004, Fernandes et al. 2006, Palmela et al. 
2011, Verma et al. 2006) may contribute to this process, which brings new insights into 
the mechanisms of toxicity by these compounds. Since Wnt signalling pathway 
activation is recognized as a mechanism of cell survival involved in the expression of 
TJ-associated proteins (Liebner et al. 2008), the present observations suggest an 
attempt to compensate the loss of integrity resulting from exposure to the insults. 
The expression and localization of the TJ proteins ZO-1 and claudin-5 are also 
affected by the tested neurotoxins. The accumulation of these proteins in the plasma 
membrane of co-cultured control cells, compared to mono-cultured cells is in line with 
the astrocytic induction of barrier properties in endothelial cells in vitro (Cardoso et al. 
2010, Deli et al. 2005, Tóth et al. 2011). It may also be related with the low serum 
concentration used in this study, as astrocyte co-cultures in the absence of serum in 
the basolateral compartment result in higher BMEC barrier indices, given their greater 
resemblance to the in vivo microenvironment (Colgan et al. 2008). Our mono-culture 
results confirm that LPS treatment alters intercellular junctions that are associated with 
BBB impairment (Singh et al. 2007). UCB-treated cells also show a redistribution of TJs 
proteins similarly to what was seen for occludin in epithelial cells (Raimondi et al. 
2006). The segmentation of claudin-5 immunostaining pattern may be related to the 
secretion of active MMPs, as it was described for occludin (Reijerkerk et al. 2006, 
Zeissig et al. 2004). Considering that Yang et al. (2007) have reported a reduction of 
claudin-5 mRNA in mice following an increase in MMP-2 expression, it is conceivable 
that activation of MMPs might be related to the loss of claudin-5. To the impairment of 
TJs and consequent increase in permeability may also account nitric oxide (Wu et al. 
2011), which is produced by exposure of BMEC and glial cells to UCB or LPS 
(Vezselka et al. 2007, Palmela et al. 2011, Silva et al. 2011). 
The increase in the permeability of co-cultured rat BMEC exposed to the 
neurotoxins might be related to the alterations in the pattern of expression and cellular 
localization of ZO-1 and claudin-5, already demonstrated at earlier time-points 
(Veszelka et al. 2007). In fact, the mRNA contents of TJ proteins ZO-1 and claudin-5, 
as well as their cellular localization decrease in bovine retinal endothelial cells treated 
by IL-1β and TNF-α (Aveleira et al. 2010), which are known to be secreted by 
astrocytes. The translocation of ZO-1 from the membrane to the nucleus has never 
been reported in endothelial cells treated with LPS. Still, a recent paper by Zhong and 
collaborators (Zhong et al. 2012) describes that ZO-1 is present in small concentrations 
in the nuclei, even in untreated cells. Therefore, our results are in agreement with the 
dual role of ZO proteins (Bauer et al. 2010), and the evident increase of the perinuclear 
staining brings new insights into a possible translocation of ZO-1 to the nucleus or 
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acting as a nuclear factor during inflammation in the presence of astrocytes. Its 
dissociation from the junctional complexes is related with increased barrier permeability 
(Choi and Kim 2008), which may further explain the mechanism for enhanced 
permeability in co-cultures. The same permeability enhancement in UCB-treated cells 
can also be related to the redistribution of claudin-5, an important contributor to TJs 
seal (Cardoso et al 2010). 
 
5. Conclusions 
The present data prove that LPS and UCB alter various aspects in rat BMEC. We 
can conclude that these neurotoxins diminish the viability of brain endothelial cells and 
alter BBB functions by inhibiting P-gp activity and inducing the secretion of active 
MMPs. Ultrastructural analysis detected newly formed caveolae-like structures and 
damage of organelles, like mitochondria and rough endoplasmic reticulum, which may 
be involved in the mechanisms of action of these neurotoxins. Moreover, this is the first 
study to demonstrate that paracellular permeability, TEER and intercellular junctions 
are altered by these compounds in rat BMEC either in mono-cultures or in co-culture 
with astrocytes. At last, our study revealed that each of the compounds has its own 
mechanism of action and temporal profile, comprising cell death (early occurring for 
UCB and only lately for LPS), the impairment of barrier properties (sustained along 
time for UCB but not for LPS), the distribution pattern of intercellular junctions as β-
catenin (opposite variations in fluorescence intensity for UCB and LPS) and 
ultrastructural alterations (shortened intercellular junctions and the increased number of 
caveolae particularly evident in LPS-treated cells). Collectively, by compromising the 
BBB integrity, the alterations resulting from exposure to LPS and/ or UCB may facilitate 
the access of the compounds to the brain further contributing to their neurotoxicity. 
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Abstract 
 
The inflammatory mediator lipopolysaccharide (LPS) has been shown to induce 
acute gliosis in neonatal mice. However, the progressive effects on the murine 
neurodevelopmental program over the week that follows systemic inflammation are not 
known. Thus, we aimed to investigate the effects induced by daily systemic LPS-
administration from postnatal days 4 through 6 on the developing CNS. LPS 
administration led to acute body and brain weight loss as well as overt structural 
changes in the brain such as cerebellar hypoplasia, neuronal loss/shrinkage, and 
delayed myelination. The delay in myelination was linked to impaired proliferation or 
differentiation of NG2 progenitor cells at early time points following LPS administration 
rather than excessive phagocytosis by CNS myeloid cells. In addition to disruptions in 
brain architecture, evidence of a robust inflammatory response to LPS was observed. 
Quantification of inflammatory biomarkers revealed decreased expression of autotaxin 
with concurrent increases in HMGB1, TLR-4, and MMP-9 expression. This was 
associated with acute astrogliosis (GFAP+ cells) in the brain parenchyma and at the 
microvasculature interface, as well as microgliosis (CX3CR1+ cells) in the parenchyma. 
This was followed by migration/proliferation of CX3CR1+ cells around the vessels at 
later time points, and posterior loss of GFAP+ astrocytes that did not appear to result 
from apoptotic cell death. Collectively, our study has uncovered a complex innate 
inflammatory reaction and associated structural changes in the brains of neonatal mice 
challenged peripherally with LPS. These findings may explain some of the 
neurobehavioral abnormalities that develop following neonatal sepsis. 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
116  
1. Introduction 
 
Sepsis is a common severe inflammatory response to an infection and is 
associated with high infant mortality rate during the pre-natal and neonatal periods. 
Survivors frequently experience white matter damage and cerebral palsy as well as 
cognitive and affective disorders (Hall et al. 2011; Paris et al. 2011). As it is usually 
induced via bacteria that express lipopolysaccharide (LPS), sepsis is often modelled in 
rodents using intraperitoneal injections of this endotoxin (Buras et al. 2005). 
Brain uptake of systemic LPS is considerably low (Banks and Erickson 2010), 
so most of its effects are mediated by brain microvascular endothelial cells (BMEC) 
and the activation of downstream signaling pathways (Grab et al. 2011). BMEC 
physically separate the brain from the blood, forming the basis of the blood-brain 
barrier (BBB). These cells express the Toll-like receptor (TLR)-4, whose activation by 
LPS leads to the synthesis and release of pro-inflammatory cytokines (Cardoso et al. 
2010; Nayak et al. 2014). In addition, LPS triggers the release of activated matrix 
metalloproteinase (MMP)-9 and MMP-2 as well as of granulocyte-macrophage colony-
stimulating factor (GM-CSF), which may contribute to the infiltration of monocytes and 
to BBB breakdown (Cardoso et al. 2012; Dohgu et al. 2011). BMEC are part of the 
neurovascular unit (NVU) that also includes the basement membrane, astrocytic 
endfeet, pericytes, microglia, neurons and even oligodendrocytes (Sá-Pereira et al. 
2012). The direct response of these cell types to inflammatory stimuli or to the released 
pro-inflammatory signals may exacerbate the damaging effects on BMEC (Grab et al. 
2011; Tripathi et al. 2009). 
Astrocytes are essential for synapse formation, induction of BBB functions and 
protection against LPS-mediated injury (Daneman et al. 2010; Descamps et al. 2003; 
Siddharthan et al. 2007). However, in the rodent central nervous system (CNS), 
astrogenesis occurs late in neurodevelopment and the microvessel ensheathment by 
their endfeet begins only around postnatal day (PND)5 (Daneman et al. 2010). In 
addition, LPS triggers astrocytic production of pro-inflammatory cytokines, particularly 
in immature cells (Falcão et al. 2005), directly influencing neurodegeneration (Falcão et 
al. 2014). LPS also induces the resident immune cells of the brain, microglia, to release 
pro-inflammatory cytokines and other inflammatory mediators like the high-mobility 
group box 1 (HMGB1) protein (Lamar et al. 2011) and autotaxin (ATX) (Awada et al. 
2012) that mediate changes in neuronal network activity and apoptosis (Nimmervoll et 
al. 2013). Though microglia progenitors colonize the mouse brain early in 
embryogenesis, the main transition from amoeboid into a ramified shape occurs during 
the second week after birth, along with increased microglial numbers and 
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simultaneously with the maturation of neurons (Harry and Kraft 2012; Nayak et al. 
2014). The morphological features of microglia and their colonization of the mouse 
brain are similar in humans (Torres-Platas et al. 2014). 
Acute (first hours) and prolonged sepsis (days rather than hours) have been 
shown to manifest differently. A robust inflammatory response is mounted during the 
acute phase, which to some degree is counterbalanced by an anti-inflammatory 
response during the later stages (Albert et al. 2003). Despite induction of an anti-
inflammatory program, studies have shown that prolonged injection of LPS can 
potentiate proinflammatory cytokine levels in the brain (Xiao et al. 2006).  It is therefore 
important to understand the pathogenesis of sepsis when proinflammatory cytokine 
levels are sustained in the developing neonatal brain for extended time periods. A 
better understanding of the sepsis-induced CNS pathogenesis will provide an important 
first step in improving survival and preventing adverse outcomes. In this study we 
aimed to investigate the acute and lasting effects of LPS-administration on murine 
neurodevelopment during the first week of life. We found that prolonged systemic 
inflammation disrupts the immature CNS by causing neuronal atrophy, a delay in 
myelination and acute reactive gliosis. 
 
 
2. Materials and Methods 
2.1. Animals 
Pregnant CD1 wild-type (WT) mice at embryonic day (E)16 were purchased 
from Harlan Ibérica (Spain) laboratories and gave birth in the animal facility of the 
Faculdade de Farmácia, Universidade de Lisboa. To better explore microglia 
activation, we used heterozygous C57BL/6 (B6) CX3CR1gfp/+ mice. These mice were 
generated by crossing B6 WT with B6 CX3CR1gfp/gfp mice that were purchased from 
The Jackson Laboratory (USA) and maintained in a closed breeding facility at The 
National Institutes of Health (NIH), Bethesda. The insertion of the green fluorescent 
protein (GFP) allows the tracking of CX3CR1+ cells, which is important to visualize 
microglia dynamic changes (Huang et al. 2006; Nayak et al. 2012). Homozygous B6 
CX3CR1gfp/gfp mice are CX3CR1 deficient and do not respond to fractalkine. On the 
other hand, both B6 WT and CX3CR1gfp/+ mice respond similarly to LPS (Jung et al. 
2000).  
Mice were housed with a 12 hour light/dark cycle and were provided with ad 
libidium access to a standard laboratory chow diet and drinking water. This study was 
carried out in strict accordance with the recommendations of European Convention for 
the Protection of Vertebrate Animals Used for Experimental and other Scientific 
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Purposes (Council Directive 86/609/EEC), as well as with those in the Guide for the 
Care and Use of Laboratory Animals at the NIH. All experimental procedures were 
performed under anesthesia, conducted in a manner to minimize animal suffering and 
all efforts were made to use the minimum number of animals. 
 
2.2. Drug Administration 
The day of birth was defined as PND1. For each strain, offspring of both genders 
were randomly divided into two groups and were treated from PND4 to PND6 with daily 
intraperitoneal injections of either endotoxin-free saline [control (W/O LPS); n ≥ 4 per 
analysis] or of LPS [6 mg/kg, Escherichia coli 055:B5; Calbiochem (Merck, Germany); 
n ≥ 4 per analysis] to induce - systemic inflammation (Erickson et al. 2012; Jin et al. 
2011). CD1 WT mice were sacrificed 1 day after the final LPS administration (LPS1) 
and at LPS9 to evaluate acute and lasting effects, respectively. B6 CX3CR1gfp/+ mice 
were sacrificed at LPS1/3/5/6/7/9 not only to determine the acute and lasting effects 
but also the delayed effects. Injection and sampling regimens are depicted in Figure 
3.1.  
 
 
 
Figure 3.1 – Schematic representation of the early induction of systemic inflammation. Offspring of 
both genders were randomly divided into two groups and treated with three intraperitoneal injections of 
either saline solution or lipopolysaccharide (LPS) at days 4, 5 and 6 after birth to induce systemic 
inflammation. CD1 wild-type mice were sacrificed at 1 and 9 days after LPS injections, and C57BL/6 (B6) 
CX3CR1
gfp/+
 mice were sacrificed at days 1/3/5/6/7/9 following LPS administration. 
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2.3. Tissue Process 
For paraffin-histological analysis, CD1 WT mice were perfused via the ascending 
aorta with 4% paraformaldehyde (PFA) in PBS. Brains were post-fixed in the indicated 
fixative for at least 24 h. Brain tissue was processed for paraffin and cut into 6 μm 
sagittal sections. For gelatin zymography and western blot analysis, the same animals 
were perfused via the ascending aorta with phosphate buffer saline solution, pH 7.4 
(PBS). Brains were quickly removed, snap-frozen and cryopreserved at -80ºC for at 
least 24 h. Protein extracts were obtained by lysing the brain tissue with 
radioimmunoprecipitation assay (RIPA) buffer (Tris Buffer 1 M pH 8.0, EDTA 0.5 M pH 
8.0, NaCl 5 M, 10% NP-40, 50% glycerol, 10% SDS) (Ratilal et al. 2014). For cryo-
histological analysis, B6 CX3CR1gfp/+ animals were perfused with 4% PFA in PBS. 
Brains were post-fixed in the same fixative for 24 h, followed by 15% and 30% sucrose 
solutions, each for at least 16h. Brain tissue was embedded in TFMTM Tissue Freezing 
Medium (TBS® Triangle Biomedical Sciences, USA), frozen at -80ºC and cut with a 
cryomicrotome into 25 μm sagittal sections. 
 
2.4. Staining for Luxol Fast Blue and Cresyl Violet 
Paraffin sections were stained with Luxol Fast Blue (VWR, USA) for 
oligodendrocyte myelin followed by with Cresyl Violet (Sigma, USA) for neuronal Nissl 
bodies’ assessment. Sections were rehydrated in xylene for 20 min and decreasing 
concentrations of ethyl alcohol for 10 min each. Sections were then incubated with a 
0.1% Luxol Fast Blue solution in 70% ethyl alcohol overnight at 56ºC. After rinse with 
70% ethyl alcohol followed by distilled water to remove excess stain, the tissue was 
differentiated in a 0.5% lithium carbonate solution. Slides were then rinsed in distilled 
water followed by 2% acetic acid solution for 5 min. Next, tissue was counterstained 
with a 1% Cresyl Violet solution for 10 min. After rinse in distilled water, sections were 
differentiated in 37.5% acetic acid and rinsed in distilled water. Slides were mounted 
with Fluoromount-G (Southern Biotech, USA) and visualized using a DFC 490 camera 
(Leica, Germany) adapted to an Axioskop bright field microscope (Zeiss, Germany). 
Width of cerebellar layers, number of neurons per field and the area of their soma were 
analyzed using ImageJ software (NIH, USA). Intensity of staining of the external 
germinal layer at LPS1 and of the white matter layer at LPS9 was analyzed using the 
same software and was expressed per µm2. 
 
2.5. Gelatin Zymography 
Determination of MMP-9 and MMP-2 was evaluated as previously described 
(Cardoso et al. 2012) with minor alterations. In short, 40 μg of protein from tissue 
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extracts were analyzed by SDS-PAGE zymography in 0.1% gelatin/10% acrylamide 
gels under non-reducing conditions. After electrophoresis, gels were washed for 1 h 
with 2.5% Triton X-100 (in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mM ZnCl2) to remove 
SDS and renature the MMPs species in the gel. Gels were then incubated in 
developing buffer (50 mM Tris pH 7.4, 5 mM CaCl2, 1 mM ZnCl2) for 72 h at 37ºC to 
induce gelatin lysis. For enzyme activity analysis, gels were stained with 0.5% 
Coomassie Brilliant Blue R-250 (Bio-Rad, USA) for 3 h at room temperature (RT), and 
distained in 30% ethanol/10% acetic acid/H2O. Gelatinase activity, detected as a white 
band on a blue background, was quantified by computerized image analysis using 
Quantity One 1-D Analysis Software (Bio-Rad, USA).  
 
2.6. Western Blot 
Western blot analysis was performed as previously described (Ratilal et al. 2014) 
with minor alterations. Briefly, 100 μg of protein from tissue extracts were separated on 
a 12% SDS-PAGE gel. Following electrophoretic transfer onto a nitrocellulose 
membrane and blocking with 5% milk solution, the blots were incubated with primary 
antibody overnight at 4ºC [rabbit anti-TLR4 (Santa Cruz, USA, #sc-10741; 1:500), 
mouse anti-HMGB1 (BioLegend, USA, #651402; 1:500), rabbit anti-ATX (Millipore, 
USA, #ABT28; 1:500) or mouse anti-β-actin (Sigma, USA, #A5441; 1:5000)] and with 
horseradish peroxidase-labeled secondary antibody [anti-mouse or anti-rabbit (Santa 
Cruz, USA, #sc-2005 and #sc-2004 respectively; 1:5000] for 1 h at RT. Protein bands 
were detected by LumiGLO® (Cell Signaling, USA) and visualized by 
chemiluminescence with ChemiDoc (Bio-Rad, USA). Expression was quantified by 
computerized image analysis using Quantity One 1-D Analysis Software (Bio-Rad, 
USA). 
 
2.7. Cryo-Immunofluorescence 
Frozen sections were used to analyze the expression of the fractalkine receptor, 
CX3CR1, as well as NG2+ glia, GFAP, myelin basic protein (MBP) and CD31 in B6 
CX3CR1gfp/+ mice. Sections were fixed for 15 min with 1% PFA in PBS. Sections were 
then treated with an Avidin/Biotin Blocking Kit (Vector Laboratories, USA, #SP-2001) 
per the manufacturer’s instructions followed by 20 min treatment with Background 
Buster (INNOVEX biosciences, USA, #NB306). Tissue was incubated 1 h at RT with 
primary antibodies: rabbit anti-NG2 (Millipore, USA, #AB5320; 1:100), rabbit anti-GFAP 
(DAKO, Denmark #Z0334; 1:200), rat anti-MBP (Millipore, USA, #MAB386; 1:100),  or 
armenian hamster anti-CD31, clone 2H8 (Chemicon, USA, #MAB1398Z; 1:200). 
Following the incubation with primary antibodies, sections were washed and incubated 
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for 1h at RT with secondary antibodies donkey Alexa Fluor 647 anti-rabbit IgG (H&L) 
(Jackson ImmunoResearch Laboratories, USA, #711-605-152; 1:200), donkey Alexa 
Fluor 647 F(ab) anti-rat IgG (H&L) (Jackson ImmunoResearch Laboratories, USA, 
#712-606-150; 1:200) or goat Rhod-X anti-armenian hamster IgG (H&L) (Jackson 
ImmunoResearch Laboratories, USA, #127-295-160; 1:200). CD31 staining was 
amplified with donkey Rhod-X F(ab) anti-goat IgG (H&L) (Jackson ImmunoResearch 
Laboratories, USA, #705-296-147; 1:200) for 1 h at RT. All working stocks of primary 
and secondary reagents were diluted in PBS containing 2% fetal bovine serum (FBS) + 
0.5% Triton-X100. Nuclei were counterstained with DAPI dye, and sections were 
mounted with IMMU-MOUNT (Thermo-Scientific, USA, #9990402). Between 
incubations, sections were washed three times with PBS. Apoptosis was detected in 
frozen sections with the ApopTag® Red In Situ Apoptosis Detection Kit (Chemicon, 
USA, #S7165), which specifically detects DNA cleavage and chromatin condensation 
associated with apoptosis, in accordance with the manufacturer’s instructions. Images 
were captured from stained frozen sections using an Olympus FV1200 confocal 
microscope equipped with 20× and 40× objectives. Images were collected using 
sequential scanning with the 405, 488, 559, and 635 nm laser lines to produce four 
color overlays. Cerebellar area was measured in tiles of DAPI-counterstained brain 
sections using ImageJ (NIH, USA). Area fraction and colocalization of the staining per 
field of each protein was quantified by computerized image analysis using ImageJ 
(NIH, USA).  
 
2.8. Sholl Analysis of CX3CR1+ cells 
To quantify morphological changes of the CX3CR1+ cells, consecutive Z-stack 
Images were converted to a maximum intensity projection image by Image J software. 
Using the Sholl analysis plugin, concentric circles were created centered on the soma, 
beginning at 5.5 μm radii and increasing 2 μm with every circle. We determined the 
number of intersections made by microglia branching processes with each successive 
increasing circle, the maximum number of intersections for the cell (Nm), as well as the 
critical value at which Nm occurred (Cr) and the maximum length at which a branch 
intersection occurred (Morrison and Filosa 2013). 
 
2.9. Statistical Analysis 
Results are expressed as means ± SEM from, at least, four independent animals 
in each treatment group. Significant differences between groups were determined by 
the two-tailed t-test performed on the basis of equal and unequal variance as 
appropriate. Comparison of more than two groups was done by ANOVA using 
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GraphPad Prism® 5.0 (GraphPad Software, San Diego, CA, USA). Statistical 
significance was considered when P values were lower than 0.05. 
 
 
3. Results 
3.1. LPS administration in the early neonatal period triggers acute weight loss 
and cerebellar hypoplasia 
Administration of LPS is known to induce a sickness behavior in adult mice, 
including weight loss (Lawson et al. 2013; Walker et al. 2013). To assess the impact of 
LPS exposure in the first postnatal week, we initially assessed body and brain weight 
oscillations, which were acutely decreased by LPS (Fig. 3.2A). Body weight loss was 
sustained up to LPS7, but eventually recovered by LPS9 (Fig. 3.2B). We further 
explored acute brain weight loss by measuring the sagittal cerebellar area. This 
revealed a disruption in its development evidenced by a ~2-fold reduction at LPS5 that 
was still evident at LPS7. No difference from the control group was observed at LPS9 
(Fig. 3.2C,D). 
 
3.2. Induction of neuronal atrophy in newborn mice by systemic inflammation 
is more marked at LPS1 than at LPS9 
Given the observed decrease in the cerebellar area, we next explored the width 
of each layer: the external germinal layer (with proliferating neuroepithelial cells), the 
molecular layer (containing the axons of granule cells and dendrites of Purkinje cells), 
the Purkinje neuronal layer, the granular layer (with small neurons called granule cells) 
and the white matter layer (with myelin fibers) (representative images of cerebellum are 
shown in Figure 3.3A). There was a significant shrinkage of the neuron-containing 
layers (external germinal, Purkinje and granular) at 24 h after the last LPS injection but 
not at LPS9 (Fig. 3.3B). In agreement, the density of neurons based on the intensity of 
staining per µm2 of cells in the external germinal layer was also markedly reduced at 
LPS1 (~2-fold) (Fig. 3.3C). Lastly, a negative impact on the density of Luxol Fast Blue-
labeled myelin fibers in the cerebellum was evident at LPS9 (Fig. 3.3D). 
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Figure 3.2 – Lipopolysaccharide (LPS) administration in the early neonatal period leads to an acute, 
but transient, body and brain weight loss as well as to a decreased cerebellar area. Body and brain 
of CD1 wild-type mice were weighed at 1 and 9 days post-LPS administration (A). Body weight of C57BL/6 
(B6) CX3CR1
gfp/+
 mice was assessed at days 1/3/5/7/9 after LPS injection (B). Cerebellar area was 
measured (C) in tiled confocal images of brain sections from B6 CX3CR1
gfp/+
 mice at days 1/3/5/7/9  
post-LPS (representative images with DAPI in D). Results are mean ± SEM from at least four animals. 
**P < 0.01 vs. without (W/O) LPS. 
 
 
We next searched for changes in neuronal density and morphology by examining 
brain regions such as in pons [mediator of cerebellar input and output (Baizer 2014)], 
the CA3 subregion of the hippocampus [responsible for short-term memory (Kesner 
2007)] and the Purkinje cell layer that provides the output of all motor coordination in 
the cerebellar cortex (Kullmann et al. 2012) (representative images are showed in 
Figure 3.3A). The number of neurons was acutely decreased at LPS1, particularly in 
pons, where it was still evident at LPS9. The neuronal loss in both hippocampus and 
cerebellum seen acutely at LPS1 was restored by LPS9 (Fig. 3.3E). On the other hand, 
the marked soma reduction observed in neurons at LPS1 persisted until LPS9 in all 
three regions (Fig. 3.3F). 
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Figure 3.3 – Early lipopolysaccharide (LPS) administration triggers acute shrinkage of cerebellar layers 
and loss of neuronal density as well as a sustained reduction of neuronal soma. Paraffin sections from 
CD1 wild-type mice at 1 and 9 days post-LPS administration were stained with Luxol Fast Blue (myelin, 
blue) followed by Cresyl Violet (Nissl bodies, purple). Representative images are shown for each condition 
in pons, hippocampus and cerebellum (A). The widths of each cerebellar layer [external germinal layer 
(EGL), molecular layer (ML), Purkinje layer, internal granular layer (IGL), white matter layer (WML)] were 
measured (B). Intensity of Cresyl violet staining in the EGL (C) and of Luxol Fast Blue in WML (D) were 
quantified per µm
2
 at 1 and 9 days after LPS administration, respectively. The number of neurons per field 
(E) and the area of neuronal cell body (soma) (F) was quantified throughout pons, in the CA3 hippocampal 
region and in the cerebellar Purkinje layer (PL). All determinations were done using ImageJ software (NIH, 
USA). Results are mean ± SEM from at least five animals. *P < 0.05 vs. without (W/O) LPS. 
 
 
3.3. LPS administration leads to a reduced myelination 
Given the significant impact on the myelin layer and the amount of neuronal 
damage evident in the pons and cerebellum, we further analyzed the effects of LPS on 
myelination in these two brain regions at days LPS1,3,5,7 and 9 (representative 
images in Fig. 3.4A). Reduced levels of MBP per unit area were observed at all time 
points, but the decreases were particularly evident at LPS5 (minimum values) and 
LPS9 in both brain regions when compared to controls (Fig. 3.4B). Considering the 
significant reduction of MBP at LPS5, we decided to investigate the contribution of 
CX3CR1+ microglia to this abnormality. We hypothesized that their phagocytotic activity 
might be associated with the delayed myelination. However, as shown in Figure 3.4C, 
this was not the case, as microglia did not contain cytoplasmic myelin signal at LPS1 or 
LPS3. To determine whether apoptosis of oligodendrocyte precursors cells (OPCs) 
could contribute to the decreased myelination, we stained tissues at LPS1 with 
ApopTag and anti-NG2 antibodies (expressed by OPCs) (Fig. 3.4D). Increased 
apoptosis was observed in the cerebellum (particularly in the external germinal layer) 
as well as in the pons; however, no overlap of NG2+ labeling with ApopTag was 
noticed. Moreover, we observed an increased number of OPCs in the cerebellum (4-
fold) and pons (1.4-fold) (Fig. 3.4E). These data suggest that there may be an 
increased proliferation of OPCs, or, alternatively, a delay in their maturation to 
myelinating cells resulting from neuroinflammation. 
 
3.4. Early neonatal LPS administration acutely decreases ATX levels while 
increasing other inflammatory biomarkers 
We next explored the neuroinflammatory reaction to systemic LPS injection by 
quantifying the expression of inflammatory biomarkers in whole brain tissue. The 
biomarkers MMP-9, MMP-2, TLR4, HMGB1 and ATX are known to be expressed by 
astrocytes, microglia, and / or BMECs during inflammatory conditions. We therefore 
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evaluated if they were affected by the LPS administration and, if so, whether the effects 
were lasting (Fig. 3.5). With the exception of MMP-2, all biomarkers were acutely 
modified by LPS administration. MMP-9 expression was modestly increased at LPS1, 
whereas TLR4 and HMGB1 levels were elevated more significantly. ATX expression, 
on the other hand, was significantly decreased. The results indicate that the pro-
inflammatory response observed 24 hours after LPS administration was not sustained, 
as all biomarkers were restored to control levels at LPS9.  
 
 
Figure 3.4 – Lipopolysaccharide (LPS) administration disrupts myelination in the cerebellum and 
pons of neonatal mice. Brain cryosections from C57BL/6 CX3CR1
gfp/+
 mice at days 1/3/5/7/9 post-LPS 
administration were immunolabeled for myelin (myelin basic protein, MBP, red). Representative confocal 
images of cerebellum and pons are displayed in A, where the overlapping of MBP and microglial marker 
CX3CR1 (green) is seen in yellow. Area fraction per field of MBP staining was quantified per region (B) 
using ImageJ software (NIH, USA). To assess microglial phagocytosis, confocal images at days LPS1 and 
LPS3 were amplified (C, overlapping of MBP and CX3CR1 is visible in yellow). Sections of animals at 
LPS1 were immunolabeled for apoptosis (ApopTag, red) and oligodendrocytes precursors (NG2 cells, 
green). Cerebellar layers are identified [external germinal layer (EGL), molecular layer (ML), Purkinje layer, 
internal granular layer (IGL)] (D). Area fraction per field of ApopTag and of NG2 positive stainings were 
determined (E) using ImageJ software (NIH, USA). *P < 0.05 and **P < 0.01 vs. without (W/O) LPS. 
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Figure 3.5 – Lipopolysaccharide (LPS) challenge promotes differential expression of inflammatory 
biomarkers in the brain. Whole brain lysates of CD1 wild-type mice at 1 day post-lipopolysaccharide 
(LPS) administration were used to determine the activities of metalloproteinase(MMP)-9 and MMP-2 by 
gelatin zymography, alongside with the expression of Toll-like receptor (TLR)-4, high-mobility group box 1 
(HMGB1) and autotaxin (ATX) by western blot. Results are expressed as fold-change from animals not 
treated with (W/O) LPS, and are mean ± SEM from at least four animals in each group. *P < 0.05 and 
**P < 0.01 vs. W/O LPS. 
 
3.5. Neonatal inflammation decreases the microglia transition from an 
amoeboid to ramified morphology 
The alterations in inflammatory biomarkers suggested that microglia might be 
involved in the response to peripheral LPS challenge. Therefore, we decided to 
examine microglial morphology following neonatal LPS administration in the pons – the 
brain region most affected by this endotoxin. Analysis of parenchymal CX3CR1gfp/+ 
cells in control mice revealed that microglia gradually changed morphology from an 
amoeboid phenotype at the end of the first week of life to a more ramified morphology 
by the second week (Fig. 3.6A). This is supported by our quantitative data showing that 
the maximum number of microglia process interactions (process maximum, Nm), and 
the distance from the soma where these interactions occurred (critical value), 
increased over time in control mice (Fig. 3.6B,C). However, these parameters were 
significantly decreased by LPS treatment. In fact, at LPS1 and LPS3 CX3CR1+ cells 
were still amoeboid. By LPS5, microglia showed elongated soma and few secondary 
processes, which progressed to further enlargement of the soma and a reduced 
number of short processes at LPS7 and LPS9 (Fig. 3.6A). Quantitatively, at LPS9 the 
maximum radius at which a branch intersection occurred (maximum branch length) 
was significantly reduced (25%). However, no alterations in the number of branches 
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that originated from microglia soma (number of primary branches) or in the cell 
branching density (Schoenen ramification index) were noticed (Fig. 3.6B,C). 
 
3.6. Decreased astrocytosis occurs after LPS5 and is inversely associated 
with microgliosis 
To further evaluate the inflammatory reaction to LPS, we assess glial responses 
(astrocytes and microglia, including their interaction with the vasculature) in the pons 
(Fig. 3.7A). There was an acute reactive astrogliosis at LPS1 that extended until LPS3 
in the parenchyma and to LPS5 around the microvessels. By LPS7 and LPS9 the 
GFAP+ staining per unit in both locations was approximately half that of controls (Fig. 
3.7B). The closest GFAP+ labeled area fraction to controls was at LPS5, when 
astrocytes showed long thin processes as seen in Figure 3.7A. Examination of 
microgliosis revealed that the area occupied by CX3CR1+ cells was markedly 
increased in association with the microvessels at LPS1 and LPS3 (Fig. 3.7C). A 
transient decrease was observed in the pons parenchyma at LPS5, when microglia 
showed a dystrophic morphology (Fig. 3.6A), followed by a remarkable increase at 
LPS7 and LPS9, but not around the microvessels (Fig. 3.7C). Collectively, these 
results suggest that the kinetics of astrocytosis and microgliosis are inversely 
correlated in the parenchyma from LPS1 to LPS9. 
 
3.7. Increased density of CX3CR1+ cells around the vessels precedes the loss 
of GFAP+ cells in pons parenchyma 
Our data pointed to a transition from astrocyte gain to loss between LPS5 and 
LPS7. In order to better understand this transition, we evaluated the glial-vasculature 
response at an intermediate time point - LPS6 (Fig. 3.8A). At this time point, GFAP+ 
staining per unit in the parenchyma was similar to control and still higher around the 
vasculature (Fig. 3.8B) similar to LPS5 (Fig. 3.7B). On the other hand, the parenchymal 
area occupied by CX3CR1+ cells at LPS6 had already increased to control levels. 
Surprisingly, the area of microvasculature covered by these cells was significantly 
increased at this time point (Fig. 3.8C), which was not visible either at LPS5 or at LPS7 
(Fig. 3.7C). These data suggest that CX3CR1+ cells migrate towards the 
microvasculature prior to the loss of perivascular GFAP+ cells. Lastly, we performed 
ApopTag staining at LPS6 to determine if the significant loss of GFAP+ staining at 
LPS7 was due to apoptosis. No difference in apoptotic cells was observed between the 
control and LPS treated mice at this time point, nor did the ApoTag staining co-localize 
with microglia or astrocytes (Fig. 3.8D,E). Thus, the reduction in GFAP+ staining at 
LPS7 likely results from a mechanism other than cell death.  
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Figure 3.6 – Morphological changes in microglia following lipopolysaccharide (LPS) administration. 
Representative confocal images of CX3CR1
+
 cells morphology from brain cryosections of C57BL/6 
CX3CR1
gfp/+
 mice at days 1/3/5/7/9 post-lipopolysaccharide (LPS) administration are shown (A). Using 
ImageJ software (NIH, USA) we performed Scholl analysis (>40 cells per animal) at days 1 and 9 post-
LPS administration (B,C). Results are mean ± SEM from at least four animals. *P < 0.05 and **P < 0.01 vs. 
respective without (W/O) LPS; 
§
P < 0.05 and 
§§
P < 0.01 vs. respective day 1 post-LPS. 
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Figure 3.7 – Early astrogliosis and increased vessel coverage by glia is followed by delayed 
parenchymal microgliosis and overall astrocytic loss. Brain cryosections of C57BL/6 CX3CR1
gfp/+
 
mice at days 1/3/5/7/9 post-lipopolysaccharide (LPS) administration were immunolabeled for astrocytes 
(glial fibrillary acidic protein, GFAP, red) along with vessel marker CD31 (cluster of differentiation 31, gray). 
Representative confocal images of glia-endothelium interactions in pons are displayed in A. Area fraction 
per field of GFAP and CX3CR1 (green) positive staining, as well as their respective colocalization with the 
vessels (B,C) were determined by ImageJ software (NIH, USA). Results are mean ± SEM from at least 
four animals. *P < 0.05 and **P < 0.01 vs. without (W/O) LPS.  
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Figure 3.8 – Loss of astrocytes in neonatal inflammation is preceded by proliferation/migration of 
CX3CR1
+
 cells in the pons. Brain cryosections of C57BL/6 CX3CR1
gfp/+
 mice at day 6 post-
lipopolysaccharide (LPS) administration were immunolabeled for astrocytes (glial fibrillary acidic protein, 
GFAP, red) and brain microvascular endothelial cells (cluster of differentiation, CD31, gray). 
Representative confocal images of each condition in pons are depicted in A. Area fraction per field of 
GFAP
+
 and CX3CR1
+
 (green) staining, along with their respective colocalization with vessels, were 
determined using ImageJ software (NIH, USA) (B,C). Parallel sections were immunolabeled for astrocytes 
(GFAP, red) and for ApopTag (gray) (Representative confocal images in D). Quantification of ApopTag 
positive staining area fraction, using the above mentioned software, is shown in E. Results are mean ± 
SEM from at least four animals. **P < 0.01 vs. without LPS; 
§
P < 0.05 and 
§§
P < 0.01 vs. day 5 post-LPS. 
 
4. Discussion 
In the present study, newborn mice were injected with LPS for three 
consecutive days as an in vivo model of sustained neonatal inflammation. Body weight, 
myelination, neurons, inflammatory biomarkers and glial cells were evaluated for a 
week after the last injection to establish the impact of peripheral LPS challenge on the 
developing neonatal brain. The acute loss in body weight indicates that LPS 
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administration induces a sickness behavior in early neonatal mice. In a study by Du et 
al. (2011), the effects of LPS in newborn mice were also studied, although the 
exposure period was longer (PND3 to PND11) and less LPS was administered per day 
(0.3 mg/kg). Nevertheless, the animals examined at PND12 maintained their body 
weight. The difference in weight observed between our studies is likely due to the lower 
dose of LPS injected, as other studies have recently reported weight loss in rats 
injected once at PND5 with 2 mg/kg LPS (Fan et al. 2013).  
We also observed an acute loss in brain weight following LPS injection. This is 
consistent with a study showing that intrauterine administration of LPS (125 μg per 
dam) in mice at E15 reduces brain weight relative to controls, even at PND14 (Wang et 
al. 2007). Again, this appears to be a dose-dependent effect, given that intrauterine 
administration of lower LPS concentrations (80 μg/kg or ~  μg per dam) does not 
induce brain weight loss in offspring at PND14 (Graf et al. 2014). The overall loss in 
brain weight may be linked in part to cerebellar hypoplasia. Several cerebellar regions 
were reduced in size following LPS administration, and our results suggest that this 
decrease might result from neuronal atrophy. In addition, we observed that there was a 
decreased soma area and associated neuronal loss in all brain regions studied. The 
aforementioned study by Du et al. (2011) also demonstrated a loss of NeuN+ neurons. 
Another study revealed no change in NeuN staining 24 h after exposure to LPS (1 
mg/kg) (Chung et al. 2010). It is important to consider, however, the latter study was 
performed on adult animals, and the negative impact of LPS is likely more pronounced 
during neuronal development.  
We also evaluated how prolonged neonatal inflammation influenced 
myelination; we observed a lasting effect on MBP levels that extended to LPS9. Most 
studies to date have evaluated this parameter during the prenatal period (Dilek et al. 
2013; Girard et al. 2012; Rousset et al. 2013). Nevertheless, a recent study in mice 
injected with small doses of LPS (0.05 mg/kg) at PND5, and sacrificed over a week 
later at PND14, reported a reduction in MBP expression (Pang et al. 2012), which is 
consistent with our findings.  Moreover, another study reported myelin loss in newborn 
mice injected daily from PND  to PND11 with 0.  mg/kg LPS (Du et al. 2011). Based 
our on data showing no phagocytic uptake of MBP by CX3CR1+ myeloid cells, we 
believe that LPS does not induce degradation of myelin, but instead slows or arrests 
the myelination process. Supporting with this theory, we observed an increased 
number of NG2+ oligodendrocyte progenitors in the cerebellum and pons the day after 
LPS administration. 
 To assess the neonatal brain’s response to systemic inflammation, we 
quantified relevant biomarkers and revealed increased expression of MMP-9, TLR4, 
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and HMGB1 at LPS1. MMPs are gelatinases that have the capacity to remodel the 
extracellular matrix, promote cellular invasion, and induce various signaling pathways 
(Sternlicht and Werb 2001).  We previously showed in vitro that increased release of 
active MMP-9 and MMP-2 by BMEC occurred within 24 h of LPS exposure (Cardoso et 
al. 2012). In vivo we observed an elevation in MMP-9 but not MMP-2 levels following 
LPS administration. Previous studies have shown that LPS-stimulated pericytes and 
microglia can release high levels of active MMP-9 (Milner 2009), which has the 
potential to disrupt brain homeostasis, degrade the extracellular matrix, and ultimately 
weaken the BBB, giving rise to leakage (Tilling et al. 1998).  
Given that MMP-9 can open the BBB (Rosenberg et al. 1998) and LPS induces 
its expression through the TLR4/NF-κB pathway (Aid et al. 2010), we examined 
whether expression of this receptor was elevated in the brain following peripheral LPS 
challenge. We observed increased expression of TLR4 at LPS1 but not LPS9. TLRs 
are expressed on immune cells, microglia as well as BMEC and respond to microbial 
infections. TLR4 is the receptor responsible for the initial inflammatory response to LPS 
and is usually elevated within hours of exposure (Shimazu et al. 1999). Although few 
studies have focused on TLR4 expression in newborn mice, a recent study reported in 
6-week-old mice that TLR4 was elevated 24 h after exposure to 1 mg/kg of LPS 
(Chung et al. 2010), which is in agreement with our data. 
HMGB1 is another interesting protein because it is an endogenous agonist for 
TLR4. It is secreted by activated immune cells and endothelial cells as well as 
stimulated neurons, astrocytes, among others (Andersson and Tracey 2011). HMGB1 
was acutely elevated in our brain homogenates at LPS1, which would potentiate TLR4 
signaling. Previous studies have demonstrated that this biomarker is markedly 
increased during neonatal inflammation (Goto et al. 2010; Kato et al. 2009).  
Interestingly, HMGB1 can induce a loss of body weight (Agnello et al. 2002) and may 
have contributed to the body weight reduction observed in our study. 
In contrast to MMP-9, TLR4, and HMGB1, we observed decreased expression 
of ATX at LPS1, which contrasts with other studies of inflammatory diseases showing 
increased ATX expression (Sevastou et al. 2013). A recent study by Awada et al. 
(2012) demonstrated that ATX inhibited microglial activation and induced an anti-
inflammatory state. Another study showed that ATX expression inhibited a bacterial 
endotoxin-induced proinﬂammatory response (Fan et al. 2008). However, the impact of 
ATX on inflammatory processes is not entirely understood. In fact, inhibition of ATX is 
sometimes proposed as a potential therapy for inflammatory diseases (Federico et al. 
2008; Gendaszewska-Darmach 2008). Li and Zhang (2009) recently demonstrated that 
LPS induced ATX expression in a monocytic cell line (THP-1), enhancing cell 
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migration. Further studies are required to determine the exact role played by ATX in the 
developing neonatal brain following a peripheral LPS challenge.    
Because the inflammatory biomarker profile suggested a role for glial cells in 
the response to sepsis, we analyzed their reactivity and interactions with brain 
microvasculature. Both astrocytes and microglia became reactive and increased their 
coverage of blood vessels early after LPS administration. This response waned over 
time, with astrocytes eventually showing reduced vascular interactions. A prolonged 
glial response to LPS was recently described in the hippocampus and brainstem of 
adult mice following induction of sepsis (Granger et al. 2013).  In addition, it has been 
shown that microglia and astrocytes proliferate in response to LPS (Chung et al. 2010; 
Nishioku et al. 2009) and E. coli (Bland et al. 2010). Our results are in agreement with 
the findings of Gómez-Nicola et al. (2008) who showed that LPS administration alone 
can induce reactivity of both microglia and astrocytes. It is conceivable that the 
neuronal atrophy and delayed myelination observed in our study is in fact linked to the 
LPS-induced glial response. Astrocytes and microglia are essential for the formation, 
trimming, and function of developing synapses (Christopherson et al. 2005; Miyamoto 
et al. 2013) as well as for CNS myelination by promoting OPCs migration, proliferation, 
and differentiation (Pang et al. 2013). Studies have reported that the loss or 
dysfunction of astrocytes can lead to demyelination or inhibited oligodendrocyte 
maturation (Lutz et al. 2009; van den Heuij et al. 2014). Others have also shown that 
disruption of microglia-mediated synaptic pruning contributes to neurodevelopmental 
disorders (Zhan et al. 2014) and produces long-lasting defects in oligodendrocyte 
maturation and myelination (Favrais et al. 2011; Volpe 2011). 
The divergent early and late astrocytic response to LPS administration was 
particularly interesting given the role that these cells play in brain homeostasis and the 
maintenance of the BBB. Sherwin et al. (2005) showed that LPS binds to microglia 
and astrocytes during neonatal neuroinflammation, and for astrocytes this is particularly 
intense around blood vessels. Importantly, astrocytes can reduce BBB permeability 
following LPS administration (Kaya et al. 2004). Therefore, we postulate that the initial 
increased astrocytic coverage of microvessels observed in our study could be a 
protective reaction to neuroinflammation. Surprisingly, this response declined over 
time, which coincided with increased CX3CR1+ staining and distribution. This change in 
microglia could be due to the release of chemoattractants by astrocytes. Astrocytes 
express CX3CL1, the ligand for CX3CR1 on microglia/macrophages. In response to 
proinflammatory cytokines, CX3CL1 expression is upregulated in cultured astrocytes 
and induces microglia chemotaxis (Hulshof et al. 2003). It is also important to note that 
the reduced association of GFAP+ cells with microvessels coincided with the 
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morphological transformation of microglia into a bushy activated state. Microglial 
activation was previously described as a modulator of astrocytic proliferation, in the 
same manner as astrocytes can modulate microglial functions such as cell proliferation, 
migration, and cell adhesion [see for review: (Seifert et al. 2006)]. In fact, it has been 
shown that 7 days following a neuroinflammatory stimulus, adult animals with reduced 
astrogliosis show increased microglial activation and neuronal loss compared to 
controls (Lu et al. 2011; Shi et al. 2012). Our failure to detect astrocyte apoptosis in the 
pons at the time of reduced GFAP+ staining suggests astrocytic deactivation or 
dedifferentiation. There is evidence that certain stimuli released by injured astrocytes 
can reprogram them into neural stem cells, which can then be redifferentiated into 
neuronal and glial cells, even in adult animals (Corti et al. 2012; Heinrich et al. 2010; 
Seri et al. 2001). This could explain the rapid increase in the number of neurons and 
microglia in our model. 
 
5. Conclusions 
In summary, our data demonstrate that systemic inflammation profoundly alters 
several anatomical and inflammatory aspects of the brain when experienced during the 
early neonatal period. Our results not only expand upon previous literature focused on 
the acute effects of LPS on the developing brain, but are also the first to document the 
progressive neuroinflammatory changes that occur in the week that follows LPS 
administration. The reciprocal relationship between astrocytes and microglia is 
interesting and warrants follow up studies to identify the nature of the cross-talk. It will 
also be important to determine the degree to which the observed changes contribute to 
long term sequelae following neonatal sepsis and whether these changes can be 
reversed therapeutically in afflicted patients. 
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Abstract 
 
Systemic inflammation during the early neonatal period (first week of life) induces 
acute neuronal degeneration and atrophy, in addition to altering glial response. 
However, the lasting effects resulting from impairment of mouse neurodevelopment 
after having this condition in either the first or the second week of life, remain unknown. 
Therefore, we aimed to determine the acute effects of lipopolysaccharide (LPS)-
induced inflammation during the second of life [examined at postnatal day (PND)14], as 
well as its lasting effects in young adults (PND53) (with onset during the first or the 
second week of life). Also, we intended to study the primed response to a second pro-
inflammatory stimulus at the same adult age compared to an adult acute response 
(animals were injected at PND52 and examined at PND53). Newborns had neuronal 
loss and atrophy as well as white matter damage. In addition, LPS triggered an acute 
pro-inflammatory response with associated astrogliosis and microgliosis. Regarding the 
lasting effects of this clinical condition, animals injected at the first week had mainly 
neurodegeneration, whereas those injected in the second week of life also depicted 
lasting injury to the white matter and loss of astrocytes. At last, we evaluated the 
primed response to a second inflammatory challenge. Animals primed in the first week 
had little effects compared to a single adult injection. On the other hand, animals 
primed during the second week of life not only had damage to the white matter, but 
also neuronal atrophy and deficient glial response. Thus, the window of neonatal 
systemic inflammation determines the lasting and primed effects in the different regions 
of the CNS. 
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1. Introduction 
 
During the perinatal period, the developing brain is particularly vulnerable to 
inflammatory conditions. In fact, approximately 25-40% of preterm births (before 37 
weeks of gestation in humans) are associated with a maternal immune response to an 
infection (Goldenberg et al. 2008; Nimmervoll et al. 2013). In general, the sequence of 
neurodevelopmental events is comparable among species (Rice and Barone 2000). At 
birth, the neurological maturity of rodent pups is similar to that of human preterm 
neonates at 24 weeks of gestation (Anand et al. 1999). The first week of rodent life 
(early neonatal period, ENP) corresponds to the third gestational trimester of human 
fetus, whereas the 2nd-4th rodent weeks (late neonatal period, LNP) can be compared 
to a term human newborn (Pressler and Auvin 2013; Rodekamp et al. 2005). During 
this critical neurodevelopmental window, one of the most common clinical conditions 
afflicting newborns is sepsis (Black et al. 2010). 
Sepsis is a severe systemic inflammatory response in attempt to eliminate 
pathogens (Stevenson et al. 2014). Sepsis-associated encephalopathy (SAE) 
manifests with a rapid decline in cognitive functions and may lead to permanent 
neurocognitive dysfunction and functional impairments, even after the patient has 
recovered (Widmann and Heneka 2014). Inflammatory mediators disrupt the blood–
brain barrier (BBB) during the early stages of SAE. Thus, several innate immune 
components can enter the brain not only through specific receptors but also due to the 
disruption of the endothelium itself (Cardoso et al. 2010; Fox et al. 2013; Nayak et al. 
2012; Nishioku et al. 2009), further inducing neuronal and glial dysfunction (Semmler et 
al. 2008; Stocchetti 2005). Reducing inflammation during sepsis improves brain 
functional recovery, hinting that SAE may indeed be a consequence of the 
inflammatory response (Boos et al. 2005; Deng et al. 2013). 
Regarding the effects of SAE in the premature brain, surviving infants are at higher 
risk for long-term neurodevelopmental disability due to the lack of antioxidant defense 
mechanisms, the poorly developed germinal matrix, as well as immature 
oligodendrocytes and astrocytes (Alshaikh et al. 2013; Leviton and Dammann 2004). 
Microglia are also maturing at this stage, with its transition from an amoeboid into a 
ramified shape only occurring during the second week of rodent life (Harry and Kraft 
2012; Nayak et al. 2014; Neiva et al. 2014). Still, during the first week of life, newborns 
profit from maternal factors that aid in the immune defense (Battersby and Gibbons 
2013). On the other hand, neonates who develop sepsis during LNP have higher 
mortality rates, especially if infected with gram-negative organisms (up to 40%) (Stoll et 
al. 1996). During these later stages, the development of the central nervous system 
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(CNS) focuses on neuronal activity (synaptogenesis and myelination) and on glial 
proliferation and differentiation (Rice and Barone 2000). 
In vivo experiments have demonstrated increased BBB permeability alongside 
neuronal damage induced by inflammation in the developing brain (Bilbo et al. 2008; 
Stolp et al. 2005a; Stolp et al. 2005b). Our own previous (and still unpublished) studies 
revealed a late pro-inflammatory response with strong glial interference following an 
ENP systemic inflammation. Thus, disturbances during this neurodevelopmental 
window may lead to severe damages that can be irreversible (Kroon et al. 2013; Rice 
and Barone 2000). 
To better understand the lasting cerebral consequences of neonatal SAE, in this 
study we aimed to determine its influence on the young adult neuronal and glial 
development, and whether such response depend on an initial ENP or LNP 
inflammation. Simultaneously, we evaluated the acute response of primed animals to a 
second stimulus, also varying the window of priming. 
 
 
2. Materials and Methods 
2.1. Animals 
CD1 mice were purchased from Harlan Ibérica laboratories (Spain). Mice were 
housed with a 12 hour light/dark cycle and were provided with ad libidium access to a 
standard laboratory chow diet and drinking water. This study was performed in 
accordance with the European Community guidelines (Directives 86/609/ECC, 
European Convention for the Protection of Vertebrate Animals used for Experimental or 
Other Scientific Purposes) and Portuguese Laws on Animal Care (Directive 1005/92). 
All experimental procedures were performed under anesthesia, conducted in a manner 
to minimize animal suffering and all efforts were made to use the minimum number of 
animals. 
 
2.2. Drug Administration 
The day of birth of the mice was defined as postnatal day (PND)1. Offspring of 
both genders were randomly divided and received intraperitoneal injections of either 
endotoxin-free saline (SF) or of lipopolysaccharide (LPS) [6 mg/kg, Escherichia coli 
055:B5; Calbiochem (Merck, Germany)] to induce systemic inflammation (Erickson et 
al. 2012; Jin et al. 2011). We followed three studies with different injection plans, as 
seen in Figure 4.1, with n ≥ 4 animals in each condition per analysis. 
Given our previous (still unpublished) data on the acute effects on 
neurodevelopment during a system inflammation in the first week of life (ENP), we 
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initially aimed to determine the acute effects of neuroinflammation during the second 
week of life (LNP). Mice were injected with LPS daily at PND11,12,13, and were 
examined the following day (PND14). We also intended to evaluate whether moving 
the window of exposure to LPS from the first to the second week of life would trigger 
different lasting impairments on neurodevelopment. Animals were injected with LPS 
during the first week (at PND4,5,6) or during the second week (PND11,12,13) and 
were examined at young adult age, more precisely at PND52. Lastly, we aimed to 
determine if a primed response during the neonatal period would differ from an acute 
adult response, and whether the induced effects depended on the neonatal period of 
the priming. Newborn animals were separated into two groups, and each received 
either the first- or the second-week LPS-administration plan. At PND52, the same 
animals received a new LPS challenge and were examined the following day (PND53).  
All animals were weighed before perfusion for posterior comparison of body 
weight. Whole brains were also weighed following perfusions. 
 
2.3. Tissue Process 
For gelatin zymography and western blot analysis, animals were anesthetized with 
a lethal dose of Pentobarbital and intracardially perfused with phosphate buffer saline 
solution, pH 7.4 (PBS). Brains were quickly removed and snap-frozen followed by 
cryopreservation at -80ºC for at least 24 h. Protein extracts were obtained by lysing the 
brain tissue with radioimmuno-precipitation assay (RIPA) buffer (Tris Buffer 1 M pH 8.0, 
EDTA 0.5 M pH 8.0, NaCl 5 M, 10% NP-40, 50% glycerol, 10% SDS). For histological 
analysis, the perfusion was performed with 4% paraformaldehyde (PFA) in PBS. Brains 
were post-fixed in the indicated fixative for at least 24 h. Brain tissue was processed for 
paraffin and cut into 6 μm sagittal sections. 
 
2.4. Staining for Luxol Fast Blue and Cresyl Violet 
Paraffin sections were stained with Luxol Fast Blue (VWR, USA) and with Cresyl 
Violet (Sigma, USA) for determination of oligodendrocyte myelination in white matter 
and neuronal Nissl bodies’. Sections were rehydrated before overnight incubation with 
0.1% Luxol Fast Blue solution, at 56ºC. After washing, slides were differentiated in a 
0.5% lithium carbonate solution, followed by 2% acetic acid solution for 5 min. Next, 
slides were counterstained with a 1% Cresyl Violet solution for 10 min, followed by 
differentiation in 37% acetic acid and a final wash in distilled water. Tissue sections 
were mounted with Fluoromount-G (Southern Biotech, USA) and visualized using a 
DFC 490 camera (Leica, Germany) adapted to an Axioskop bright field microscope 
(Zeiss, Germany). Using ImageJ 1.48x software (NIH, USA). Width of each cerebellar 
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layer was evaluated in photos with magnification of 100x. The numbers of neurons per 
field and their soma area in the cerebellar Purkinje layer, CA3 hippocampal region and 
throughout the pons regions were quantified in photos of 400x magnification. 
 
 
 
 
 
Figure 4.1 – Schematic representation of lipopolysaccharide (LPS) administration plans and 
evaluated parameters. Mice were given endotoxin-free saline (SF)/LPS injections according to different 
injection plans: at the postnatal days (PND) 4, 5 and 6, or at PND 11, 12 and 13, corresponding to early or 
late neonatal periods, respectively. Mice were examined the day after the last neonatal injection (PND14) 
to study acute effects, or at PND53 to determine the lasting consequences. A second LPS injection was 
administered at PND52 and mice were examined the day after (PND53) to evaluate the primed effects. 
Body weight, activity and expression of inflammatory biomarkers in whole brain [matrix 
metalloproteinase(MMP)-9 and -2, toll-like receptor (TLR)4, high mobility group box 1 (HMGB1) and 
autotaxin (ATX)], as well as alterations in white matter, neurons, astrocytes and microglia were evaluated 
in the cerebellum, the hippocampus and the pons at each time point. 
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2.5. Gelatin Zymography 
For evaluation of the activity of matrix metalloproteinase (MMP)-9 and MMP-2, 40 
μg of protein from tissue extracts were analyzed by SDS-PAGE zymography in 0.1% 
gelatin/10% acrylamide gels under non-reducing conditions. After electrophoresis, gels 
were washed for 1 h with 2.5% Triton X-100 (in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mM 
ZnCl2) to remove SDS and renature the MMPs species in the gel. Gels were next 
incubated in developing buffer (50 mM Tris pH 7.4, 5 mM CaCl2, 1 mM ZnCl2) for 72 h 
at 37ºC to induce gelatin lysis. For enzyme activity analysis, gels were stained with 
0.5% Coomassie Brilliant Blue R-250 (Bio-Rad, USA) for 3 h at room temperature (RT), 
and distained in 30% ethanol/10% acetic acid solution. Gelatinase activity, detected as 
a white band on a blue background, was quantified by computerized image analysis 
using Quantity One 1-D Analysis Software (Bio-Rad, USA).  
 
2.6. Western Blot 
Western blot analysis was performed using 100 μg of protein from tissue extracts. 
Proteins were separated on a 12% SDS-PAGE gel and following electrophoretic 
transfer onto a nitrocellulose membrane and blocking with 5% milk solution, the blots 
were incubated with primary antibody overnight at 4ºC [rabbit anti-Toll-like 
receptor(TLR)-4 (Santa Cruz, USA, #sc-10741; 1:500), mouse anti-high mobility group 
box (HMGB)-1 (BioLegend, USA, #651402; 1:500), rabbit anti-autotaxin (ATX) 
(Millipore, USA, #ABT28; 1:500) or mouse anti-β-actin (Sigma, USA, #A5441; 1:5000)] 
and with horseradish peroxidase-labelled secondary antibody [anti-mouse or anti-rabbit 
(Santa Cruz, USA, #sc-2005 and #sc-2004 respectively; 1:5000] for 1 h at RT. Protein 
bands were detected by LumiGLO® (Cell Signaling, USA) and visualized by 
chemiluminescence with ChemiDoc (Bio-Rad, USA). Expression was quantified by 
computerized image analysis using Quantity One 1-D Analysis Software (Bio-Rad, 
USA). 
 
2.7. Paraffin-Immunofluorescence 
Paraffin sections were used to assess the expression of GFAP for astrocyte 
detection and of ionized calcium binding adaptor molecule (Iba)1 for microglia staining). 
Briefly, heat antigen retrieval was performed in rehydrated tissue sections (3.7 mM 
sodium citrate, 1 mM EDTA, pH 6.0). Tissue was incubated overnight at 4ºC in 1% 
bovine serum albumin (BSA) (Sigma, USA) + 0.1% Triton-X100 (Roche) with primary 
antibodies mouse anti-GFAP (Novocastra, Leica, Germany, #GFAP-GA5, 1:100) and 
rabbit anti-Iba1 (WAKO, Japan, #019-19741; 1:250). Sections were incubated with 
secondary antibody Alexa 488 anti-rabbit IgG or Alexa 594 anti-mouse IgG (Invitrogen, 
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USA, #A11008 and #A11005 respectively; 1:500), overnight at 4ºC. Nuclei were 
counterstained with DAPI dye. After dehydration, slides were mounted with DPX (BDH 
Prolabo, UK). Images were captured using an AxioCam HRM camera (Zeiss, 
Germany) adapted to an AxioScope.A1 microscope (Zeiss, Germany). Images were 
collected using sequential scanning with the 405, 488 and 594 nm laser lines to 
produce three color overlays. Cell counting was performed using a magnification of 
630x. Immunopositive cells with identified nuclei counterstaining by DAPI were counted 
throughout the cerebellum, the hippocampus and the pons regions using Image J 1.48x 
Software (NIH, USA). Results are presented as number of cells per field. 
 
2.8. Statistical Analysis 
Results are expressed as means ± SEM from, at least, four independent animals 
in each LPS-treatment group. Significant differences between control and LPS-treated 
animals for each time point were determined by the two-tailed t-test performed on the 
basis of equal and unequal variance as appropriate. Comparison of more than two 
groups was done by ANOVA one-way with Bonferroni post-hoc test using GraphPad 
Prism® 5.0 (GraphPad Software, San Diego, CA, USA). Statistical significance was 
considered when P values were lower than 0.05. 
 
 
3. Results 
3.1. LPS administration during the second week of life acutely alters the 
normal morphology of the CNS 
The second week of life in the mouse species comprises the beginning of glial 
maturation, namely the ramification of microglia (Harry and Kraft 2012) and the 
trimming of overlapping astrocytic processes (Bushong et al. 2004). To better 
understand if the changes seen in our previous study (Chapter 3) depend on the 
neonatal window of LPS-treatment, we here evaluated the acute response to systemic 
inflammation induced during the second week of life. We first determined body and 
brain weights but did not observe any changes. 
 
Exposure to LPS in the second week of life leads to acute neurodegeneration and 
damage of the white matter. Given that LPS induces acute neurodegeneration when 
administrated at the first week of life (Chapter 3), we also assayed the number of 
neurons and their soma area following treatment with the endotoxin in the second-
week. As depicted in Figure 4.2, PND14 animals had significant neuronal loss in the 
pons and the cerebellum (0.9-fold, P<0.05) (Fig. 4.2B), as well as an acute atrophy in 
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the soma area of neurons from the pons (Fig. 4.2C). Since our previous data also 
indicated that a first-week exposure to LPS delays myelination, along with the 
shrinkage of neuron-containing cerebellar layers (Chapter 3), we next analyzed 
cerebellar changes in animals exposed to LPS on the second-week. Curiously, PND14 
mice had an acute shrinkage of the white matter layer (~0.5-fold) in addition to lighter 
staining of Luxol Fast Blue that suggests myelin loss (Fig. 4.2D). No further acute 
alterations were observed in the remaining cerebellar layers (data not shown). These 
results point to a greater neuronal susceptibility in the pons of animals treated in the 
second week of life, whereas the cerebellar region hints a particular vulnerability in the 
white matter. 
 
 
 
Figure 4.2 - Late neonatal systemic inflammation triggers acute neurodegeneration and 
demyelination in newborn animals. Paraffin sections from newborn mice that exposed to 
lipopolysaccharide (LPS)-administration in the late neonatal period (PND14), were stained with Luxol Fast 
Blue (myelin) followed by Cresyl Violet (Nissl bodies’). Representative images of the pons, the 
hippocampus and the cerebellum are shown in A. Number of neurons per field and their soma area were 
evaluated (B,C). Width of the white matter layer of the cerebellum was measured and results expressed in 
µm (D). All results are mean ± SEM of at least four independent experiments. *P <0.05 and **P <0.01 vs. 
respective control (endotoxin-free saline, SF). 
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LPS-induced systemic inflammation in the second week of life triggers a mild pro-
inflammatory response. As seen in our previous study (Chapter 3), neuroinflammation 
during the first week of life enhances the activity or expression of the inflammatory 
biomarkers MMP-9, TLR4 and its mediator HMGB1. On the other hand the expression 
of ATX was decreased in response to the neonatal inflammation. Thus, we further 
evaluated the reflex of a system inflammation induced during the second week of life in 
these inflammatory biomarkers (Fig.4.3). At PND14 MMP-9 was slightly though 
significantly increased (1.1-fold, P<0.05) whereas MMP-2 remained at control levels. 
Surprisingly, TLR4 was unaltered in spite of the significant increased expression of 
HMGB1. As for ATX, the decrease in its expression was not statistically significant. 
Thus, there appears to be a different acute inflammatory response between the first 
and the second week of life. 
 
 
Figure 4.3 - Systemic inflammation in the second week of life triggers a mild pro-inflammatory 
response with increased activity of matrix metalloproteinase (MMP)-9 and overexpression of high-
mobility group box (HMGB)-1. Whole brain lysates of newborn mice with lipopolysaccharide (LPS)-
administration in the late neonatal period (PND14) were used to determine the activity of MMP-9 and 
MMP-2 by gelatin zymography, alongside with the expression of inflammatory biomarkers Toll-like receptor 
(TLR)4, HMGB1 and autotaxin (ATX) by western blot. Results are expressed as fold-change from control ± 
SEM from at least four animals. *P <0.05 vs. control. 
 
 
An LPS-challenge during the second week of life promotes the proliferation of glial 
cells. MMP-9 was revealed to contribute to the inflammatory response by glia activation 
(Annese et al. 2014). Thus, and despite the fact that TLR4 and ATX were unaltered at 
the times studied, we evaluated the acute response of microglia and astrocytes to an 
LPS-challenge during the second week of life, based on immunofluorescence of 
GFAP+ astrocytes and Iba1+ microglia in the newborn mouse brain (Figure 4.4). There 
was an acute astrogliosis at PND14, mainly in the pons (~2-fold) followed closely by 
the hippocampus and the cerebellum. Regarding microglial response, both the pons 
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and the hippocampus depicted an acute increase compared to SF treated newborns 
(~1.5-fold). These results point to a possible connection between exacerbated glial 
response in the pons and the observed neurodegeneration in this region. 
 
 
Figure 4.4 - Late neonatal systemic inflammation induces acute astrogliosis and microglia 
proliferation/migration. Paraffin sections from newborn mice that exposed to lipopolysaccharide (LPS)-
administration in the late neonatal period (PND14) were immunolabelled for astrocytes (glial fibrillary acidic 
protein, GFAP, red) and for microglia-like cells (ionized calcium binding adaptor molecule, Iba1, green). 
Nuclei were counterstained with DAPI (blue). Representative images of the pons, the hippocampus and 
the cerebellum are shown in A. Number of GFAP
+
 cells and of Iba1
+
 cells in the parenchyma, per field, 
were determined (B,C). All results are mean ± SEM of at least four independent experiments. *P <0.05 and 
**P <0.01 vs. respective control (endotoxin-free saline, SF). 
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3.2. LPS challenge in the first or second weeks of life originate different 
lasting effects. 
Injury to the developing CNS is frequently associated with long-term neurological 
deficits (Nimmervoll et al. 2013; Volpe 2003; Zavitsanou et al. 2013). In order to assess 
the impact of LPS exposure in the first or second weeks of life, we evaluated the lasting 
neuronal and white matter effects, as well as the density of glial cells, in young adult 
mice (PND53). 
 
LPS administration in the first week of life induces lasting neurodegeneration in the 
brains of young adult mice. Our data revealed that a LPS-challenge in the first week of 
life induced lasting neuronal loss in hippocampal CA3 region and cerebellar Purkinje 
layer (Fig. 4.5A). Though the pons did not present neuronal loss, there was lasting 
neuronal soma reduction (Fig. 4.5B). We also searched changes in the width of 
cerebellar layers, in body and brain weights, in the activity and expression of 
inflammatory biomarkers, as well as in the number of GFAP+ cells and Iba1+ cells. Still, 
no other lasting effects were found (data not shown). 
 
Figure 4.5 - Systemic inflammation in the first week after birth induces lasting neuronal loss in the 
hippocampus and the cerebellum, in addition to soma atrophy in pons. Paraffin sections from young 
adult mice (PND53) with lipopolysaccharide (LPS)-administration in the first week of life, were stained for 
neurons with Cresyl Violet (Nissl bodies). Number of neurons per field in the pons, CA3 region 
(hippocampus) and Purkinje layer (cerebellum) were determined (A), as well as their soma area (B). All 
results are mean ± SEM of at least four independent experiments. *P <0.05 vs. respective control 
(endotoxin-free saline, SF). 
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LPS-induced inflammation in the second week of life leads to lasting neuronal atrophy, 
shrinkage of the cerebellar white matter layer and loss of astrocytes. Given that young 
adult mice exposed to systemic inflammation in the first week of life had lasting 
neurodegeneration, we analyzed young adult mice subjected to LPS-challenge during 
the second week. Alike young adult animals with LPS-treatment in the first week, 
changing the window of injections to the second week does not induce last effects on 
body and brain weights, nor on the activity and expression of inflammatory biomarkers. 
As for the effects on neurons, our data revealed that the neuronal atrophy seen in the 
pons of PND14 animals is still significant at young adulthood (Fig. 4.6A). We further 
analyzed the cerebellar consequences, more precisely on the width of each layer, and 
observed a lasting shrinkage of the white matter layer at PND53 (Fig. 4.6B), with no 
further alterations in the remaining layers (data not shown). These results point to 
different neuronal lasting effects depending on the neonatal week at which exposure to 
LPS occurs, with the first week being more demising. On the other hand there appears 
to be a bigger susceptibility of the white matter when subjected to an inflammatory 
stimulus in the second week of life. 
Surprisingly, these young adult animals also had persistent reduced numbers of 
GFAP+ astrocytes in the hippocampus and the cerebellum, but no lasting effects were 
found regarding the number of Iba1+ cells (Fig. 4.6C). These results, along with the 
lasting effects observed in the animals that were exposed to LPS in the first week of 
life, may unveil a possible connection between the degree of white matter demise and 
the reactivity of astrocytes. 
 
3.3. Animals treated with LPS during the second week of life are more 
susceptible to a second LPS-challenge. 
The consequences of priming the immune system are still not consensual. Though 
some defend that the priming of inflammatory response by LPS may exert a protective 
effect (Ahmed et al. 2000), others advocate that it results in an exaggerated local 
inflammatory response (Puntener et al. 2012). This led to us to evaluate the response 
of young adult animals primed during the first or second week of life to a second LPS-
challenge at PND52, compared to an acute adult response at the same age (SF during 
the neonatal period and only one injection of LPS at PND52). 
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Figure 4.6 - Late neonatal systemic inflammation triggers lasting neuronal atrophy in the pons, 
cerebellar demyelination, in addition to decreased numbers of astrocytes. Paraffin sections from 
young adult mice (PND53) with lipopolysaccharide (LPS)-administration in the late neonatal period , were 
stained with Luxol Fast Blue (myelin) and Cresyl Violet (Nissl bodies), to determine the number of neurons 
per field and their soma area (A). Width of the white matter layer of the cerebellum was also measured and 
results are presented in µm (B). In parallel, other paraffin sections were immunolabelled for astrocytes 
(glial fibrillary acidic protein, GFAP, red) and for microglia-like cells (ionized calcium binding adaptor 
molecule, Iba1, green). Nuclei were counterstained with DAPI (blue). Number of GFAP
+
 cells and of Iba1
+
 
cells in the parenchyma were determined per field (C). All results are mean ± SEM of at least four 
independent experiments. *P <0.05 and **P <0.01 vs. respective control (endotoxin-free saline, SF). 
 
 
Second LPS-challenge induces loss in body weight. We first studied the physical 
response by determining body and brain weights, with no changes in the latter. We 
observed that a second LPS-challenge at PND52 induced additional loss in body 
weight in animals that were primed during the first week of life compared to an adult 
acute response (Table 4.1). Even though animals primed at the second week of life 
displayed a similar body weight to those primed in the first week, the correspondent 
adult acute LPS-treatment also induced loss of body weight [0.9-fold compared to no 
LPS administration (SF at neonatal period and SF at PND52), P < 0.01]. 
 
Priming in the first week of life sensitizes cerebellar neurons, whereas priming in the 
second week reduces the cerebellar white matter layer. Next, we evaluated the 
outcome of a double LPS-challenge on neurons and white matter. Concerning the 
effects on neurodevelopment, we found no differences in the number of neurons in 
primed animals compared to an adult acute response, apart from an increase in 
Purkinje neurons in animals that were primed in first week of life (Fig. 
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4.7A).Interestingly, we observed an exacerbated atrophy of the neuronal soma in these 
same Purkinje neurons (Fig. 4.7B). On the other hand, animals that were primed 
during the second week only presented neuronal atrophy in the hippocampus. Thus, 
neurons appear to be vulnerable both in animals primed during the first and during 
second weeks, though with differences between brain regions. 
Afterwards, we measured the width of each cerebellar layer (Fig. 4.7C). 
Interestingly, we observed different outcomes depending on the age of priming. After a 
second LPS-challenge, animals primed during the first week had significantly narrower 
cerebellar layers, more specifically the molecular, Purkinje neuronal and internal 
granular layers. On the other hand, animals that were primed during the second week 
of life had narrower internal granular and white matter layers after a second LPS-
exposure. As for the previous parameter, the neurons in the cerebellum are more 
susceptible to inflammation when primed in the first week.  
 
Table 4.1 - Priming of the inflammatory response during the first week of life triggers weight loss 
following a second challenge. 
 
 
 
Animals were weighed (g) after lipopolysaccharide-challenge. All results are the mean value ± SEM of at 
least eight independent experiments. **P <0.01 vs. respective adult acute response. 
 
 
Second LPS-challenge leads to enhanced pro-inflammatory response in animals 
primed during the second week of life. We further determined the activity or expression 
of the abovementioned inflammatory biomarkers (Fig. 4.8A), we observed that animals 
primed during the first neonatal week had little pro-inflammatory response to the 
second stimulus, but presented a robust increased expression of ATX when compared 
to an adult acute response. Animals primed during the second week also had high 
levels of ATX, as well as of HMGB1. 
 
 
 Neonatal age determines second inflammatory response in young adult mice 
 
159 
 
Figure 4.7 - The type of effects on neurons and the regions affected by a primed response on 
young adult mice depend on the neonatal week of priming. Paraffin sections from young adult mice 
that with lipopolysaccharide (LPS)-administration in the first or second weeks of life followed by a second 
LPS-challenge at adult age, were stained with Luxol Fast Blue (myelin) followed by Cresyl Violet (Nissl 
bodies). Number of neurons per field and their soma area were evaluated (A,B). Width of the cerebellar 
molecular (ML), Purkinje (PL), internal granular (IGL) and white matter (WML) layers was measured in µm 
(D). All results are fold-change from respective adult acute response ± SEM of at least four independent 
experiments. *P <0.05 and **P <0.01 vs. adult acute response. 
 
Second LPS-challenge induces different astrocyte and microglia responses depending 
on the age of priming. Lastly, we evaluated if the timing of neonatal priming would 
result in different outcomes in astrocytic (GFAP+) (Fig. 4.8B) and microglial (Iba1+) 
(Fig. 4.8C) proliferation. Animals that were primed during the first neonatal week 
depicted a similar astrocytic proliferation of an adult acute response, but a lower 
microglial response in the pons and the cerebellum was observed. Interestingly, these 
are the main regions affected both by lasting and primed neuronal demise. 
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Regarding the animals primed during the second week, lower numbers of 
astrocytes and microglia were present in the hippocampus. The cerebellum of these 
animals depicted a slightly higher number of microglial cells than in an acute response. 
The differences to priming in the first week may hint on the  interactions involved in the 
neuronal demise observed in this study. 
 
 
Figure 4.8 - Inflammatory response of animals primed in the first week of life is milder than in 
animals primed during the second week. In A, whole brain lysates of young adult mice, with 
lipopolysaccharide (LPS)-administration in the first or second weeks of life followed by a second LPS-
challenge at adult age, were used to determine the activity of matrix metalloproteinase (MMP)-9 and MMP-
2 by gelatin zymography. The expression of inflammatory biomarkers Toll-like receptor (TLR)-4, high-
mobility group box (HMGB)-1 and autotaxin (ATX) were quantified by western blot. Paraffin sections from 
the same mice were immunolabelled for astrocytes (glial fibrillary acidic protein, GFAP, red) and for 
microglia-like cells (ionized calcium binding adaptor molecule, Iba1, green). Nuclei were counterstained 
with DAPI (blue). Number of GFAP
+
 cells (B) and of Iba1
+
 cells (C) in the parenchyma were determined 
per field. All results are fold-change from respective adult acute response ± SEM of at least four 
independent experiments. *P <0.05 and **P <0.01 vs. adult acute response. 
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4. Discussion 
In the present study, we establish the acute, lasting and primed responses of 
neonatal systemic inflammation. We demonstrate that the neonatal acute response of 
neurons and inflammatory mediators varies with the age at which LPS exposure 
occurs. We also demonstrate that an inflammatory episode during the first week of life 
has more lasting effects on neurons, whereas it alters lastly both white matter and 
astrocytes if the induction occurs during the second week. At last, we provide novel 
insights into the primed responses at both neonatal ages, again revealing a more 
neuron-related demise in animals primed in the first week, and a more glial response 
for the second week priming. 
We observed that LPS administration during the second week of life did not alter 
body and brain weights. Another study that studied the effect of LPS administration (0.3 
mg/kg) on newborn mice from PND3 to PND11 (Du et al. 2011), revealed that body 
weight is maintained at PND12 and thus consistent with our results. Regarding the 
body weight loss seen in primed young adults following a second LPS-challenge 
(though it was only significant compared to the adult acute response in animals with 
priming during the first week of life), both groups had significant weight loss when 
compared to controls with only SF administration. In line with our results, another study 
has reported that a second injection of LPS induces weight loss in primed animals 
regardless of the neonatal week of the first injection (Spencer et al. 2007). As for the 
fact that one single dose of LPS in adulthood induced weight loss in animals that 
received SF during the second week of life but not during the first, Avitsur and Sheridan 
(2009) have studied the influence of maternal separation at PND4 or PND9 on the 
adulthood response to LPS-administration. This work concluded that the mere handling 
of the pups may actually be an inductor of stress, particularly in the 2 week of life and 
thus similarly to our study. To point that, even though our SF-treatment pups were 
separated from dams for short periods of time, it was through three consecutive days 
for it may further contribute to this outcome.  
We further determined the effects on neurons and white matter. Our results have 
shown neuronal loss and atrophy at PND14, as well as reduction of the white matter in 
cerebellum. In consistence with our data, the aforementioned study of LPS 
administration from PND3 to PND11 also demonstrated neuron loss at PND12, in 
addition to myelin loss (Du et al. 2011). Oligodendrocyte precursors (OPC) are 
vulnerable to LPS exposure during the perinatal period, leading to the arrest of their 
maturation (van den Heuij et al. 2014). A recent study (Bénardais et al. 2014) has also 
revealed that animals previously injected with LPS (0.2 mg/kg) in the first neonatal 
week have delayed myelin removal in the corpus callosum when it was induced at the 
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age of 8 to 9 weeks, along with enhanced early remyelination. Moreover, exposure of 
preterm sheep to LPS reduced neuroinflammation and white matter injury after a final 
dose 10 days later (van den Heuij et al. 2014). Still, in vitro studies have showed that 
inflammation may also injure OPC leading to maturation-dependent cell death and loss 
of cellular processes (Back et al. 1998; Oka et al. 1993). Thus, the observed reduction 
of white matter may be related to the particular vulnerability of oligodendrocytes and 
OPCs. Again, the difference between the groups that received one dose of LPS at 
adulthood and one dose SF either at the first or at the second weeks may be due to 
dam’s separation. 
Our current data further revealed that LPS-administration during the first week of 
life does not induce enduring alterations in the cerebellar layers of adults. Indeed, the 
opposite was only observed in young adults subjected to LPS-treatment during the 
second week of life, namely in the white matter layer. As for the neonatal priming, 
animals that were primed during the first week of life had decreased molecular, 
Purkinje and internal granular layers. Those primed in the second week had further 
reduction of the cerebellar white matter layer and of the internal granular layer. The 
decrease in both molecular and purkinje layers could be related to the loss of Purkinje 
neurons. In agreement with our data, white matter injury has been formerly connected 
to neurodevelopmental damage in neonatal sepsis survivors, involving the production 
of pro-inflammatory cytokines, BBB disruption and impaired autoregulation of cerebral 
blood flow (Graham et al. 2004; Khwaja and Volpe 2008; Volpe 2008). The narrowing 
of the internal granular layer could be related to impairment of granule cells 
proliferation. This process occurs mostly during the first two weeks of life, more 
precisely between PND5 and PND10 (Xu et al. 2013). As so, these cells might be 
particularly vulnerable to subsequent LPS-induced damage. 
We further evaluated the acute and enduring effects of neonatal inflammation on 
neurons neuronal development. We determined that exposure to LPS during the first 
week of life induced lasting neuronal atrophy in young adults, with no further damage 
after a second exposure (primed animals). Other studies where systemic inflammation 
was induced in the first week after birth also had no overall adult neuronal loss (Cai et 
al. 2013; Fan et al. 2011). Still, the animals presented motor function deficits and loss 
of dendrites. Similarly, a study in adult mice reported that LPS affected neurogenesis 
giving rise to neurons with less synaptic contacts along with decreased dendritic 
volume and complexity (Valero et al. 2014). Moreover, neonatal inflammation has been 
revealed to specifically affect dividing neurons but not post-mitotic cells (Järlestedt et 
al. 2013). It is conceivable that the hippocampal and brainstem lesions here 
demonstrated may underline the long-term cognitive disorders observed in SAE 
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survivors (Sonneville et al. 2013). As for late neonatal exposure to LPS, our data 
revealed an acute neuronal loss in the pons by double LPS challenge (primed acute at 
PND53), as well as neuronal atrophy in the pons (enduring at PND53) and 
hippocampus (primed acute at PND53). The work by Järlestedt et al. (2013) 
demonstrated reduced number of neurons at PND41, 32 days after LPS, though in the 
hippocampus. Still, we only observed neuronal atrophy in this region. This divergence 
could be due to the exact days of neonatal administration, as our pups were exposed 
to LPS at days 11, 12 and 13 – later than PND9 as in his study –, and we only 
observed enduring neuronal loss in the hippocampus of pups injected at days 4, 5 and 
6. Overall, lasting effects on neurons are more severe in young adult mice with 
inflammation during the first week of life, whereas the primed acute effects are more 
harmful in animals with inflammation during the second week of life. Thus, permanency 
of type of cells and regions impaired seem to depend on the neonatal age at which 
systemic inflammation is induced (Pandharipande et al. 2013). 
Neuronal apoptosis can originate from the subsequent production of inflammatory 
mediators by sepsis-induced activation of astrocytes and microglia (Liu et al. 2001). 
The acute response of MMPs to LPS administration during the second week of life are 
consistent with our own previous results still unpublished on neonatal inflammation 
during the first week of life (Chapter 3), were we demonstrated an increased the activity 
of MMP-9 with no changes in MMP-2. Tough HMGB1 was overexpressed, the same 
was not observed for TLR4. This may be intricately related to the fact that ATX 
expression was also not altered. Regarding the response of adult TLR4 to a second 
exposure, it was lower than in adult acute inflammation regardless of the neonatal 
period at which the first exposure was inflicted. A study by Murray et al. (2012) 
demonstrated that animals with inflammation during the first week of life displayed no 
alterations in TLR4 expression when treated with LPS as adults. These mechanisms 
for LPS tolerance maintains TLR4 expression suppressed for over 24 h (Bosisio et al. 
2002; Nomura et al. 2000). TLR4 is intimately connected to cyclooxygenase-2 (COX-
2), given that the activation of the first leads to the production of the last (Parente et al. 
2013). Given this relationship, an attenuated fever response by decreased COX-2 
expression may result from similar TLR4 decreased expression and vice-versa (Karikó 
et al. 2004; Kis et al. 2006; Spencer et al. 2011). A few studies state that neonatal LPS 
exposure at PND14 attenuates LPS-induced fever in adults (Ellis et al. 2005; Spencer 
et al. 2006) and thus also in line with our data on young adults primed during the 
second week. The response of HMGB1 and ATX to a second systemic LPS 
administration in adults are usually elevated for a few days (Awada et al. 2012; Chavan 
et al. 2012; Terrando et al. 2010), as seen in mice that were primed during the second 
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week of life. There are no further studies on the influence of neonatal inflammation in 
the adult expression of HMGB1 that could justify the difference from its priming at the 
first or second weeks of life. Still, it is important to bear in mind that this molecule has a 
late kinetic activity (Goto et al. 2010; Kato et al. 2009; Nagamori et al. 2012) and, thus, 
it may still be overexpressed at other time-points in young adult animals primed during 
the first week of life. 
Inflammatory mediators could be produced by activated microglia and astrocytes, 
an event that has been described in rat models of SAE and in humans (Deng et al. 
2013; Lemstra et al. 2007). Microglial activation is one of the earliest changes observed 
in SAE (Nayak et al. 2014; Semmler et al. 2005). Interestingly, the microglial numbers 
in the adult animals here studied were alike in general. A recent study has 
demonstrated that exposure to LPS at PND7 or at PND21 trigger similar microglial 
densities, suggesting that there may be a maximum number of microglia allowed to 
proliferate in the brain (Smith et al. 2014). Still, it has been demonstrated that LPS-
administration during the first week of life produces more activated microglia in 
response to a second challenge (Bland et al. 2010). We, however, observed the 
opposite with more microglia than in an adult acute response in the cerebellum of 
animals primed during the second week of life. 
Microglial activation may affect other brain cells such as astrocytes and neurons 
(van Gool et al. 2010). Though our study depicted similar numbers of an adult acute 
response, the increase in GFAP+ astrocytes is associated with SAE in rat models in 
order to repair the injured CNS (Rezaie and Dean 2002; Semmler et al. 2008). Also to 
point that preterm sheep with administrated LPS present astrocytosis following a 
second dose (van den Heuij et al. 2014). In our study, the response of adult astrocytes 
to a second stimulus appears to be deeply connected to the neonatal week of the first 
exposure. Surprisingly, mice primed during the second week had decreased numbers 
of GFAP+ cells in response to a second pro-inflammatory induction. Recent studies 
have demonstrated that early inflammation triggers acute and brain alterations, with 
significant astrogliosis and microglial activation in LPS-exposed adult mice (Cai et al. 
2013; Dada et al. 2014; Fan et al. 2011; Murray et al. 2012). Still, Järlestedt et al. 
(2013) have recently demonstrated that LPS administration at PND9 leads to reduced 
numbers of astrocytes in young adult animals, even without a second exposure, as 
seen in our data. In addition, even though there is generally less 
microgliosis/proliferation in the primed mice following the double LPS challenge, 
microglia may still be activated (Bland et al. 2010). This has been revealed to diminish 
the density of astrocytes and increase neuronal damage (Sonneville et al. 2012), 
coinciding with our results. The morphology of hippocampal astrocytes in the neonatal 
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period may also influence the final outcome in young adults. At PND7 their processes 
overlap, whereas around PND14 these are trimmed giving cells a mature appearance 
(Bushong et al. 2003; Bushong et al. 2004; Freeman 2010). Therefore, the inability to 
repair inflammatory damage in the first week of life might prime these cells for future 
responses, whereas the same might not happen in the second week of the developing 
CNS. 
 
 
5. Conclusions 
In conclusion, the present data revealed that neonatal systemic inflammation 
induces not only enduring effects in young adults but also influences the response to 
future inflammatory exposure. More importantly, we hereby demonstrate that the 
neonatal window of neuroinflammation determines the type of cell and region 
responses in the CNS and thus its neurodevelopmental outcome. Further studies need 
to be done in order to further identify the permanent damaging effects in the CNS, as 
well as the mechanisms behind the differential response associated with the 
developmental window of CNS development after birth, opening new target-driven 
medicines and hopefully suppressing long-term sequelae in patients after neonatal 
sepsis. 
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1. Concluding Remarks 
The deleterious effects of UCB and lipopolysaccharide LPS to brain cells, either 
alone or in combination, have already been examined in our previous studies (Falcão 
et al. 2005; Fernandes et al. 2004; Silva et al. 2010; Veszelka et al. 2007). In addition, 
it has been demonstrated that astrocytes are particularly sensitive to these molecules 
(Falcão et al. 2005; Fernandes et al. 2004). Despite this, little was known about the 
aggravating effects of UCB and/or LPS on the BBB dynamic properties. This led us to 
evaluate the effects of UCB and LPS on a simplified in vitro model of the BBB formed 
by rat BMEC monocultures, as well as to assess the consequences of astrocytic 
reactivity on BBB integrity using co-cultures of rat BMEC and astrocytes. After 
understanding the in vitro effects induced by these two insults that are common in 
neonatal conditions, we performed in vivo studies to better evaluate glial response and 
its influence on neurodevelopment, using LPS as a trigger of neuroinflammation in a 
newborn mouse model. We investigated the influence of LPS administration during the 
first week of life in the developing NVU. Thereafter, we evaluated the acute effects of 
LPS during the second week of life, the lasting effects in young adult animals resulting 
from exposure to the inflammatory stimuli in the neonatal period, as well as the primed 
response in a second stimulus at young adulthood (Fig. 5.1). 
In the first study (Chapter 2) we demonstrated that both LPS and UCB induce 
apoptosis in BMEC after 24h, though only UCB triggered LDH release. The inhibition of 
P-gp activity by these molecules occurs at different time-points, as LPS effect was 
earlier and transient whereas it is prolonged for UCB. Considering that UCB is a 
substrate of P-gp (Sequeira et al. 2007), our findings hint that P-gp might not have the 
capacity to export both UCB and R123 simultaneously. By further assessing the 
integrity of the BMEC monolayer, we observed that MMPs activity, BMEC permeability 
and TEER were especially altered at earlier time-points, reaching a peak of 
impairment. Overall, damage to organelles by UCB was shown to be more remarkable 
than that triggered by LPS, as confirmed by ultrastructural analysis. This can be related 
to alterations in the dynamic properties of cellular membranes upon interaction with 
UCB (Brito et al. 2001; Rodrigues et al. 2002). The effects of LPS in mono-cultures 
permeability and TEER become less marked with the incubation duration, since this 
molecule would only directly interact with TLR4 of BMEC in the first hours of exposure 
(Singh and Jiang 2004). UCB, on the other hand, has resulted in an increased toxicity. 
This appears to be connected with the fact that TJs are hardly visible in UCB-treated 
BMEC, probably facilitaing the paracellular passage of UCB across the endothelium. 
Thus, UCB might also the release of soluble factors when BMEC are co-cultured with 
astrocytes, that may further alter the expression and localization of TJ as well as of AJ. 
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Figure 5. 1 - Schematic representation of the major findings achieved in the present work. Studies 
performed in vitro in primary cultures of rat brain microvascular endothelial cells (BMEC) showed that 
common neonatal inflammatory stimuli, like unconjugated bilirubin (UCB) and lipopolysaccharide (LPS), 
lead to cell death and damaged organelles. In addition, these molecules increase the number of caveolae, 
inhibit the activity of P-glycoprotein (P-gp), and compromise the integrity of the intercellular junctions. Our 
in vivo studies on neonatal sepsis further showed that the timing of chronic systemic inflammation 
determines not only the lasting effects but also the primed response of the neurovascular unit (NVU) to 
other inflammatory episodes. Indeed, the induction of inflammation in the first neonatal week leads to 
neurodegeneration and with no further neuronal damages after a second episode. On the other hand, if 
the neonatal inflammatory response occurs in the second week of life, the young adult animals present not 
only neurodegeneration, but also lower levels of myelin and fewer astrocytes. Surprisingly, a primed 
response triggers neuronal loss and microglia’s proliferation/migration though only in animals that 
sustained neuroinflammation during the second week of life. OPC, oligodendrocyte precursor cell; PND, 
postnatal day. 
 
In addition, despite astrocytes being able to strengthen BMEC barrier properties 
(Cardoso et al. 2010; Deli et al. 2005; Descamps et al. 2003; Toth et al. 2011; Veszelka 
et al. 2007), their inflammatory response (Didier et al. 2003) may actually worsen the 
effects of LPS through accumulation not only of β-catenin in the perinuclear region, but 
also of ZO-1 that had never been reported previously. Altogether, this chapter revealed 
that each compound has its own mechanism of action and temporal damaging profile. 
Events occur earlier and transiently in LPS-treated cells, thus not aggravating in its 
majority the UCB-induced cell demise. Surprisingly, the presence of glial cells alters 
these profiles and further contributes to BBB disruption. 
Afterwards (Chapter 3), we demonstrated that neonatal repeated administration of 
LPS injections lead to prolonged cerebellar hypoplasia which seems to be directly 
associated with the thinning of cerebellar layers. This may also be connected to the 
neuronal loss and decreased soma area observed in all studied regions. The surprising 
decrease in autotaxin’s expression confirmed its important role in oligodendrocyte 
process network formation and expansion (Dennis et al. 2008; Yuelling et al. 2012). 
Indeed, myelination was already delayed at this time-point, with a parallel increase of 
OPC whose maturation was possibly arrested. The present results revealed different 
MMP-2 activity from our studies in Chapter 2, probably due to the fact that this enzyme 
can be deactivated in vivo but not in vitro (Mizoguchi et al. 2008). Also, LPS triggers a 
late pro-inflammatory response (Goto et al. 2010; Mun-Bryce et al. 2002; Nagamori et 
al. 2012) that is sustained up to one day, namely by microglia (Shimazu et al. 1999; 
Takata et al. 2011). The co-localization of microglia and astrocytes with the 
microvasculature in response to LPS may be a protective attempt to reduce BBB 
permeability (Kaya et al. 2004). Astonishingly, the hypertrophic and intermediate-
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activated morphologies of microglia coincided with the decrease in GFAP+ cells. 
Microglial activation modulates astrocytic proliferation and vice-versa (Seifert et al. 
2006). Thus, microglial transformation into these morphologies could either cause the 
loss of GFAP+ cells, or be in fact induced by signals released from astrocytes, like 
CX3CL1 (Hulshof et al. 2003). Collectively, these data show that glial cells may be 
intimately involved in the LPS-induced neuronal and myelination atrophies, given that 
the physical association between these cells is essencial for proper synapse and 
myelin formation (Ji et al. 2013; Miyamoto et al. 2013; Moore et al. 2011; Pang et al. 
2013). Moreover, it also indicates that GFAP+ cells could in fact be a result of astrocytic 
reprogramming into NPC, repopulating the neuronal lineage (Corti et al. 2012; Heinrich 
et al. 2010; Yang et al. 2012) or even giving rise to microglia (Elmore et al. 2014). 
In our final experimental approach we determined the acute effects of systemic 
inflammation during the second week of life. In addition, we evaluated the lasting 
effects of neonatal systemic inflammation on neurodevelopment in young adult 
animals, as well as whether differences were determined by the neonatal period of 
neuroinflammation onset. Moreover, we determined if the priming of the inflammatory 
response during the neonatal period caused alterations in the adult inflammatory 
response to a second LPS-stimulus, compared to a single injection at adulthood (adult 
acute response) (Chapter 4). These studies demonstrated that neuroinflammation 
during the second week of life did not induce loss of body and brain weights, which is 
consistent with other studies on neonatal inflammation (Du et al. 2011). Still, these 
animals presented acute neuronal loss and atrophy (as seen in Chapter 3), as well as 
shrinkage of the cerebellar white matter. Other studies have shown that myelin is 
particularly vulnerable during the perinatal period (van den Heuij et al. 2014) which, 
along with the neuronal atrophy here observed, could justify this result. Moreover, there 
was increased acute astrogliosis and microgliosis, in agreement with other models of 
SAE (Deng et al. 2013; Lemstra et al. 2007). Our studies (Chapter 4) further 
demonstrated that the administration of LPS during the first week of life did not induce 
lasting effects on the cerebellar layers of young adult animals, nor did it 
exacerbate/protect the response of an adult acute response to LPS insult. On the other 
hand, in animals with LPS administration during the second week there was sustained 
white matter reduction, which was exacerbated by a second stimulus at young adult 
age in addition to a decrease in the internal granular layer. Therefore, the white matter 
damage is more severe in animals with systemic inflammation during the second week 
of life, probably due to a greater vulnerability of oligodendrocytes and their precursors 
(Back et al. 1998; Oka et al. 1993). The restoration of myelin at adulthood in animals 
treated with LPS during the first week of life may be due to the process of OPC 
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maturation being only delayed (Chapter 3), whereas its loss in those treated during the 
second week could possibly be related to their death. As for neuronal demise, this 
appears to be significant in animals with systemic inflammation during the first week of 
life, given that these animals have lasting neuronal atrophy and loss in all brain regions 
examined. This is consistent with previous studies suggesting that the neonatal age at 
which inflammation is induced determines the cell type and the region that will be 
affected (Pandharipande et al. 2013). Our data also revealed that the time-point of 
neonatal priming determines the adult response of HMGB1, whereas the expression of 
TLR4 is always lower in animals with priming in either neonatal week compared to an 
adult acute response. Inflammation during the first week followed by a second 
exposure in young adults does not exacerbate HMGB1 expression, though it is 
significantly increased in young adults when priming occurs during the second week. 
As for the unresponsiveness of TLR4, this could be due to a primed tolerance that 
suppresses its activation for 24h (Bosisio et al. 2002; Nomura et al. 2000). Given that 
microglial activation and neuronal damage are associated with altered TLR4 
expression (Murray et al. 2012) we would expect an attenuated glial response. Indeed, 
we observed a decrease in Iba1+ cells proliferation/migration in animals primed during 
the first week, but not in those primed during the second week. This suggests that 
astrocytes and microglia may have been primed by an ENP inflammation and, given 
the overall impact of this second response, it may exert a protective effect. Overall, this 
chapter revealed that neonatal systemic inflammation induces long-term neuronal and 
myelin damage and influences future inflammatory responses, with distinctive outcome 
depending on the neonatal age of the inflammatory onset. 
In conclusion, this thesis enlightened many fundamental questions on the 
interactions within the NVU in response to common problematic clinical conditions in 
the neonatal period. We were able to demonstrate that these conditions alter BBB 
permeability by the disruption of intercellular junctions and degradation of ECM. In 
addition, the direct and indirect stimulation of astrocytes further disrupts BBB integrity, 
and may as well modulate the progression of microglial maturation. Ultimately, the 
inflammatory response within the developing NVU leads to lasting neuronal and white 
matter atrophies, which severity depends on the neonatal age of the inflammatory 
injury. Still, other important questions were raised in this thesis, namely the true role of 
astrocytes and microglia in the neuronal outcome after inflammation: demising or 
repairing? Therefore, more studies are needed in order to better understand the 
differences between early and late neonatal neuro-glia-vascular inflammatory 
responses, so as to modulate them accordingly by using more directed and specific 
therapeutic approaches. 
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